inline xbrl viewer application relies heavily javascript need allow javascript to use this application inline viewer menu menu information save xbrl instance save xbrl zip file open html setting help section section additional search option include fact name include fact content include label include definition include dimension reference option include topic include sub topic include paragraph include publisher include section match case clear search submit search data data amount text only calculation only negative only additional item only tag tag all standard only custom only filter more filter selecting will take moment period measure axis explicit typed member explicit typed scale balance debit credit reset all filter link fact loading inline form tagged section search all search in internal section only search in external section only clear section search submit section search help getting started the inline xbrl viewer allows user to quickly easily review detail of the tagged information in inline document automatically placing top and bottom highlight border around tagged numeric fact and left and right border each block tagged fact hovering tagged fact will highlight shade all content related to the tagged fact and clicking on tagged fact will reveal tagging detail in the fact review window navigation search and filter option also provided to easily refine and identify specific type of tagged information fact review window the fact review window show the tagging detail for the currently selected fact highlighted solid blue border are four category of fact detail which viewed an value indicates there is available information for the item within the given category attribute all primary information applicable describing the tagged fact including period sign decimal dimensional detail ax and member scale measure and data type label detailed documentation definition for the tag used and label reference authoritative reference information applicable for the selected tag calculation balance and calculation hierarchy detail numeric non dimensioned item only searching there are two way to search the document fact and section to search information enter keyword in search box and select the magnifying glass icon to return matching result search operator and via and and or via or or are available to refine search fact the search fact box can be used to find tagged fact matching entered keywords by default tag name tag label and tagged content are included in search tagged fact matching the search criterion are shown with yellow colored default shading on the page and appear in the fact list select the button to the left of the magnifying glass icon to clear the search the content included in search can be increased to included tag definition dimension and authoritative reference by selecting the cog wheel icon to the left of the search box see setting for more information section the search section box can be used to filter the tagged section of the financial statement filter filter change the number of highlighted fact and item in the fact list by providing several way to review and pinpoint certain tagged information multiple filter can be used data filter filter option allow the user to refine the highlighted tagged fact by data type all display all tagged data default amount only numeric fact only text only textual fact only calculation only numeric fact participating in calculation only negative only negative numeric amount only additional item only tagged fact without corresponding html presentation hidden fact only tag filter these filter allow the user to refine the highlighted fact by tag type all display all tagged data default standard only fact with standard tag common taxonomy us_gaap ifrs dei custom only fact with extension custom tag unique to the entity document more filter additional filter allow user to further refine the highlighted fact period list of all used context year and reporting period measure list of all used unit of measure dollar applicable axis list of all used axis dimension applicable dimension applicable scale list of all used scaled option thousand million applicable balance debit credit applicable multiple filter work in conjunction with each other for example selecting the amount only data filter and custom only tag filter will highlight only numeric tagged fact using custom tag and list in the fact list active filter are displayed in the filter toolbar are selected active filter can be removed individually by unchecking or selecting all option for each filter or all at once via the reset all filter option fact list result on the toolbar select the count to the right of the word fact fact to reveal the fact list result navigable listing of all currently highlighted tagged fact the count represents the current number of fact by default all tagged fact are displayed in the fact list result the list content and count reflects the currently highlighted fact filter and search criterion refine the list to match the highlighted tagged fact navigation control are available to move the list well move the current view to the corresponding highlighted fact location automatically fact in the fact result list is selected will reveal the fact review window certain letter may appear to the right of an item in the fact result list to indicate certain property the letter appears for fact it indicates the fact is additional data hidden with potentially no corresponding html presentation if the letter appears the fact is tagged with custom tag if the letter appears the fact is tagged with dimensional information section the section toolbar item provides listing of the tagged section of the inline document section are divided three group document entity information financial statement note to the financial statement by expanding group and selecting section item in the listing inline xbrl viewer will navigate to that section when the tagged section feature is open the search section box will additionally filter the list of section to only section that match the entered criterion menu information the information menu item provides additional detail the current inline document and customizable viewer setting company and document basic company and document information tag fact and tag standard and custom information file file used additional item additional hidden data that tagged potentially corresponding location in the html save xbrl instance the save xbrl instance menu item allows an xbrl instance document xml that is extracted from the inline document to be saved locally for use by software supporting the xbrl format save xbrl zip the save xbrl zip menu item allows zip file zip that contains the provided xbrl instance document and related custom taxonomy file to be saved locally setting the setting menu item provides the ability to customize viewer feature tagged fact hover on display the hover fact review window for any tagged fact hide the hover fact review window for any tagged fact default may impact performance with certain web browser auto scrolling position this setting will have no effect on ie or safari top selecting fact from the section menu or the fact menu will automatically scroll that element to the top of the inline xbrl viewer window default center selecting fact from the section menu or the fact menu will automatically scroll that element to the middle of the inline xbrl viewer window highlight color use the save and reset button to save the selected setting or reset to default tagged data change the highlight color of the tagged fact border search result change the background color of tagged item matching the search result selected fact change the color of highlight border used to identify the currently selected fact tag shading hover change the color of the shading applied to tagged data on hover search option match case match the specific case of the entered search keyword include label extends search to include tag label include definition extends search to include tag definition include dimension extends search to include dimensional detail include reference extends search to include authoritative reference information optionally specify the reference part to include in the search topic subtopic section help this content version indicates the current build of the inline xbrl viewer application fact select page loading abbv fasb org gaap costofgoodsandservicessold http fasb org gaap researchanddevelopmentexpenseexcludingacquiredinprocesscost http fasb org gaap sellinggeneralandadministrativeexpensehttp fasb org gaap costofgoodsandservicessold http fasb org gaap researchanddevelopmentexpenseexcludingacquiredinprocesscost http fasb org gaap sellinggeneralandadministrativeexpensehttp fasb org gaap costofgoodsandservicessold http fasb org gaap researchanddevelopmentexpenseexcludingacquiredinprocesscost http fasb org gaap sellinggeneralandadministrativeexpensehttp fasb org gaap otherassetsnoncurrenthttp fasb org gaap otherassetsnoncurrenthttp fasb org gaap propertyplantandequipmentnethttp fasb org gaap propertyplantandequipmentnethttp fasb org gaap accountspayableandaccruedliabilitiescurrenthttp fasb org gaap accountspayableandaccruedliabilitiescurrenthttp fasb org gaap otherliabilitiesnoncurrenthttp fasb org gaap otherliabilitiesnoncurrenthttp fasb org gaap longtermdebtandcapitalleaseobligationscurrenthttp fasb org gaap longtermdebtandcapitalleaseobligationscurrenthttp fasb org gaap longtermdebtandcapitalleaseobligationshttp fasb org gaap longtermdebtandcapitalleaseobligationshttp fasb org gaap sellinggeneralandadministrativeexpensehttp fasb org gaap costofgoodsandservicessoldhttp fasb org gaap costofgoodsandservicessoldhttp fasb org gaap costofgoodsandservicessoldhttp fasb org gaap interestincomeexpensenonoperatingnethttp fasb org gaap interestincomeexpensenonoperatingnethttp fasb org gaap interestincomeexpensenonoperatingnethttp fasb org gaap foreigncurrencytransactiongainlossbeforetaxhttp fasb org gaap foreigncurrencytransactiongainlossbeforetaxhttp fasb org gaap foreigncurrencytransactiongainlossbeforetaxhttp fasb org gaap interestincomeexpensenonoperatingnethttp fasb org gaap interestincomeexpensenonoperatingnethttp fasb org gaap interestincomeexpensenonoperatingnethttp fasb org gaap interestincomeexpensenonoperatingnethttp fasb org gaap interestincomeexpensenonoperatingnethttp fasb org gaap interestincomeexpensenonoperatingnethttp fasb org gaap interestincomeexpensenonoperatingnethttp fasb org gaap interestincomeexpensenonoperatingnethttp fasb org gaap interestincomeexpensenonoperatingnethttp fasb org gaap othernonoperatingincomeexpensehttp fasb org gaap othernonoperatingincomeexpensehttp fasb org gaap gaap commonstockmemberexch gaap commonstockmemberexch xnysabbv xnysabbv xnysabbv xnysabbv xnysabbv xnysabbv usdxbrli gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap buildingmembersrt gaap buildingmembersrt gaap equipmentmembersrt maximummemberus gaap gaap finitelivedintangibleassetsmemberabbv allerganplcmemberus gaap allerganplcmemberus gaap allerganplcmemberus gaap gaap collaborativearrangementmemberabbv gaap otheroperatingincomeexpensememberabbv gaap collaborativearrangementmemberabbv gaap collaborativearrangementmemberabbv maximummemberus gaap collaborativearrangementmemberabbv gaap collaborativearrangementmemberabbv maximummemberus gaap collaborativearrangementmemberabbv gaap collaborativearrangementmemberabbv acquirediprdandmilestonesmemberabbv gaap collaborativearrangementmemberabbv maximummemberus gaap collaborativearrangementmemberabbv gaap collaborativearrangementmemberabbv maximummemberus gaap collaborativearrangementmemberabbv gaap collaborativearrangementmemberabbv gaap collaborativearrangementmemberabbv gaap collaborativearrangementmemberabbv maximummemberus gaap collaborativearrangementmemberabbv gaap gaap gaap gaap collaborativearrangementmemberabbv gaap collaborativearrangementmemberabbv gaap collaborativearrangementmembercountry usabbv gaap collaborativearrangementmembercountry usabbv gaap collaborativearrangementmembercountry usabbv gaap collaborativearrangementmemberabbv janssenbiotechincmemberus gaap gaap collaborativearrangementmemberabbv janssenbiotechincmemberus gaap gaap collaborativearrangementmemberabbv janssenbiotechincmemberus gaap gaap collaborativearrangementmemberabbv gaap collaborativearrangementmemberabbv gaap collaborativearrangementmemberabbv genentechinc gaap collaborativearrangementmemberabbv genentechinc gaap collaborativearrangementmemberabbv genentechinc gaap collaborativearrangementmemberabbv genentechinc gaap collaborativearrangementmembercountry usabbv genentechinc gaap collaborativearrangementmembercountry usabbv genentechinc gaap collaborativearrangementmembercountry usabbv genentechinc gaap gaap gaap gaap weightedaveragememberus gaap weightedaveragememberus gaap gaap employeeseverancememberus gaap costofsalesmemberabbv gaap employeeseverancememberus gaap costofsalesmemberabbv gaap employeeseverancememberus gaap costofsalesmemberabbv gaap costofsalesmemberabbv allerganintegrationplanmemberus gaap gaap costofsalesmemberabbv allerganintegrationplanmemberus gaap gaap costofsalesmemberabbv allerganintegrationplanmemberus gaap gaap employeeseverancememberus gaap researchanddevelopmentexpensememberabbv gaap employeeseverancememberus gaap researchanddevelopmentexpensememberabbv gaap employeeseverancememberus gaap researchanddevelopmentexpensememberabbv gaap researchanddevelopmentexpensememberabbv allerganintegrationplanmemberus gaap gaap researchanddevelopmentexpensememberabbv allerganintegrationplanmemberus gaap gaap researchanddevelopmentexpensememberabbv allerganintegrationplanmemberus gaap gaap employeeseverancememberabbv allerganintegrationplanmemberus gaap gaap employeeseverancememberabbv allerganintegrationplanmemberus gaap gaap employeeseverancememberabbv allerganintegrationplanmemberus gaap allerganintegrationplanmemberus gaap otherrestructuringmemberus gaap allerganintegrationplanmemberus gaap otherrestructuringmemberus gaap allerganintegrationplanmemberus gaap otherrestructuringmemberus gaap gaap employeeseverancememberabbv gaap employeeseverancememberabbv gaap employeeseverancememberabbv allerganintegrationplanmemberus gaap allerganintegrationplanmemberus gaap allerganintegrationplanmemberus gaap gaap employeeseverancememberabbv allerganintegrationplanmemberus gaap gaap employeeseverancememberabbv allerganintegrationplanmemberus gaap gaap employeeseverancememberabbv allerganintegrationplanmemberus gaap otherrestructuringplansmemberus gaap otherrestructuringplansmemberus gaap otherrestructuringplansmemberus gaap gaap gaap gaap gaap seniornotesmemberabbv gaap gaap gaap gaap gaap seniornotesmemberabbv gaap seniornotesmemberabbv gaap seniornotesmemberabbv gaap seniornotesmemberabbv gaap seniornotesmemberabbv gaap seniornotesmemberabbv gaap gaap gaap seniornotesmemberabbv gaap seniornotesmemberabbv gaap seniornotesmemberabbv gaap seniornotesmemberabbv gaap seniornotesmemberabbv gaap seniornotesmemberabbv gaap seniornotesmemberabbv gaap seniornotesmemberabbv gaap gaap gaap loanspayablememberabbv gaap loanspayablememberabbv gaap gaap gaap gaap gaap seniornotesmemberabbv gaap seniornotesmemberabbv gaap seniornotesmemberabbv gaap seniornotesmemberabbv gaap seniornotesmemberabbv gaap seniornotesmemberabbv gaap seniornotesmemberabbv gaap seniornotesmemberabbv gaap gaap gaap seniornotesmemberabbv gaap seniornotesmemberabbv gaap seniornotesmemberabbv gaap seniornotesmemberabbv gaap seniornotesmemberabbv gaap seniornotesmemberabbv gaap seniornotesmemberabbv gaap seniornotesmemberabbv gaap seniornotesmemberabbv gaap seniornotesmemberabbv gaap gaap gaap seniornotesmemberabbv gaap seniornotesmemberabbv gaap seniornotesmemberabbv gaap seniornotesmemberabbv gaap seniornotesmemberabbv gaap seniornotesmemberabbv gaap seniornotesmemberabbv gaap seniornotesmemberabbv gaap seniornotesmemberabbv gaap seniornotesmemberabbv gaap seniornotesmemberabbv gaap seniornotesmemberabbv gaap seniornotesmemberabbv gaap seniornotesmemberabbv gaap gaap gaap seniornotesmemberabbv gaap seniornotesmemberabbv gaap seniornotesmemberabbv gaap seniornotesmemberabbv gaap seniornotesmemberabbv gaap seniornotesmemberabbv gaap seniornotesmemberabbv gaap seniornotesmemberabbv gaap seniornotesmemberabbv gaap seniornotesmemberabbv gaap seniornotesmemberabbv gaap gaap loanspayablememberus gaap gaap seniornotesmemberabbv gaap seniornotesmemberabbv gaap seniornotesmemberabbv gaap seniornotesmemberabbv gaap seniornotesmemberabbv gaap seniornotesmemberabbv gaap seniornotesmemberabbv gaap seniornotesmemberabbv gaap seniornotesmemberabbv gaap seniornotesmemberabbv gaap seniornotesmemberabbv gaap gaap gaap gaap gaap gaap gaap gaap designatedashedginginstrumentmemberus gaap cashflowhedgingmemberus gaap gaap designatedashedginginstrumentmemberus gaap cashflowhedgingmemberus gaap gaap designatedashedginginstrumentmemberus gaap cashflowhedgingmemberus gaap gaap designatedashedginginstrumentmemberus gaap treasurylockmemberus gaap gaap designatedashedginginstrumentmemberus gaap cashflowhedgingmemberus gaap gaap foreignexchangeforwardmemberus gaap gaap foreignexchangeforwardmemberus gaap gaap seniornotesmemberus gaap designatedashedginginstrumentmemberus gaap gaap seniornotesmemberus gaap designatedashedginginstrumentmemberus gaap gaap designatedashedginginstrumentmemberus gaap foreignexchangeforwardmemberus gaap gaap designatedashedginginstrumentmemberus gaap foreignexchangeforwardmemberus gaap gaap fairvaluehedgingmemberus gaap designatedashedginginstrumentmemberus gaap gaap fairvaluehedgingmemberus gaap designatedashedginginstrumentmemberus gaap gaap designatedashedginginstrumentmemberus gaap cashflowhedgingmemberus gaap foreignexchangeforwardmemberus gaap gaap designatedashedginginstrumentmemberus gaap cashflowhedgingmemberus gaap foreignexchangeforwardmemberus gaap gaap designatedashedginginstrumentmemberus gaap accountspayableandaccruedliabilitiesmemberus gaap cashflowhedgingmemberus gaap gaap designatedashedginginstrumentmemberus gaap accountspayableandaccruedliabilitiesmemberus gaap cashflowhedgingmemberus gaap gaap othernoncurrentassetsmemberus gaap designatedashedginginstrumentmemberus gaap cashflowhedgingmemberus gaap gaap othernoncurrentassetsmemberus gaap designatedashedginginstrumentmemberus gaap cashflowhedgingmemberus gaap gaap designatedashedginginstrumentmemberus gaap cashflowhedgingmemberus gaap otherliabilitiesmemberus gaap gaap designatedashedginginstrumentmemberus gaap cashflowhedgingmemberus gaap otherliabilitiesmemberus gaap gaap designatedashedginginstrumentmemberus gaap foreignexchangeforwardmemberus gaap netinvestmenthedgingmemberus gaap gaap designatedashedginginstrumentmemberus gaap foreignexchangeforwardmemberus gaap netinvestmenthedgingmemberus gaap gaap designatedashedginginstrumentmemberus gaap accountspayableandaccruedliabilitiesmemberus gaap foreignexchangeforwardmemberus gaap gaap designatedashedginginstrumentmemberus gaap accountspayableandaccruedliabilitiesmemberus gaap foreignexchangeforwardmemberus gaap gaap othernoncurrentassetsmemberus gaap designatedashedginginstrumentmemberus gaap foreignexchangeforwardmemberus gaap gaap othernoncurrentassetsmemberus gaap designatedashedginginstrumentmemberus gaap foreignexchangeforwardmemberus gaap gaap designatedashedginginstrumentmemberus gaap otherliabilitiesmemberus gaap foreignexchangeforwardmemberus gaap gaap designatedashedginginstrumentmemberus gaap otherliabilitiesmemberus gaap foreignexchangeforwardmemberus gaap gaap foreignexchangeforwardmemberus gaap nondesignatedmemberus gaap gaap foreignexchangeforwardmemberus gaap nondesignatedmemberus gaap gaap accountspayableandaccruedliabilitiesmemberus gaap foreignexchangeforwardmemberus gaap gaap accountspayableandaccruedliabilitiesmemberus gaap foreignexchangeforwardmemberus gaap gaap designatedashedginginstrumentmemberus gaap cashflowhedgingmemberus gaap prepaidexpensesandothercurrentassetsmemberus gaap gaap designatedashedginginstrumentmemberus gaap cashflowhedgingmemberus gaap prepaidexpensesandothercurrentassetsmemberus gaap gaap designatedashedginginstrumentmemberus gaap accountspayableandaccruedliabilitiesmemberus gaap cashflowhedgingmemberus gaap gaap designatedashedginginstrumentmemberus gaap accountspayableandaccruedliabilitiesmemberus gaap cashflowhedgingmemberus gaap gaap fairvaluehedgingmemberus gaap designatedashedginginstrumentmemberus gaap prepaidexpensesandothercurrentassetsmemberus gaap gaap fairvaluehedgingmemberus gaap designatedashedginginstrumentmemberus gaap prepaidexpensesandothercurrentassetsmemberus gaap gaap fairvaluehedgingmemberus gaap designatedashedginginstrumentmemberus gaap accountspayableandaccruedliabilitiesmemberus gaap gaap fairvaluehedgingmemberus gaap designatedashedginginstrumentmemberus gaap accountspayableandaccruedliabilitiesmemberus gaap gaap fairvaluehedgingmemberus gaap othernoncurrentassetsmemberus gaap designatedashedginginstrumentmemberus gaap gaap fairvaluehedgingmemberus gaap othernoncurrentassetsmemberus gaap designatedashedginginstrumentmemberus gaap gaap fairvaluehedgingmemberus gaap designatedashedginginstrumentmemberus gaap otherliabilitiesmemberus gaap gaap fairvaluehedgingmemberus gaap designatedashedginginstrumentmemberus gaap otherliabilitiesmemberus gaap gaap designatedashedginginstrumentmemberus gaap gaap designatedashedginginstrumentmemberus gaap gaap designatedashedginginstrumentmemberus gaap gaap designatedashedginginstrumentmemberus gaap gaap designatedashedginginstrumentmemberus gaap gaap designatedashedginginstrumentmemberus gaap gaap gaap gaap seniornotesmemberus gaap gaap seniornotesmemberus gaap gaap seniornotesmemberus gaap gaap designatedashedginginstrumentmemberus gaap cashflowhedgingmemberus gaap gaap designatedashedginginstrumentmemberus gaap cashflowhedgingmemberus gaap gaap designatedashedginginstrumentmemberus gaap foreignexchangeforwardmemberus gaap gaap designatedashedginginstrumentmemberus gaap foreignexchangeforwardmemberus gaap gaap designatedashedginginstrumentmemberus gaap foreignexchangeforwardmemberus gaap gaap foreignexchangeforwardmemberus gaap gaap foreignexchangeforwardmemberus gaap gaap foreignexchangeforwardmemberus gaap gaap designatedashedginginstrumentmemberus gaap treasurylockmemberus gaap gaap designatedashedginginstrumentmemberus gaap treasurylockmemberus gaap gaap designatedashedginginstrumentmemberus gaap treasurylockmemberus gaap gaap designatedashedginginstrumentmemberus gaap cashflowhedgingmemberus gaap gaap designatedashedginginstrumentmemberus gaap cashflowhedgingmemberus gaap gaap designatedashedginginstrumentmemberus gaap cashflowhedgingmemberus gaap gaap fairvaluehedgingmemberus gaap designatedashedginginstrumentmemberus gaap gaap fairvaluehedgingmemberus gaap designatedashedginginstrumentmemberus gaap gaap fairvaluehedgingmemberus gaap designatedashedginginstrumentmemberus gaap gaap interestexpensememberus gaap seniornotesmemberus gaap fairvaluehedgingmemberus gaap gaap interestexpensememberus gaap seniornotesmemberus gaap fairvaluehedgingmemberus gaap gaap interestexpensememberus gaap seniornotesmemberus gaap fairvaluehedgingmemberus gaap gaap gaap gaap gaap gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap moneymarketfundsmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap gaap gaap gaap gaap gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap moneymarketfundsmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap gaap measurementinputdiscountratemembersrt maximummemberus gaap weightedaveragememberus gaap gaap measurementinputdiscountratemembersrt maximummemberus gaap weightedaveragememberus gaap probabilityofpaymentforunachievedmilestonesmembersrt probabilityofpaymentforunachievedmilestonesmembersrt probabilityofpaymentforunachievedmilestonesmembersrt probabilityofpaymentforunachievedmilestonesmembersrt probabilityofpaymentforunachievedmilestonesmembersrt probabilityofpaymentforunachievedmilestonesmembersrt probabilityofpaymentforroyaltiesbyindicationmembersrt maximummemberabbv weightedaveragememberabbv probabilityofpaymentforroyaltiesbyindicationmembersrt maximummemberabbv weightedaveragememberabbv projectedyearofpaymentsmembersrt maximummemberabbv projectedyearofpaymentsmembersrt projectedyearofpaymentsmembersrt maximummemberabbv projectedyearofpaymentsmembersrt probabilityofpaymentforroyaltiesexcludingapprovedindicationsmembersrt maximummemberabbv gaap gaap gaap estimateoffairvaluefairvaluedisclosurememberus gaap gaap estimateoffairvaluefairvaluedisclosurememberus gaap gaap estimateoffairvaluefairvaluedisclosurememberus gaap gaap gaap gaap estimateoffairvaluefairvaluedisclosurememberus gaap gaap estimateoffairvaluefairvaluedisclosurememberus gaap gaap estimateoffairvaluefairvaluedisclosurememberus gaap gaap principaluscustomersmemberus gaap accountsreceivablememberus gaap principaluscustomersmemberus gaap accountsreceivablememberus gaap gaap salesrevenuenetmemberus gaap productconcentrationriskmemberabbv gaap salesrevenuenetmemberus gaap productconcentrationriskmemberabbv gaap salesrevenuenetmemberus gaap productconcentrationriskmemberabbv gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap definedbenefitplanequitysecuritiesuslargecapmemberus gaap pensionplansdefinedbenefitmemberus gaap gaap definedbenefitplanequitysecuritiesuslargecapmemberus gaap gaap gaap definedbenefitplanequitysecuritiesuslargecapmemberus gaap gaap gaap definedbenefitplanequitysecuritiesuslargecapmemberus gaap gaap gaap definedbenefitplanequitysecuritiesusmidcapmemberus gaap pensionplansdefinedbenefitmemberus gaap gaap definedbenefitplanequitysecuritiesusmidcapmemberus gaap gaap gaap definedbenefitplanequitysecuritiesusmidcapmemberus gaap gaap gaap definedbenefitplanequitysecuritiesusmidcapmemberus gaap gaap gaap pensionplansdefinedbenefitmemberus gaap definedbenefitplanequitysecuritiesnonusmemberus gaap gaap gaap pensionplansdefinedbenefitmemberus gaap gaap gaap pensionplansdefinedbenefitmemberus gaap gaap gaap pensionplansdefinedbenefitmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap ustreasuryandgovernmentmemberus gaap gaap gaap pensionplansdefinedbenefitmemberus gaap gaap gaap pensionplansdefinedbenefitmemberus gaap gaap gaap pensionplansdefinedbenefitmemberus gaap gaap corporatedebtsecuritiesmemberus gaap pensionplansdefinedbenefitmemberus gaap gaap corporatedebtsecuritiesmemberus gaap gaap gaap corporatedebtsecuritiesmemberus gaap gaap gaap corporatedebtsecuritiesmemberus gaap gaap gaap pensionplansdefinedbenefitmemberus gaap foreigngovernmentdebtsecuritiesmemberus gaap gaap gaap pensionplansdefinedbenefitmemberus gaap gaap gaap pensionplansdefinedbenefitmemberus gaap gaap gaap pensionplansdefinedbenefitmemberus gaap gaap otherdebtsecuritiesmemberus gaap pensionplansdefinedbenefitmemberus gaap gaap gaap otherdebtsecuritiesmemberus gaap gaap gaap otherdebtsecuritiesmemberus gaap gaap gaap otherdebtsecuritiesmemberus gaap gaap mutualfundmemberus gaap pensionplansdefinedbenefitmemberus gaap gaap gaap mutualfundmemberus gaap gaap mutualfundmemberus gaap gaap gaap mutualfundmemberus gaap gaap gaap realestatememberus gaap pensionplansdefinedbenefitmemberus gaap gaap gaap realestatememberus gaap gaap gaap realestatememberus gaap gaap gaap realestatememberus gaap definedbenefitplanotherassetsmemberus gaap pensionplansdefinedbenefitmemberus gaap definedbenefitplanotherassetsmemberus gaap gaap definedbenefitplanotherassetsmemberus gaap gaap definedbenefitplanotherassetsmemberus gaap gaap gaap pensionplansdefinedbenefitmemberus gaap gaap gaap gaap gaap gaap gaap gaap pensionplansdefinedbenefitmemberus gaap gaap definedbenefitplanequitysecuritiesuslargecapmemberus gaap pensionplansdefinedbenefitmemberus gaap gaap definedbenefitplanequitysecuritiesuslargecapmemberus gaap gaap gaap definedbenefitplanequitysecuritiesuslargecapmemberus gaap gaap gaap definedbenefitplanequitysecuritiesuslargecapmemberus gaap gaap gaap definedbenefitplanequitysecuritiesusmidcapmemberus gaap pensionplansdefinedbenefitmemberus gaap gaap definedbenefitplanequitysecuritiesusmidcapmemberus gaap gaap gaap definedbenefitplanequitysecuritiesusmidcapmemberus gaap gaap gaap definedbenefitplanequitysecuritiesusmidcapmemberus gaap gaap gaap pensionplansdefinedbenefitmemberus gaap definedbenefitplanequitysecuritiesnonusmemberus gaap gaap gaap pensionplansdefinedbenefitmemberus gaap gaap gaap pensionplansdefinedbenefitmemberus gaap gaap gaap pensionplansdefinedbenefitmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap ustreasuryandgovernmentmemberus gaap gaap gaap pensionplansdefinedbenefitmemberus gaap gaap gaap pensionplansdefinedbenefitmemberus gaap gaap gaap pensionplansdefinedbenefitmemberus gaap gaap corporatedebtsecuritiesmemberus gaap pensionplansdefinedbenefitmemberus gaap gaap corporatedebtsecuritiesmemberus gaap gaap gaap corporatedebtsecuritiesmemberus gaap gaap gaap corporatedebtsecuritiesmemberus gaap gaap gaap pensionplansdefinedbenefitmemberus gaap foreigngovernmentdebtsecuritiesmemberus gaap gaap gaap pensionplansdefinedbenefitmemberus gaap gaap gaap pensionplansdefinedbenefitmemberus gaap gaap gaap pensionplansdefinedbenefitmemberus gaap gaap otherdebtsecuritiesmemberus gaap pensionplansdefinedbenefitmemberus gaap gaap gaap otherdebtsecuritiesmemberus gaap gaap gaap otherdebtsecuritiesmemberus gaap gaap gaap otherdebtsecuritiesmemberus gaap gaap mutualfundmemberus gaap pensionplansdefinedbenefitmemberus gaap gaap gaap mutualfundmemberus gaap gaap mutualfundmemberus gaap gaap gaap mutualfundmemberus gaap gaap gaap realestatememberus gaap pensionplansdefinedbenefitmemberus gaap gaap gaap realestatememberus gaap gaap gaap realestatememberus gaap gaap gaap realestatememberus gaap definedbenefitplanotherassetsmemberus gaap pensionplansdefinedbenefitmemberus gaap definedbenefitplanotherassetsmemberus gaap gaap definedbenefitplanotherassetsmemberus gaap gaap definedbenefitplanotherassetsmemberus gaap gaap gaap pensionplansdefinedbenefitmemberus gaap gaap gaap gaap gaap gaap gaap gaap pensionplansdefinedbenefitmemberus gaap gaap definedbenefitplanequitysecuritiesmemberus gaap gaap definedbenefitplandebtsecuritymemberus gaap definedbenefitplanotherassetsmemberus gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap restrictedstockunitsrsumembersrt maximummemberus gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap reclassificationoutofaccumulatedothercomprehensiveincomememberus gaap netinvestmenthedgingmemberus gaap gaap reclassificationoutofaccumulatedothercomprehensiveincomememberus gaap netinvestmenthedgingmemberus gaap gaap reclassificationoutofaccumulatedothercomprehensiveincomememberus gaap netinvestmenthedgingmemberus gaap gaap reclassificationoutofaccumulatedothercomprehensiveincomememberus gaap foreignexchangeforwardmemberus gaap gaap reclassificationoutofaccumulatedothercomprehensiveincomememberus gaap foreignexchangeforwardmemberus gaap gaap reclassificationoutofaccumulatedothercomprehensiveincomememberus gaap foreignexchangeforwardmemberus gaap gaap treasurylockmemberus gaap reclassificationoutofaccumulatedothercomprehensiveincomememberus gaap gaap treasurylockmemberus gaap reclassificationoutofaccumulatedothercomprehensiveincomememberus gaap gaap treasurylockmemberus gaap reclassificationoutofaccumulatedothercomprehensiveincomememberus gaap gaap reclassificationoutofaccumulatedothercomprehensiveincomememberus gaap accumulatedgainlosscashflowhedgeincludingnoncontrollinginterestmemberus gaap gaap reclassificationoutofaccumulatedothercomprehensiveincomememberus gaap accumulatedgainlosscashflowhedgeincludingnoncontrollinginterestmemberus gaap gaap reclassificationoutofaccumulatedothercomprehensiveincomememberus gaap accumulatedgainlosscashflowhedgeincludingnoncontrollinginterestmemberus gaap gaap reclassificationoutofaccumulatedothercomprehensiveincomememberus gaap gaap reclassificationoutofaccumulatedothercomprehensiveincomememberus gaap gaap reclassificationoutofaccumulatedothercomprehensiveincomememberus gaap lawsuitabbv class_actionabbv direct_purchaserabbv gaap sellinggeneralandadministrativeexpensesmemberabbv elliottassociatesl usabbv immunologymemberabbv usabbv immunologymemberabbv usabbv immunologymemberabbv immunologymemberabbv humiramemberus gaap immunologymemberabbv humiramemberus gaap immunologymemberabbv humiramemberus gaap immunologymemberabbv immunologymemberabbv immunologymemberabbv skyrizimembercountry usabbv skyrizimembercountry usabbv skyrizimembercountry usabbv skyrizimemberabbv immunologymemberus gaap skyrizimemberabbv immunologymemberus gaap skyrizimemberabbv immunologymemberus gaap skyrizimemberabbv skyrizimemberabbv skyrizimemberabbv rinvoqmembercountry usabbv rinvoqmembercountry usabbv rinvoqmembercountry usabbv rinvoqmemberabbv immunologymemberus gaap rinvoqmemberabbv immunologymemberus gaap rinvoqmemberabbv immunologymemberus gaap rinvoqmemberabbv rinvoqmemberabbv rinvoqmemberabbv hematologiconcologymemberabbv imbruvicamembercountry hematologiconcologymemberabbv imbruvicamembercountry hematologiconcologymemberabbv imbruvicamembercountry hematologiconcologymemberabbv imbruvicamemberus gaap hematologiconcologymemberabbv imbruvicamemberus gaap hematologiconcologymemberabbv imbruvicamemberus gaap hematologiconcologymemberabbv hematologiconcologymemberabbv hematologiconcologymemberabbv venclextamemberabbv hematologiconcologymembercountry venclextamemberabbv hematologiconcologymembercountry venclextamemberabbv hematologiconcologymembercountry venclextamemberabbv hematologiconcologymemberus gaap venclextamemberabbv hematologiconcologymemberus gaap venclextamemberabbv hematologiconcologymemberus gaap venclextamemberabbv venclextamemberabbv venclextamemberabbv aestheticsmembercountry usabbv aestheticsmembercountry usabbv aestheticsmembercountry usabbv aestheticsmemberabbv botoxcosmeticmemberus gaap aestheticsmemberabbv botoxcosmeticmemberus gaap aestheticsmemberabbv botoxcosmeticmemberus gaap aestheticsmemberabbv aestheticsmemberabbv aestheticsmemberabbv aestheticsmembercountry usabbv aestheticsmembercountry usabbv aestheticsmembercountry usabbv aestheticsmemberabbv juvedermcollectionmemberus gaap aestheticsmemberabbv juvedermcollectionmemberus gaap aestheticsmemberabbv juvedermcollectionmemberus gaap aestheticsmemberabbv aestheticsmemberabbv aestheticsmemberabbv aestheticsmembercountry usabbv aestheticsmembercountry usabbv aestheticsmembercountry usabbv aestheticsmemberabbv otheraestheticsmemberus gaap aestheticsmemberabbv otheraestheticsmemberus gaap aestheticsmemberabbv otheraestheticsmemberus gaap aestheticsmemberabbv aestheticsmemberabbv aestheticsmemberabbv neurosciencemembercountry usabbv neurosciencemembercountry usabbv neurosciencemembercountry usabbv neurosciencememberus gaap nonusmemberabbv neurosciencememberus gaap nonusmemberabbv neurosciencememberus gaap nonusmemberabbv neurosciencememberabbv neurosciencememberabbv neurosciencememberabbv neurosciencemembercountry usabbv neurosciencemembercountry usabbv neurosciencemembercountry usabbv neurosciencememberabbv vraylarmemberus gaap neurosciencememberabbv vraylarmemberus gaap neurosciencememberabbv vraylarmemberus gaap neurosciencememberabbv neurosciencememberabbv neurosciencememberabbv neurosciencemembercountry usabbv neurosciencemembercountry usabbv neurosciencemembercountry usabbv neurosciencememberabbv duodopamemberus gaap neurosciencememberabbv duodopamemberus gaap neurosciencememberabbv duodopamemberus gaap neurosciencememberabbv neurosciencememberabbv neurosciencememberabbv neurosciencemembercountry usabbv neurosciencemembercountry usabbv neurosciencemembercountry usabbv neurosciencememberabbv quliptamembercountry neurosciencememberabbv quliptamembercountry neurosciencememberabbv quliptamembercountry neurosciencememberabbv otherneurosciencemembercountry neurosciencememberabbv otherneurosciencemembercountry neurosciencememberabbv otherneurosciencemembercountry neurosciencememberabbv otherneurosciencememberus gaap neurosciencememberabbv otherneurosciencememberus gaap neurosciencememberabbv otherneurosciencememberus gaap neurosciencememberabbv neurosciencememberabbv neurosciencememberabbv eyecaremembercountry usabbv eyecaremembercountry usabbv eyecaremembercountry usabbv eyecarememberus gaap nonusmemberabbv eyecarememberus gaap nonusmemberabbv eyecarememberus gaap nonusmemberabbv eyecarememberabbv eyecarememberabbv eyecarememberabbv eyecaremembercountry usabbv eyecaremembercountry usabbv eyecaremembercountry usabbv eyecarememberus gaap nonusmemberabbv eyecarememberus gaap nonusmemberabbv eyecarememberus gaap nonusmemberabbv eyecarememberabbv eyecarememberabbv eyecarememberabbv eyecarememberabbv restasismembercountry eyecarememberabbv restasismembercountry eyecarememberabbv restasismembercountry eyecarememberabbv restasismemberus gaap eyecarememberabbv restasismemberus gaap eyecarememberabbv restasismemberus gaap eyecarememberabbv eyecarememberabbv eyecarememberabbv othereyecarememberabbv eyecaremembercountry othereyecarememberabbv eyecaremembercountry othereyecarememberabbv eyecaremembercountry othereyecarememberabbv eyecarememberus gaap othereyecarememberabbv eyecarememberus gaap othereyecarememberabbv eyecarememberus gaap othereyecarememberabbv othereyecarememberabbv othereyecarememberabbv otherkeyproductsmembercountry usabbv otherkeyproductsmembercountry usabbv otherkeyproductsmembercountry usabbv otherkeyproductsmemberabbv mavyretmemberus gaap otherkeyproductsmemberabbv mavyretmemberus gaap otherkeyproductsmemberabbv mavyretmemberus gaap otherkeyproductsmemberabbv otherkeyproductsmemberabbv otherkeyproductsmemberabbv creonmemberabbv otherkeyproductsmembercountry creonmemberabbv otherkeyproductsmembercountry creonmemberabbv otherkeyproductsmembercountry linzessconstellamemberabbv otherkeyproductsmembercountry linzessconstellamemberabbv otherkeyproductsmembercountry linzessconstellamemberabbv otherkeyproductsmembercountry linzessconstellamemberabbv otherkeyproductsmemberus gaap linzessconstellamemberabbv otherkeyproductsmemberus gaap linzessconstellamemberabbv otherkeyproductsmemberus gaap linzessconstellamemberabbv linzessconstellamemberabbv linzessconstellamemberabbv statessecurities and exchange commissionwashington mark one annual report pursuant to section or of the security exchange act of the fiscal year ended december or transition report pursuant to section or of the security exchange act of the transition period from to commission file number abbvie inc exact name of registrant specified in it charter delaware state or other jurisdiction ofincorporation or organization employeridentification number north waukegan roadnorth chicago illinois address including zip code and telephone number of principal executive office security registered pursuant to section of the act title of each classtrading symbol name of each exchange on which registeredcommon stock par value per shareabbv new york stock exchangechicago stock senior note due york stock senior note due york stock senior note due york stock senior note due york stock senior note due york stock senior note due york stock senior note due york stock senior note due york stock exchangeindicate by check mark if the registrant is well known seasoned issuer defined in rule of the security act yes no indicate by check mark if the registrant is not required to file report pursuant to section or of the act yes no indicate by check mark whether the registrant filed all report required to be filed by section or of the security exchange act of the preceding month or for shorter period that the registrant required to file such report and ha been subject to such filing requirement for the past day yes no indicate by check mark whether the registrant ha submitted electronically every interactive data file required to be submitted pursuant to rule of regulation during the preceding month or for such shorter period that the registrant wa required to submit such file yes no indicate by check mark whether the registrant is large accelerated filer an accelerated filer non accelerated filer or smaller reporting company see the definition of large accelerated filer accelerated filer and smaller reporting company in rule of the exchange act large accelerated filer accelerated filer non accelerated filer smaller reporting company emerging growth company if an emerging growth company indicate by check mark if the registrant ha elected not to use the extended transition period for complying with any new or revised financial accounting standard provided pursuant to section of the exchange act indicate by check mark whether the registrant ha filed report on and attestation to it management assessment of the effectiveness of it internal control over financial reporting section of the sarbanes oxley act by the registered public accounting firm that prepared or issued it audit report if security are registered pursuant to section of the act indicate by checkmark whether the financial statement of the registrant included in the filing reflect the correction of an error to previously issued financial statement indicate by check mark whether any of those error correction are restatement that required recovery analysis of incentive based compensation received by any of the registrant executive officer during the relevant recovery period pursuant to indicate by check mark whether the registrant is shell company defined in rule of the act yes no the aggregate market value of the share of voting stock held by non affiliate of the registrant computed by reference to the closing price reported on the new york stock exchange of the last business day of abbvie inc recently completed second fiscal quarter june wa abbvie ha no non voting common equity number of common share outstanding of january document incorporated by referenceportions of the abbvie inc proxy statement are incorporated by reference into part iii the definitive proxy statement will be filed on or about march abbvie inc form kfor the year ended december table of contentspage no part iitem risk unresolved staff legal mine safety about executive iiitem market for registrant common equity related stockholder matter and issuer purchase of equity reserved management discussion and analysis of financial condition and result of quantitative and qualitative disclosure about market financial statement and supplementary change in and disagreement with accountant on accounting and financial control and other disclosure regarding foreign jurisdiction that prevent iiiitem director executive officer and corporate executive security ownership of certain beneficial owner and management and related stockholder certain relationship and related transaction and director principal accounting fee and ivitem exhibit financial statement form part iitem businessoverviewabbvie or the company refer to abbvie inc or abbvie inc and it consolidated subsidiary the context requires abbvie is global diversified research based biopharmaceutical company positioned for success with comprehensive product portfolio that ha leadership position across immunology oncology aesthetic neuroscience and eye care abbvie us it expertise dedicated people and unique approach to innovation to develop and market advanced therapy that address of the world most complex and serious disease abbvie wa incorporated in delaware on april on january abbvie became an independent publicly traded company result of the distribution by abbott laboratory abbott of of the outstanding common stock of abbvie to abbott shareholder segmentsabbvie operates single global business segment dedicated to the research and development manufacturing commercialization and sale of innovative medicine and therapy this operating structure enables the chief executive officer chief operating decision maker codm to allocate resource and ass business performance on global basis in order to achieve established long term strategic goal consistent with this structure global research and development and supply chain organization is responsible for the discovery development manufacturing and supply of product commercial effort that coordinate the marketing sale and distribution of these product are organized by geographic region or therapeutic area all of these activity are supported by global corporate administrative staff the determination of single business segment is consistent with the consolidated financial information regularly reviewed by the codm for purpose of assessing performance allocating resource and planning and forecasting future period see note segment and geographic area information to the consolidated financial statement included under item financial statement and supplementary data and the sale information related to abbvie key product and geography included under item management discussion and analysis of financial condition and result of operation productsabbvie portfolio of product includes broad line of therapy that address some of the world most complex and serious disease immunology product abbvie maintains an extensive immunology portfolio across rheumatology dermatology and gastroenterology abbvie immunology product address unmet need for patient with autoimmune disease these product are humira humira adalimumab is biologic therapy administered subcutaneous injection it is approved to treat the following autoimmune disease in the united state canada and mexico collectively north america and in the european union condition principal marketsrheumatoid arthritis moderate to severe north america european unionpsoriatic arthritis north america european unionankylosing spondylitis north america european unionadult crohn disease moderate to severe north america european unionplaque psoriasis moderate to severe chronic north america european unionjuvenile idiopathic arthritis moderate to severe polyarticular north america european unionulcerative colitis moderate to severe north america european unionaxial spondyloarthropathy european unionpediatric crohn disease moderate to severe north america european unionhidradenitis suppurativa moderate to severe north america european unionpediatric enthesitis related arthritis european unionnon infectious intermediate posterior and panuveitisnorth america european unionpediatric ulcerative colitis moderate to severe canada european unionpediatric uveitisnorth america european form humira is also approved in japan for the treatment of intestinal behçet disease and pyoderma gangrenosum humira is sold in numerous other market worldwide including japan china brazil and australia and accounted for approximately of abbvie total net revenue in skyrizi skyrizi risankizumab is an interleukin il inhibitor that selectively block il by binding to it subunit it is biologic therapy approved to treat the following autoimmune disease in north america the european union and japan conditionprincipal marketsplaque psoriasis moderate to severe north america european union japanpsoriatic arthritisu european unionadult crohn disease moderate to severe canada european unionskyrizi is also approved in japan for the treatment of plaque psoriasis psoriatic arthritis erythrodermic psoriasis in patient have an inadequate response to conventional therapy and for induction and maintenance in moderately to severely active crohn disease skyrizi is approved in multiple country globally including the united state canada and the european union for the treatment of moderate to severe plaque psoriasis in adult who are candidate for systemic therapy or phototherapy in psoriatic disease psoriasis or psoriatic arthritis skyrizi is administered quarterly subcutaneous injection following two induction dos when administered for crohn disease skyrizi is given in three induction dos via iv infusion followed by subcutaneous injection via an on body injector every eight week rinvoq rinvoq upadacitinib is an oral once daily selective and reversible jak inhibitor that is approved to treat the following inflammatory disease in north america the european union and japan condition principal marketsrheumatoid arthritis moderate to severe north america european union japanpsoriatic arthritis canada european union japanankylosing spondylitis european unionatopic dermatitis moderate to severe canada european union japanaxial spondyloarthropathyu european unionulcerative colitisu european unionin the united state rinvoq is indicated for both the treatment of moderate to severe active rheumatoid arthritis for active psoriatic arthritis for moderately to severely active ulcerative colitis for active ankylosing spondylitis and for active non radiographic axial spondyloarthritis in adult patient who have an inadequate response or intolerance to one or more tnf blocker it is also indicated for the treatment of moderate to severe atopic dermatitis in adult and child year of age and older whose disease is not adequately controlled with other systemic drug product including biologics or when use of those therapy are inadvisable in the european union rinvoq is indicated for the treatment of moderate to severe rheumatoid arthritis in adult for active psoriatic arthritis in adult who have an inadequate response or intolerance to disease modifying anti rheumatic medicine dmards and for active axial spondyloarthritis in adult it is also indicated for the treatment of moderate to severe atopic dermatitis in adult and child year of age and older and for moderately to severely active ulcerative colitis in adult oncology product abbvie oncology product target some of the most complex and difficult to treat cancer these product are imbruvica imbruvica ibrutinib is an oral once daily therapy that inhibits protein called bruton tyrosine kinase imbruvica wa one of the first medicine to receive united state food and drug administration fda approval granted breakthrough therapy designation and is one of the few therapy to receive four separate designation imbruvica currently is approved for the treatment of adult patient with blood cancer such chronic lymphocytic leukemia cll well certain form of non hodgkin lymphoma imbruvica is approved in adult and pediatric patient one year and older with chronic graft versus host disease after failure of one or more line of systemic therapy venclexta venclyxto venclexta venetoclax is cell lymphoma bcl inhibitor used to treat hematological malignancy venclexta is approved by the fda for adult with cll or small lymphocytic lymphoma in addition venclexta form is approved in combination with azacitidine or decitabine or low dose cytarabine to treat adult with newly diagnosed acute myeloid leukemia who are year of age or older or have other medical condition that prevent the use of standard chemotherapy aesthetic product abbvie aesthetic portfolio consists of facial injectables plastic and regenerative medicine body contouring and skincare product which hold market leading position in the and in key market around the world these product are botox cosmetic botox cosmetic is an acetylcholine release inhibitor and neuromuscular blocking agent indicated for treatment in three area temporary improvement in the appearance of moderate to severe glabellar line frown line the eyebrow moderate to severe crow foot and moderate to severe forehead line in adult received it initial fda approval in botox cosmetic is approved for use in all major market around the world the juvederm collection of filler the juvederm collection of filler is portfolio of hyaluronic acid based dermal filler with variety of approved indication in the and in other major market around the world to augment or treat volume loss in the cheek chin lip and lower face other aesthetic other aesthetic product include but are not limited to alloderm regenerative dermal tissue coolsculpting body contouring technology natrelle breast implant the skinmedica skincare line latisse eyelash solution and diamondglow dermabrasion technology neuroscience product abbvie neuroscience product address some of the most difficult to treat neurologic disease these product are botox therapeutic botox therapeutic onabotulinumtoxina injection is an acetylcholine release inhibitor and neuromuscular blocking agent that is injected into muscle tissue in the united state it is approved to treat numerous indication including chronic migraine overactive bladder in adult who have an inadequate response to an anticholinergic medication and urinary incontinence due to detrusor overactivity associated with neurologic condition in adult who have an inadequate response to an anticholinergic medication in addition botox therapeutic is approved to treat spasticity in patient two year of age and older cervical dystonia in adult well other condition botox is marketed in other country around the world and license will vary botox therapeutic is marketed by gsk in japan vraylar vraylar cariprazine is dopamine preferring receptor partial agonist and receptor partial agonist vraylar is indicated for acute and maintenance treatment of schizophrenia in adult acute treatment of manic or mixed episode associated with bipolar disorder in adult acute treatment of depressive episode associated with bipolar disorder in adult and an adjunctive treatment in major depressive disorder duopa and duodopa carbidopa and levodopa abbvie levodopa carbidopa intestinal gel for the treatment of advanced parkinson disease is marketed duopa in the united state and duodopa outside of the united state ubrelvy ubrelvy ubrogepant is calcitonin gene related peptide receptor antagonist indicated for the acute treatment of migraine with or without aura in adult ubrelvy is commercialized in the united state israel saudi arabia united arab emirate and ha been approved in canada qulipta qulipta atogepant is calcitonin gene related peptide receptor antagonist indicated for the preventive treatment of episodic migraine in adult qulipta is commercialized in the united state and ha recently been approved for use in canada eye care product abbvie eye care product address unmet need and new approach to help preserve and protect patient vision these product are lumigan ganfort lumigan bimatoprost ophthalmic solution is once daily topical prostaglandin analog indicated for the reduction of elevated intraocular pressure iop in patient with open angle glaucoma oag or ocular hypertension oht ganfort is once daily topical fixed combination of bimatoprost and timolol for the reduction of iop in adult patient with oag or oht lumigan is sold in the united state and numerous market around the world ganfort is approved in the european union and some market in south america the middle east and asia alphagan combigan alphagan brimonidine tartrate ophthalmic solution is an alpha adrenergic receptor agonist indicated for the reduction of elevated iop in patient with open angle glaucoma or ocular hypertension combigan brimonidine tartrate timolol maleate ophthalmic solution is approved for reducing elevated iop in patient with glaucoma who require additional or adjunctive iop lowering therapy both alphagan and combigan are available for sale in the united state and numerous market around the world form restasis restasis is calcineurin inhibitor immunosuppressant indicated to increase tear production in patient whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca restasis is approved in the united state and number of other market in south america the middle east and asia other eye care other eye care product include ozurdex refresh optive xen and durysta other key product abbvie other key product include among other thing treatment for patient with hepatitis virus hcv metabolic and hormone product that target number of condition including exocrine pancreatic insufficiency and hypothyroidism well endocrinology product for the palliative treatment of advanced prostate cancer treatment of endometriosis and central precocious puberty and for the preoperative treatment of patient with anemia caused by uterine fibroid these product are mavyret maviret mavyret glecaprevir pibrentasvir is approved in the united state and european union maviret for the treatment of adult and pediatric patient year and older or weighing at least kilogram with chronic hcv genotype infection without cirrhosis and with compensated cirrhosis child pugh it is also indicated for the treatment of adult and pediatric patient year and older or weighing at least kilogram with hcv genotype infection who previously have been treated with regimen containing an hcv inhibitor or an protease inhibitor but not both it is an week pan genotypic treatment for patient without cirrhosis and following the expedition study also in patient with compensated cirrhosis who are new to treatment creon creon pancrelipase is pancreatic enzyme therapy for exocrine pancreatic insufficiency condition that occurs in patient with cystic fibrosis chronic pancreatitis and several other condition lupron lupron leuprolide acetate which is also marketed lucrin and lupron depot is product for the palliative treatment of advanced prostate cancer treatment of endometriosis and central precocious puberty and for the preoperative treatment of patient with anemia caused by uterine fibroid lupron is approved for daily subcutaneous injection and one month three month four month and six month intramuscular injection linz constella linz linaclotide is once daily guanylate cyclase agonist used in adult to treat irritable bowel syndrome with constipation ibs and chronic idiopathic constipation the product is marketed linz in the united state and constella outside of the united state synthroid synthroid levothyroxine sodium tablet usp is used in the treatment of hypothyroidism abbvie ha the right to sell creon and synthroid only in the united state marketing sale and distribution capabilitiesabbvie utilizes combination of dedicated commercial resource regional commercial resource and distributorships to market sell and distribute it product worldwide abbvie directs it primary marketing effort toward securing the prescription or recommendation of it brand of product by physician external expert and other health care provider managed care provider for example health maintenance organization and pharmacy benefit manager hospital and state and federal government agency for example state medicaid program the united state department of veteran affair and the united state department of defense are also important customer abbvie also market directly to consumer although in the united state many of the company product must be sold pursuant to prescription outside of the united state abbvie focus it promotional and market access effort on external expert payer physician and health system abbvie also provides patient support program closely related to it product abbvie product are generally sold worldwide directly to wholesaler distributor government agency health care facility specialty pharmacy and independent retailer from abbvie owned distribution center and public warehouse certain product including aesthetic product and device are also sold directly to physician and other licensed healthcare provider although abbvie business doe not have significant seasonality abbvie product revenue may be affected by end customer and retail buying pattern fluctuation in wholesaler inventory level and other factor in the united state abbvie distributes pharmaceutical product principally through independent wholesale distributor with some sale directly to retailer pharmacy patient or other customer in three wholesale distributor mckesson corporation cardinal health inc and amerisourcebergen corporation accounted for substantially all of abbvie pharmaceutical product sale in the united state no individual wholesaler accounted for greater of abbvie gross revenue in the united state outside the united state abbvie sell product primarily to wholesaler or through distributor and depending on the market work through largely centralized national payer system to agree on reimbursement term form certain product are co marketed or co promoted with other company abbvie ha no single customer that if the customer lost would have material adverse effect on the company business no material portion of abbvie business is subject to renegotiation of profit or termination of contract at the election of the government order are generally filled on current basis and order backlog is not material to abbvie business competitionthe market for abbvie product are highly competitive abbvie competes with other research based pharmaceutical and biotechnology company that discover manufacture market and sell proprietary pharmaceutical product therapy and biologics for example abbvie immunology product compete with anti tnf product jak inhibitor and other competitive product intended to treat number of disease state and abbvie oncology product compete with btk inhibitor in addition in the past few year number of other company have started to develop have successfully developed and or are currently marketing product that are being positioned competitor to botox the search for technological innovation in pharmaceutical product is significant aspect of competition the introduction of new product by competitor and change in medical practice and procedure can result in product obsolescence price is also competitive factor in addition the substitution of generic and biosimilar pharmaceutical product for branded pharmaceutical product creates competitive pressure on abbvie product that not have patent protection new product or treatment brought to market by abbvie competitor could cause revenue for abbvie product to decrease due to price reduction and sale volume decrease biosimilars competition for abbvie biologic product is affected by the approval of follow on biologics also known biosimilars biologics have added major therapeutic option for the treatment of many disease including some for which therapy were unavailable or inadequate the cost of developing and producing biologic therapy is typically dramatically higher than for small molecule medication and many biologic medication are used for ongoing treatment of chronic disease such rheumatoid arthritis or inflammatory bowel disease or for the treatment of previously untreatable cancer significant investment in biologics infrastructure and manufacturing are necessary to produce biologic product humira is now facing direct biosimilar competition in europe the united state and other country and abbvie will continue to face competitive pressure from these biologics and from orally administered product in the united state the fda regulates biologics under the federal food drug and cosmetic act the ffdca the public health service act phsa and the regulation implementing these statute the enactment of federal health care reform legislation in march provided pathway for approval of biosimilars under the phsa but the approval process for and science behind biosimilars is complex approval by the fda is dependent upon many factor including showing that the biosimilar is highly similar to the original product and ha no clinically meaningful difference from the original product in term of safety purity and potency the type of data that could ordinarily be required in an application to show similarity may include analytical data bioequivalence study and study to demonstrate chemical similarity animal study including toxicity study and clinical study furthermore the law provides that only biosimilar product that is determined to be interchangeable will be considered by the fda substitutable for the original biologic product without the intervention of the health care provider who prescribed the original biologic product to prove that biosimilar product is interchangeable the applicant must demonstrate that the product can be expected to produce the clinical result the original biologic product in any given patient and if the product is administered more than once in patient that safety risk and potential for diminished efficacy of alternating or switching between the use of the interchangeable biosimilar biologic product and the original biologic product is no greater than the risk of using the original biologic product without switching the law continues to be interpreted and implemented by the fda result it full ultimate impact implementation and meaning remains subject to uncertainty intellectual property protection and regulatory exclusivitygenerally upon approval product may be entitled to certain kind of exclusivity under applicable intellectual property and regulatory regime abbvie intellectual property is materially valuable to the company and abbvie seek patent protection available in all significant market and or country for each product in development in the united state the expiration date for patent is year after the filing date given that patent relating to pharmaceutical product are often obtained early in the development process and given the amount of time needed to complete clinical trial and other development activity required for regulatory approval the length of time between product launch and patent expiration is significantly le than year the drug price competition and patent term restoration act of commonly known the hatch waxman act permit patent holder to seek patent extension commonly called patent term restoration for patent on product or process for making the product regulated by the ffdca the length of the patent extension is roughly based on percent of the period of time from the filing of an investigational new drug application nda for form compound to the submission of the nda for such compound plus percent of the time period from nda submission to regulatory approval the extension however can not exceed five year and the patent term remaining after regulatory approval can not exceed year biological product licensed under the phsa are similarly eligible for term of patent restoration pharmaceutical product may be entitled to other form of legal or regulatory exclusivity upon approval the scope length and requirement for each of these exclusivities vary both in the united state and in other jurisdiction in the united state if the fda approves conventional drug product that contains an active ingredient not previously approved the product is typically entitled to five year of non patent regulatory exclusivity specific condition of use approved for individual product may also be entitled to three year of exclusivity if approval wa based on the fda reliance on new clinical study essential to approval submitted by the nda applicant if the nda applicant study the product for use by child the fda may grant pediatric exclusivity which extends by day all existing exclusivities patent and regulatory related to the product for product that are either used to treat condition that afflict relatively small population or for which there is not reasonable expectation that the research and development cost will be recovered the fda may designate the pharmaceutical an orphan drug and grant it seven year of exclusivity other type of regulatory exclusivity may also be available such generating new antibiotic incentive now gain exclusivity which can provide new antibiotic or new antifungal drug an additional five year of exclusivity to be added to certain exclusivities already provided for by law applicable law and regulation dictate the scope of any exclusivity to which product or particular characteristic of product is entitled upon approval in any particular country in certain instance regulatory exclusivity may offer protection where patent protection is no longer available or for period of time in excess of patent protection it is not possible to estimate for each product in development the total period and scope of exclusivity to which it may become entitled regulatory approval is obtained or sometimes even later however given the length of time required to complete clinical development of pharmaceutical product the period of exclusivity that might be achieved in any individual case would not generally be expected to exceed minimum of three year and maximum of year these estimate do not consider other factor such the difficulty of recreating the manufacturing process for particular product or other proprietary knowledge that may delay the introduction of generic or other follow on product after the expiration of applicable patent and other regulatory exclusivity period biologics may be entitled to exclusivity under the biologics price competition and innovation act which wa passed on march title vii to the patient protection and affordable care act the law provides pathway for approval of biosimilars following the expiration of year of regulatory exclusivity for the innovator biologic and potential additional day extension term for conducting pediatric study biologics are also eligible for orphan drug exclusivity discussed the law also includes an extensive process for the innovator biologic and biosimilar manufacturer to litigate patent infringement validity and enforceability the european union ha also created pathway for approval of biosimilars and ha published guideline for approval of certain biosimilar product the more complex nature of biologics and biosimilar product ha led to close regulatory scrutiny over follow on biosimilar product which can reduce the effect of biosimilars on sale of the innovator biologic compared to the sale erosion caused by generic version of small molecule pharmaceutical product abbvie owns or ha licensed right to substantial number of patent and patent application abbvie license or owns patent portfolio of thousand of patent family each of which includes united state patent application and or issued patent and may also contain the non united state counterpart to these patent and application these patent and application including various patent that expire during the period to the early in aggregate are believed to be of material importance in the operation of abbvie business however abbvie belief that no single patent license trademark or related group of patent license or trademark except for those related to adalimumab which is sold under the trademark humira are material in relation to the company business whole abbvie ha entered into settlement and license agreement with several adalimumab biosimilar manufacturer under the agreement the license in the united state begin in and the license in europe began in in addition the following patent license and trademark are significant those related to ibrutinib which is sold under the trademark imbruvica those related to risankizumab which is sold under the trademark skyrizi and those related to upadacitinib which is sold under the trademark rinvoq the united state composition of matter patent covering ibrutinib is expected to expire in with pediatric regulatory exclusivity extending until may however no generic entry for any ibrutinib product is expected prior to march the united state composition of matter patent covering risankizumab is expected to expire in and the united state composition of matter patent covering upadacitinib is expected to expire in abbvie may rely in some circumstance on trade secret to protect it technology abbvie seek to protect it technology and product candidate in part by confidentiality agreement with it employee consultant advisor form contractor and collaborator these agreement may be breached and abbvie may not have adequate remedy for any breach in addition abbvie trade secret may otherwise become known or be independently discovered by competitor to the extent that abbvie employee consultant advisor contractor and collaborator use intellectual property owned by others in work for the company dispute may arise to the right in related or resulting know and invention licensing acquisition and other arrangementsin addition to it independent effort to develop and market product abbvie enters into arrangement such acquisition option to acquire agreement licensing arrangement option to license arrangement strategic alliance co promotion arrangement co development and co marketing agreement and joint venture the acquisition and option to acquire agreement typically include among other term and condition non refundable purchase price payment or option fee option exercise payment milestone or earn out and other customary term and obligation the licensing and other arrangement typically include among other term and condition non refundable upfront license fee option fee and option exercise payment milestone payment and royalty and or profit sharing obligation see note licensing acquisition and other arrangement other licensing acquisition activity to the consolidated financial statement included under item financial statement and supplementary data third party agreementsabbvie ha agreement with third party for process development product distribution analytical service and manufacturing of certain product abbvie procures certain product and service from limited number of supplier and in some case single supply source in addition abbvie ha agreement with third party for active pharmaceutical ingredient and product manufacturing formulation and development service fill finish and packaging service transportation and distribution and logistics service for certain product abbvie doe not believe that these manufacturing related agreement are material abbvie business is not substantially dependent on any individual agreement in most case abbvie maintains alternate supply relationship that it can utilize without undue disruption of it manufacturing process if third party fails to perform it contractual obligation abbvie seek to maintain sufficient inventory of product to minimize the impact of any supply disruption abbvie is also party to certain collaboration and other arrangement discussed in note licensing acquisition and other arrangement other licensing acquisition activity to the consolidated financial statement included under item financial statement and supplementary data source and availability of raw materialsabbvie purchase in the ordinary course of business raw material and supply essential to it operation from numerous supplier around the world in addition certain medical device and component necessary for the manufacture of abbvie product are provided by unaffiliated third party supplier despite the disruption to the global supply chain caused by covid abbvie ha continued to supply patient with no material supply impact except for the previously disclosed supply issue impacting lupron given the general increased global volatility due to the pandemic abbvie is monitoring and taking action to mitigate potential supply shortage which may impact the fulfillment of product demand research and development activitiesabbvie make significant investment in research and development and ha numerous compound and complementary device in clinical development including potential treatment for complex life threatening disease abbvie ability to discover and develop new compound is enhanced by the company use of integrated discovery and development project team which include chemist biologist physician and pharmacologist who work on the same compound team abbvie also partner with third party such biotechnology company other pharmaceutical company and academic institution to identify and prioritize promising new treatment that complement and enhance abbvie existing portfolio abbvie also supplement it research and development effort with acquisition the research and development process generally begin with discovery research which focus on the identification of molecule that ha desired effect given disease if preclinical testing of an identified compound prof successful the compound move into clinical development which generally includes the following phase phase involves the first human test in small number of healthy volunteer or patient to ass safety tolerability and dos for later phase phase test different dos of the drug in disease state in order to ass efficacy phase test drug that demonstrates favorable result in the earlier phase in significantly larger patient population to further demonstrate efficacy and safety in order to meet requirement to enable global approval form preclinical data and clinical trial from all of the development phase provide the data required to prepare and submit an nda biological license application bla or other submission for regulatory approval to the fda or similar government agency outside the united state the specific requirement scope of clinical trial for obtaining regulatory approval vary across different country and geographic region the research and development process from discovery through new drug launch typically take to year and can be even longer the research and development of new pharmaceutical product ha significant amount of inherent uncertainty there is no guarantee when or if molecule will receive the regulatory approval required to launch new drug or indication in addition to the development of new product delivery device and new formulation research and development project also may include phase trial sometimes called post marketing study for such project clinical trial are designed and conducted to collect additional data regarding among other parameter the benefit and risk of an approved drug regulation discovery and clinical developmentunited state securing approval to market new pharmaceutical product in the united state requires substantial effort and financial resource and take several year to complete the applicant must complete preclinical test and submit protocol to the fda commencing clinical trial clinical trial are intended to establish the safety and efficacy of the pharmaceutical product and typically are conducted in sequential phase although the phase may overlap or be combined if the required clinical testing is successful the result are submitted to the fda in the form of an nda or bla requesting approval to market the product for one or more indication the fda review an nda or bla to determine whether product is safe and effective for it intended use and whether it manufacturing is compliant with current good manufacturing practice cgmp compliance with regulatory requirement is assured through periodic announced or unannounced inspection by the fda and other regulatory authority and these inspection associated with clinical development may include the sponsor investigator site laboratory hospital and manufacturing facility of abbvie subcontractor or other third party manufacturer failure to comply with applicable regulatory requirement can result in enforcement action by the fda including rejection of an nda or bla even if an nda or bla receives approval the applicant must comply with post approval requirement for example holder of an approval must report adverse reaction provide updated safety and efficacy information and comply with requirement concerning advertising and promotional material and activity also quality control and manufacturing procedure must continue to conform to cgmp after approval and certain change to the manufacturing procedure and finished product must be submitted and approved by the fda prior to implementation the fda periodically inspects manufacturing facility to ass compliance with cgmp which imposes extensive procedural and record keeping requirement in addition condition of approval the fda may require post marketing testing and surveillance to further ass and monitor the product safety or efficacy after commercialization which may require additional clinical trial patient registry observational data or additional work on chemistry manufacturing and control any post approval regulatory obligation and the cost of complying with such obligation could expand in the future further the fda continues to regulate product labeling and prohibits the promotion of product for unapproved or off label us along with other labeling restriction outside the united state abbvie is subject to similar regulatory requirement outside the united state for approval and marketing of pharmaceutical product abbvie must obtain approval of clinical trial application or product from applicable supervising regulatory authority before it can commence clinical trial or marketing of the product in target market the approval requirement and process for each country can vary and the time required to obtain approval may be longer or shorter than that required for fda approval in the united state for example abbvie may submit marketing authorization in the european union under either centralized or decentralized procedure the centralized procedure is mandatory for the approval of biotechnology product and many pharmaceutical product and provides for single marketing authorization that is valid for all european union member state under the centralized procedure single marketing authorization application is submitted to the european medicine agency after the agency evaluates the application it make recommendation to the european commission which then make the final determination on whether to approve the application the decentralized procedure provides for mutual recognition of individual national approval decision and is available for product that are not subject to the centralized procedure in japan application for approval of new product are made through the pharmaceutical and medical device agency pmda japan specific trial and or bridging study to demonstrate that the non japanese clinical data applies to japanese patient may be required after completing comprehensive review the pmda report to the ministry of health labour and welfare which then approves or denies the application form similarly application for new product in china are submitted to the center for drug evaluation of the national medical product administration for technical review and approval of product for marketing in china clinical data in chinese subject are usually required to support approval in china requiring the inclusion of china in global pivotal study or separate china asian clinical trial the regulatory process in many emerging market continues to evolve many emerging market including those in asia generally require regulatory approval to have been obtained in large developed market such the united state or europe before the country will begin or complete it regulatory review process similar to the requirement in japan and china certain country notably south korea taiwan india and russia also generally require that clinical study that include data from patient in those country be conducted in order to support local regulatory approval the requirement governing the conduct of clinical trial and product licensing also vary in addition post approval regulatory obligation such adverse event reporting and cgmp compliance generally apply and may vary by country for example after marketing authorization ha been granted in the european union periodic safety report must be submitted and other pharmacovigilance measure may be required such risk management plan regulation commercialization distribution and manufacturingthe manufacturing marketing sale promotion and distribution of abbvie product are subject to comprehensive government regulation government regulation by various national regional federal state and local agency both in the united state and other country address among other matter inspection of and control over research and laboratory procedure clinical investigation product approval and manufacturing labeling packaging marketing and promotion pricing and reimbursement sampling distribution quality control post marketing surveillance record keeping storage and disposal practice abbvie operation are also affected by trade regulation in many country that limit the import of raw material and finished product and by law and regulation that seek to prevent corruption and bribery in the marketplace including the united state foreign corrupt practice act and the united kingdom bribery act which provide guidance on corporate interaction with government official and require safeguard for the protection of personal data in addition abbvie is subject to law and regulation pertaining to health care fraud and abuse including state and federal anti kickback and false claim law in the united state prescription drug manufacturer such abbvie are also subject to tax well application product user and other fee compliance with these law and regulation is costly and materially affect abbvie business among other effect health care regulation substantially increase the time difficulty and cost incurred in obtaining and maintaining approval to market newly developed and existing product abbvie expects compliance with these regulation to continue to require significant technical expertise and capital investment to ensure compliance failure to comply can delay the release of new product or result in regulatory and enforcement action the seizure or recall of product the suspension or revocation of the authority necessary for product production and sale and other civil or criminal sanction including fine and penalty in addition to regulatory initiative abbvie business can be affected by ongoing study of the utilization safety efficacy and outcome of health care product and their component that are regularly conducted by industry participant government agency and others these study can lead to update to the data regarding utilization safety and efficacy of previously marketed product in some case these study have resulted and may in the future result in the discontinuance of or limitation on marketing of such product domestically or worldwide and may give rise to claim for damage from person who believe they have been injured result of their use access to human health care product continues to be subject of oversight investigation and action by governmental agency legislative body and private organization in the united state and other country major focus is cost containment effort to reduce health care cost are also being made in the private sector notably by health care payer and provider which have instituted various cost reduction and containment measure abbvie expects insurer and provider to continue attempt to reduce the cost of health care product outside the united state many country control the price of health care product directly or indirectly through reimbursement payment pricing coverage limitation or compulsory licensing political and budgetary pressure in the united state and in other country may also heighten the scope and severity of pricing pressure on abbvie product for the foreseeable future united state specifically federal law require pharmaceutical manufacturer to pay certain statutorily prescribed rebate to state medicaid program on prescription drug reimbursed under state medicaid plan and the effort by state to seek additional rebate may affect abbvie business similarly the veteran health care act of prerequisite to participation in medicaid and other federal health care program requires that manufacturer extend additional discount on pharmaceutical product to various federal agency including the united state department of veteran affair department of defense and public health service entity and institution in addition recent legislative change would require similarly discounted price to be offered to tricare program beneficiary the veteran health care form act of also established the drug discount program which requires pharmaceutical manufacturer to provide product at reduced price to various designated health care entity and facility in the united state most state also have generic substitution legislation requiring or permitting dispensing pharmacist to substitute different manufacturer generic version of pharmaceutical product for the one prescribed in addition the federal government follows diagnosis related group drg payment system for certain institutional service provided under medicare or medicaid and ha implemented prospective payment system pps for service delivered in hospital outpatient nursing home and home health setting drg and pps entitle health care facility to fixed reimbursement based on the diagnosis and or procedure rather than actual cost incurred in patient treatment thereby increasing the incentive for the facility to limit or control expenditure for many health care product medicare reimburses part drug based on average sale price plus certain percentage to account for physician administration cost which have been reduced in the hospital outpatient setting medicare enters into contract with private plan to negotiate price for most patient administered medicine delivered under part under the patient protection and affordable care act and the health care and education reconciliation act together the affordable care act abbvie pay fee related to it pharmaceutical sale to government program in addition abbvie provides discount of for branded prescription drug sold to patient who fall into the medicare part coverage gap or donut hole the affordable care act also includes provision known the physician payment sunshine act which require manufacturer of drug and biologics covered under medicare and medicaid to record any transfer of value to physician and teaching hospital and to report this data to the center for medicare and medicaid service for subsequent public disclosure similar reporting requirement have also been enacted on the state level in the united state and an increasing number of country worldwide either have adopted or are considering similar law requiring disclosure of interaction with health care professional failure to report appropriate data may result in civil or criminal fine and or penalty european union the european union ha adopted directive and other legislation governing labeling advertising distribution supply pharmacovigilance and marketing of pharmaceutical product such legislation provides mandatory standard throughout the european union and permit member state to supplement these standard with additional regulation european government also regulate pharmaceutical product price through their control of national health care system that fund large part of the cost of such product to consumer result patient are unlikely to use pharmaceutical product that is not reimbursed by the government in many european country the government either regulates the pricing of new product at launch or subsequent launch through direct price control or reference pricing in recent year many country have also imposed new or additional cost containment measure on pharmaceutical product difference between national pricing regime create price differential within the european union that can lead to significant parallel trade in pharmaceutical product most government also promote generic substitution by mandating or permitting pharmacist to substitute different manufacturer generic version of pharmaceutical product for the one prescribed and by permitting or mandating that health care professional prescribe generic version in certain circumstance many government are also following similar path for biosimilar therapy in addition government use reimbursement list to limit the pharmaceutical product that are eligible for reimbursement by national health care system japan in japan the national health insurance system maintains drug price list specifying which pharmaceutical product are eligible for reimbursement and the ministry of health labour and welfare set the price of the product on this list the government generally introduces price cut round every other year and also mandate price decrease for specific product new product judged innovative or useful that are indicated for pediatric use or that target orphan or small population disease however may be eligible for pricing premium the government ha also promoted the use of generic where available emerging market many emerging market take step to reduce pharmaceutical product price in some case through direct price control and in others through the promotion of generic biosimilar alternative to branded pharmaceutical since abbvie market it product worldwide certain product of local nature and variation of product line must also meet other local regulatory requirement certain additional risk are inherent in conducting business outside the united state including price and currency exchange control change in currency exchange rate limitation on participation in local enterprise expropriation nationalization and other governmental action form regulation medical devicesmedical device are subject to regulation by the fda state agency and foreign government health authority fda regulation well various federal and state law govern the development clinical testing manufacturing labeling record keeping and marketing of medical device product agency in the united state abbvie medical device product candidate including abbvie breast implant must undergo rigorous clinical testing and an extensive government regulatory clearance or approval process prior to sale in the united state and other country the lengthy process of clinical development and submission for clearance or approval and the continuing need for compliance with applicable law and regulation require the expenditure of substantial resource regulatory clearance or approval when and if obtained may be limited in scope and may significantly limit the indicated us for which product may be marketed cleared or approved product and their manufacturer are subject to ongoing review and discovery of previously unknown problem with product may result in restriction on their manufacture sale and or use or require their withdrawal from the market united state abbvie medical device product are subject to extensive regulation by the fda in the united state unless an exemption applies each medical device abbvie market in the united state must have clearance or premarket approval application pma in accordance with the ffdca and it implementing regulation the fda classifies medical device into one of three class depending on the degree of risk associated with each medical device and the extent of control that are needed to ensure safety and effectiveness device deemed to pose lower risk are placed in either class or class ii and device deemed by the fda to pose the greatest risk such life sustaining life supporting or implantable device or device deemed to be not substantially equivalent to previously cleared device are placed in class iii in general class iii device can not be marketed in the united state unless the fda approves the device after submission of pma and any change to the device subsequent to initial fda approval must also be reviewed and approved by the fda the majority of abbvie medical device product including abbvie breast implant are regulated class iii medical device class iii device may have significant additional obligation imposed in it condition of approval and the time in which it take to obtain approval can be long compliance with regulatory requirement is assured through periodic unannounced facility inspection by the fda and other regulatory authority and these inspection may include the manufacturing facility of abbvie subcontractor or other third party manufacturer failure to comply with applicable regulatory requirement can result in enforcement action by the fda which may include any of the following sanction warning letter or untitled letter fine injunction and civil penalty recall or seizure of abbvie product operating restriction partial suspension or total shutdown of production refusing abbvie request for clearance or pma approval of new product withdrawing clearance or pma approval that are already granted and criminal prosecution clinical trial is almost always required to support pma application and is sometimes required for premarket notification clinical trial generally require submission of an application for an investigational device exemption ide which must be supported by appropriate data such animal and laboratory testing result showing that it is safe to test the device in human and that the testing protocol is scientifically sound study sponsor must obtain approval for it ide from the fda and it must also obtain approval of it study from the institutional review board overseeing the trial the result of clinical testing may not be sufficient to obtain approval of the investigational device once device is approved the manufacture and distribution of the device remains subject to continuing regulation by the fda including quality system regulation requirement which involve design testing control documentation and other quality assurance procedure during the manufacturing process medical device manufacturer and their subcontractor are required to register their establishment and list their manufactured device with the fda and are subject to periodic unannounced inspection by the fda and certain state agency for compliance with regulatory requirement manufacturer must also report to the fda if their device may have caused or contributed to death or serious injury or malfunctioned in way that could likely cause or contribute to death or serious injury or if the manufacturer conduct field correction or product recall or removal to reduce risk to health posed by device or to remedy violation of the ffdca that may present health risk further the fda continues to regulate device labeling and prohibits the promotion of product for unapproved or off label us along with other labeling restriction european union medical device product that are marketed in the european union must comply with the requirement of the medical device regulation the mdr which came into effect in may the mdr provides for regulatory oversight with respect to the design manufacture clinical trial labeling and adverse event reporting for medical device to ensure that medical device marketed in the european union are safe and effective for their intended us medical device that comply with the mdr are entitled to bear conformité européenne marking evidencing such compliance and may be marketed in the european union failure to comply with these domestic and international regulatory requirement could affect abbvie ability to market and sell abbvie product in these country form environmental mattersabbvie belief that it operation comply in all material respect with applicable law and regulation concerning environmental protection regulation under federal and state environmental law impose stringent limitation on emission and discharge to the environment from various manufacturing operation abbvie capital expenditure for pollution control in were approximately million and operating expenditure were approximately million in capital expenditure for pollution control are estimated to be approximately million and operating expenditure are estimated to be approximately million abbott wa identified one of many potentially responsible party in investigation and or remediation at several location in the united state including puerto rico under the comprehensive environmental response compensation and liability act commonly known superfund some of these location were transferred to abbvie in connection with the separation and distribution and abbvie ha become party to these investigation and remediation abbott wa also engaged in remediation at several other site some of which have been transferred to abbvie in connection with the separation and distribution in cooperation with the environmental protection agency or similar agency while it is not feasible to predict with certainty the final cost related to those investigation and remediation activity abbvie belief that such cost together with other expenditure to maintain compliance with applicable law and regulation concerning environmental protection not have material adverse effect on the company financial position cash flow or result of operation employeesabbvie employed approximately employee in over country of january outside the united state some of abbvie employee are represented by union or work council abbvie belief that it ha good relation with it employee human capital managementattracting retaining and providing meaningful growth and development opportunity to abbvie employee is critical to the company success in making remarkable impact on people life around the world abbvie leverage numerous resource to identify and enhance strategic and leadership capability foster employee engagement and create culture where diverse talent is productive and engaged abbvie invests in it employee through competitive compensation benefit and employee support program and offer best in class development and leadership opportunity abbvie ha developed deep talent base through ongoing investment in functional and leadership training and by sourcing world class external talent ensuring sustainable talent pipeline abbvie continuously cultivates and enhances it working culture and embrace equality diversity and inclusion fundamental to the company mission attracting and developing talent attracting and developing high performing talent is essential to abbvie continued success abbvie implement detailed talent attraction strategy with an emphasis on stem skill set diverse talent base and other critical skillsets including drug discovery clinical development market access and business development abbvie ha also invested in integrated inclusive practice across the end to end hiring process and introduced inclusive recruitment live training requirement for all people leader and recruiter abbvie also invests in competitive compensation and benefit program in addition to offering comprehensive suite of benefit ranging from medical and dental coverage to retirement disability and life insurance program abbvie also provides health promotion program mental health awareness campaign and employee assistance program in several country financial wellness support on site health screening and immunization in several country and on site fitness and rehabilitation center in abbvie launched on site health care clinic at certain location offering convenient and affordable access to quality healthcare flu shot and vaccine in addition the abbvie employee assistance fund part of the abbvie foundation support two program for global employee the abbvie possibility scholarship for child of employee which is an annual merit based scholarship for use at accredited college university or vocational technical school and the employee relief program which is financial assistance to support short term need of employee when faced with large scale disaster hurricane individual disaster home fire or financial hardship the death of spouse finally abbvie empowers manager and their team with tool tip and guideline on effectively managing workload managing team from distance and supporting flexible work practice in implemented where we work abbvie hybrid work model offering eligible employee predictable flexibility new abbvie employee are given tailored onboarding experience for faster integration and to support performance one of abbvie mentorship program allows employee to self nominate mentor or mentees and facilitates meaningful relationship supporting employee career and development goal form abbvie also provides structured broad based development opportunity focusing on high performance skill and leadership training abbvie talent philosophy hold leader accountable for building high performing organization and the company provides development opportunity for all level of leadership abbvie learn develop perform program offer year long self directed leadership education supplemented with tool and resource and leverage leader role model and teacher in addition foundational success factor to abbvie leadership pipeline is the company professional development program which attract graduate postgraduate and post doctoral talent to participate in formal development program lasting to three year with the objective of strengthening functional and leadership capability culture abbvie shared value of transforming life acting with integrity driving innovation embracing diversity and inclusion and serving the community form the core of the company culture abbvie articulates the behavior associated with these value in the way we work core set of working behavior that emphasize how the company achieves result is equally important achieving them the way we work are designed to ensure that every abbvie employee is aware of the company cultural expectation abbvie integrates the way we work into all talent process forming the basis for assessing performance prioritizing development and ultimately rewarding employee abbvie belief it culture creates strong engagement which is measured regularly through confidential third party all employee survey and this engagement support abbvie mission of making remarkable impact on people life equity equality diversity inclusion eed cornerstone of abbvie human capital management approach is to prioritize fostering an inclusive and diverse workforce recently abbvie adopted five year equality diversity inclusion roadmap that defines key global focus area objective and associated initiative and includes implementation plan organized by business function and geography abbvie senior leader have adopted formal goal aligned with executing this strategy in recent year abbvie board of director ha prioritized oversight of abbvie response to the racial justice movement including overseeing internal program designed to ensure that abbvie is attracting retaining and developing diverse talent through december woman represented percent of management position globally and in the united state percent of abbvie workforce wa comprised of member of historically underrepresented population an increase from further abbvie is committed to pay equity and conduct pay equity analysis annually critical component of abbvie strategy is to instill an inclusive mindset in all abbvie leader and employee the company continues to realize the full value of it diverse workforce from recruitment through retirement abbvie employee resource group also help the company nurture an inclusive culture by building community and creating connection and opportunity for mentoring professional development talent attraction and networking in abbvie reiterated it commitment to racial equality and social justice by among other thing expanding it employee matching program to to for donation to civil right nonprofit fostering racial equity and by reaffirming it commitment to clinical trial diversity additional information about abbvie effort on racial equality and social justice is provided on the company website at http abbvie com our company equality inclusion diversity our commitment to racial justice html internet informationcopies of abbvie annual report on form quarterly report on form current report on form and amendment to those report filed or furnished pursuant to section or of the security exchange act of are available free of charge through abbvie investor relation website investor abbvie com soon reasonably practicable after abbvie electronically file the material with or furnishes it to the security and exchange commission sec abbvie corporate governance guideline outline of directorship qualification code of business conduct and the charter of abbvie audit committee compensation committee nomination and governance committee and public policy committee are all available on abbvie investor relation website investor abbvie com item risk factorsyou should carefully consider the following risk and other information in this form in evaluating abbvie and abbvie common stock any of the following risk could materially and adversely affect abbvie result of operation financial condition or cash flow the risk factor generally have been separated into two group risk related to abbvie business and risk related to abbvie common stock based on the information currently known to it abbvie belief that the following information identifies the most significant risk factor affecting it in each of these category of risk however the risk and uncertainty abbvie face are not limited to those set forth in the risk factor described below and may not be in order of importance or probability of occurrence additional risk and uncertainty not presently known to abbvie or that abbvie currently belief to be immaterial may also adversely affect it business in addition past financial performance may not be reliable indicator of future performance and historical trend should not be used to anticipate result or trend in future period form if any of the following risk and uncertainty develops into actual event these event could have material adverse effect on abbvie business result of operation financial condition or cash flow in such case the trading price of abbvie common stock could decline risk related to abbvie businessthe expiration or loss of patent protection and license including the loss of exclusivity for humira and increased competition from biosimilars may adversely affect abbvie revenue and operating earnings abbvie relies on patent trademark and other intellectual property protection in the discovery development manufacturing and sale of it product in particular patent protection is in the aggregate important in abbvie marketing of pharmaceutical product in the united state and most major market outside of the united state patent covering abbvie product normally provide market exclusivity which is important for the profitability of many of abbvie product patent for certain of it product expire abbvie could face competition from lower priced generic or biosimilar product the expiration or loss of patent protection for product typically is followed promptly by substitute that may significantly reduce sale for that product in short amount of time if abbvie competitive position is compromised because of generic biosimilars or otherwise it could have material adverse effect on abbvie business and result of operation in addition proposal emerge from time to time for legislation to further encourage the early and rapid approval of generic drug or biosimilars any such proposal that are enacted into law could increase the impact of generic competition large pharmaceutical company and generic manufacturer of pharmaceutical product continue to expand into the biotechnology field and form partnership to pursue biosimilars company have developed and are developing biosimilars that compete with abbvie biologic product including humira competitor obtain marketing approval for biosimilars referencing abbvie biologic product abbvie product may become subject to competition from such biosimilars with the attendant competitive pressure and consequence expiration of or successful challenge to abbvie applicable patent right could also trigger competition from other product assuming any relevant exclusivity period ha expired result abbvie could face increased litigation and administrative proceeding with respect to the validity and or scope of patent relating to it biologic product for example humira accounted for approximately of abbvie total net revenue in humira is facing competition from biosimilar product in the united state beginning in due to the loss of exclusivity which abbvie anticipates will cause significant decline in humira revenue and could adversely affect abbvie revenue and operating earnings abbvie principal patent and trademark are described in greater detail in item business intellectual property protection and regulatory exclusivity and item management discussion and analysis of financial condition and result of operation result of operation and litigation regarding these patent is described in item legal proceeding abbvie major product could lose patent protection earlier than expected which could adversely affect abbvie revenue and operating earnings significant portion of abbvie revenue and operating earnings are derived from several major product third party or government authority may challenge or seek to invalidate or circumvent abbvie patent and patent application for example manufacturer of generic pharmaceutical product file and may continue to file abbreviated new drug application with the fda seeking to market generic form of abbvie product prior to the expiration of relevant patent owned or licensed by abbvie by asserting that the patent are invalid unenforceable and or not infringed in addition petitioner have filed and may continue to file challenge to the validity of abbvie patent under the leahy smith america invents act which created inter partes review and post grant review procedure for challenging patent validity in administrative proceeding at the united state patent and trademark office although most of the challenge to abbvie intellectual property have come from other business government may also challenge intellectual property right for example court decision and potential legislation relating to patent such legislation regarding biosimilars and other regulatory initiative may result in further erosion of intellectual property protection in addition certain government outside the united state have indicated that compulsory license to patent may be sought to further their domestic policy or on the basis of national emergency such hiv aid if triggered compulsory license may diminish or eliminate sale and profit from those jurisdiction and negatively affect abbvie result of operation abbvie normally responds to challenge by vigorously defending it patent including by filing patent infringement lawsuit patent litigation administrative proceeding and other challenge to abbvie patent are costly and unpredictable and may deprive abbvie of market exclusivity for patented product to the extent abbvie intellectual property is form successfully challenged circumvented or weakened or to the extent such intellectual property doe not allow abbvie to compete effectively abbvie business will suffer to the extent that country do not enforce abbvie intellectual property right or require compulsory licensing of abbvie intellectual property abbvie revenue and operating earnings will be reduced third party intellectual property may prevent abbvie from selling it product or have material adverse effect on abbvie profitability and financial condition third party may claim that an abbvie product infringes upon their intellectual property in addition in it pursuit of valid business opportunity abbvie may be required to challenge intellectual property right held by others that it belief were improperly granted resolving an intellectual property infringement or other claim can be costly and time consuming and may require abbvie to enter into license agreement abbvie can not guarantee that it would be able to obtain license agreement on commercially reasonable term successful claim of patent or other intellectual property infringement could subject abbvie to significant damage or an injunction preventing the manufacture sale or use of the affected abbvie product or product any of these event could have material adverse effect on abbvie profitability and financial condition abbvie research and development effort may not succeed in developing and marketing commercially successful product and technology which may cause it revenue and profitability to decline to remain competitive abbvie must continue to launch new product and new indication and or brand extension for existing product such launch must generate revenue sufficient both to cover it substantial research and development cost and to replace revenue of profitable product that are lost to or displaced by competing product or therapy failure to do so would have material adverse effect on abbvie revenue and profitability accordingly abbvie commits substantial effort fund and other resource to research and development and must make ongoing substantial expenditure without any assurance that it effort will be commercially successful high rate of failure in the biopharmaceutical industry is inherent in the research and development of new product and failure can occur at any point in the research and development process including after significant fund have been invested product that appear promising in development may fail to reach the market for numerous reason including failure to demonstrate effectiveness safety concern superior safety or efficacy of competing therapy failure to achieve positive clinical or pre clinical outcome beyond the current standard of care inability to obtain necessary regulatory approval or delay in the approval of new product and new indication limited scope of approved us excessive cost to manufacture or the failure to obtain or maintain intellectual property right or infringement of the intellectual property right of others decision about research study made early in the development process of pharmaceutical product candidate can affect the marketing strategy once such candidate receives approval more detailed study may demonstrate additional benefit that can help in the marketing but they also consume time and resource and may delay submitting the pharmaceutical product candidate for regulatory approval abbvie can not guarantee that proper balance of speed and testing will be made with respect to each pharmaceutical product candidate or that decision in this area would not adversely affect abbvie result of operation even if abbvie successfully develops and market new product or enhancement to it existing product they may be quickly rendered obsolete by changing clinical preference changing industry standard or competitor innovation abbvie innovation may not be accepted quickly in the marketplace because of existing clinical practice or uncertainty over third party reimbursement abbvie can not state with certainty when or whether any of it product under development will be launched whether it will be able to develop license or otherwise acquire compound or product or whether any product will be commercially successful failure to launch successful new product or new indication for existing product may cause abbvie product to become obsolete causing abbvie revenue and operating result to suffer abbvie is subject to cost containment effort and pricing pressure that could cause reduction in revenue and operating earnings and change in the term of rebate and chargeback program which are common in the pharmaceutical industry could have material adverse effect on abbvie operation cost containment effort by government and private organization are described in greater detail in item business regulation commercialization distribution and manufacturing to the extent these cost containment effort are not offset by greater demand increased patient access to health care or other factor abbvie revenue and operating earnings will be reduced in the united state the european union and other country abbvie business ha experienced downward pressure on product pricing and this pressure could increase in the future abbvie is subject to increasing public and legislative pressure with respect to pharmaceutical pricing in the united state practice of managed care group and institutional and governmental purchaser well federal law and regulation related to medicare and medicaid contribute to pricing pressure in particular the inflation reduction act of form requires the government to negotiate price for select high expenditure medicare part drug price effective beginning in and part drug price effective beginning in ii manufacturer to pay rebate for medicare part and part drug when price for those drug increase faster than inflation beginning in for part and for part and iii medicare part redesign replacing the current coverage gap provision and establishing cap for of pocket cost for medicare beneficiary beginning in with manufacturer being responsible for of cost up to the cap and after that cap is reached the inflation reduction act is to be implemented through forthcoming agency action the outcome of which can not be reasonably determined with certainty additionally change to tax law now require minimum tax generally applied to corporation on adjusted financial statement income beginning in and ii non deductible excise tax provision on net stock repurchase to be applied to repurchase beginning in abbvie continues to evaluate the impact that the inflation reduction act may have on the company the potential for continuing change to the health care system in the united state and the increased purchasing power of entity that negotiate on behalf of medicare medicaid and private sector beneficiary may result in additional pricing pressure in major market worldwide government play significant role in funding health care service and determining the pricing and reimbursement of pharmaceutical product consequently in those market abbvie is subject to government decision making and budgetary action with respect to it product in particular many european country have ongoing government mandated price reduction for many pharmaceutical product and abbvie anticipates continuing pricing pressure in europe difference between country pricing regulation could lead to third party cross border trading in abbvie product that result in reduction in revenue and operating earnings rebate related to government program such fee for service medicaid or medicaid managed care program arise from law and regulation abbvie can not predict with certainty if additional government initiative to contain health care cost or other factor could lead to new or modified regulatory requirement that include higher or incremental rebate or discount other rebate and discount program arise from contractual agreement with private payer various factor including market factor and the ability of private payer to control patient access to product may provide payer the leverage to negotiate higher or additional rebate or discount that could have material adverse effect on abbvie operation portion of abbvie near term pharmaceutical pipeline relies on collaboration with third party which may adversely affect the development and sale of it product abbvie depends on alliance and joint venture with pharmaceutical and biotechnology company for portion of the product in it near term pharmaceutical pipeline failure by these party to meet their contractual regulatory or other obligation to abbvie or any disruption in the relationship between abbvie and these third party could have an adverse effect on abbvie pharmaceutical pipeline and business in addition abbvie collaborative relationship for research and development extend for many year and may give rise to dispute regarding the relative right obligation and revenue of abbvie and it collaboration partner including the ownership of intellectual property and associated right and obligation this could result in the loss of intellectual property right or protection delay the development and sale of potential pharmaceutical product affect the effective sale and delivery of abbvie commercialized product and lead to lengthy and expensive litigation administrative proceeding or arbitration biologics carry unique risk and uncertainty which could have negative impact on abbvie business and result of operation the successful discovery development manufacturing and sale of biologics is long expensive and uncertain process there are unique risk and uncertainty with biologics for example access to and supply of necessary biological material such cell line may be limited and current governmental regulation restrict access to and regulate the transport and use of such material in addition the development manufacturing and sale of biologics is subject to regulation that are often more complex and extensive than the regulation applicable to other pharmaceutical product result manufacturing biologics especially in large quantity is often complex and may require the use of innovative technology such manufacturing also requires facility specifically designed and validated for this purpose and sophisticated quality assurance and quality control procedure biologics are also frequently costly to manufacture because production input are derived from living animal or plant material and some biologics can not be made synthetically failure to successfully discover develop manufacture and sell biologics including humira and skyrizi could have negative impact on abbvie business and result of operation new product and technological advance by abbvie competitor may negatively affect abbvie result of operation abbvie competes with other research based pharmaceutical and biotechnology company that research develop manufacture market and sell proprietary pharmaceutical product and biologics for example humira competes with anti form tnf product and other competitive product intended to treat number of disease state and mavyret maviret competes with other available hepatitis treatment option in addition in the past few year number of other company have started to develop have successfully developed and or are currently marketing product that are being positioned competitor to botox all of these competitor may introduce new product or develop technological advance that compete with abbvie product in therapeutic area such immunology hematologic oncology aesthetic neuroscience and eye care in addition abbvie product lose exclusivity competition surrounding such product will increase and generic and biosimilar product will increasingly penetrate the market abbvie can not predict with certainty the timing or impact of the introduction by competitor of new product or technological advance such competing product may be safer more effective more effectively marketed or sold have lower price or better insurance coverage or reimbursement level or have superior performance feature than abbvie product and this may negatively impact abbvie business and result of operation the manufacture of many of abbvie product is highly exacting and complex process and if abbvie or one of it supplier encounter problem manufacturing abbvie product abbvie business could suffer the manufacture of many of abbvie product is highly exacting and complex process due in part to strict regulatory requirement problem may arise during manufacturing for variety of reason including equipment malfunction failure to follow specific protocol and procedure problem with raw material delay related to the construction of new facility or the expansion of existing facility including those intended to support future demand for abbvie product change in manufacturing production site and limit to manufacturing capacity due to regulatory requirement change in the type of product produced physical limitation that could inhibit continuous supply man made or natural disaster and environmental factor if problem arise during the production of batch of product such batch of product may have to be discarded and abbvie may experience product shortage or incur added expense this could among other thing lead to increased cost lost revenue damage to customer relation time and expense spent investigating the cause and depending on the cause similar loss with respect to other batch or product if problem are not discovered before the product is released to the market recall and product liability cost may also be incurred abbvie us raw material and component in it pharmaceutical and biologic manufacturing process including those sourced from single supplier and an interruption in the supply of those raw material and component could adversely affect abbvie business and result of operation abbvie us raw material and component in it pharmaceutical and biologic manufacturing process that may be sourced from single supplier the failure of abbvie supplier and particularly it single source supplier to fulfill their contractual obligation in timely manner or result of regulatory noncompliance or physical disruption at manufacturing site may impair abbvie ability to deliver it product to customer on timely and competitive basis which could adversely affect abbvie business and result of operation increase in demand on any of abbvie supplier could result in delay and disruption in the manufacturing distribution and sale of it product and or product shortage leading to lost revenue finding an alternative supplier could take significant amount of time and involve significant expense due to the nature of the product and the need to obtain regulatory approval abbvie can not guarantee that it will be able to reach agreement with alternative provider or that regulatory authority would approve abbvie use of such alternative business interruption insurance may not provide adequate compensation in the case of failure by supplier certain aspect of abbvie operation are highly dependent upon third party service provider abbvie relies on supplier vendor and other third party service provider to research develop manufacture commercialize promote and sell it product reliance on third party manufacturer reduces abbvie oversight and control of the manufacturing process some of these third party provider are subject to legal and regulatory requirement privacy and security risk and market risk of their the failure of critical third party service provider to meet it obligation could have material adverse impact on abbvie operation and result if any third party service provider have violated or are alleged to have violated any law or regulation during the performance of their obligation to abbvie it is possible that abbvie could suffer financial and reputational harm or other negative outcome including possible legal consequence significant safety or efficacy issue could arise for abbvie product which could have material adverse effect on abbvie revenue and financial condition pharmaceutical product receive regulatory approval based on data obtained in controlled clinical trial of limited duration following regulatory approval these product will be used over longer period of time in many patient additional and perhaps more extensive study may also be conducted which may be sponsored by abbvie but could also be sponsored by competitor insurance company government institution scientist investigator or other interested party if new safety or efficacy issue are reported or if new scientific information becomes available including result of post marketing phase trial or if government change standard regarding safety efficacy or labeling abbvie may be required to amend form the condition of use for product for example abbvie may voluntarily provide or be required to provide updated information on product label or narrow it approved indication either of which could reduce the product market acceptance if safety or efficacy issue with an abbvie product arise sale of the product could be halted by abbvie or by regulatory authority and regulatory action could be taken by such regulatory authority safety or efficacy issue affecting supplier or competitor product also may reduce the market acceptance of similar abbvie product new data about abbvie product or product similar to it product could negatively impact demand for abbvie product due to actual or perceived safety issue or uncertainty regarding efficacy and in some case could result in product withdrawal furthermore new data and information including information about product misuse may lead government agency professional society practice management group or organization involved with various disease to publish guideline or recommendation related to the use of abbvie product or the use of related therapy or place restriction on sale such guideline or recommendation may lead to lower sale of abbvie product abbvie is subject to product liability claim and other lawsuit that may adversely affect it business result of operation and reputation in the ordinary course of business abbvie is the subject of product liability claim and lawsuit alleging that abbvie current or historical product or the product of other company that it promotes have resulted or could result in an unsafe condition for or injury to patient for example lawsuit are pending against allergan abbvie subsidiary and certain of it former officer alleging they made misrepresentation and omission regarding allergan textured breast implant product liability claim and lawsuit and safety alert or product recall regardless of their ultimate outcome may have material adverse effect on abbvie business result of operation and reputation and on it ability to attract and retain customer consequence may also include additional cost decrease in market share for the product in question lower revenue and exposure to other claim abbvie evaluates it risk and ha determined that the cost of obtaining product liability insurance outweighs the likely benefit of the coverage that is available and such abbvie product liability loss are self insured abbvie is also the subject of other claim legal proceeding and investigation in the ordinary course of business which relate to intellectual property commercial security and other matter adverse outcome in such claim legal proceeding and investigation may also adversely affect abbvie business result of operation and reputation for example allergan wa named defendant in approximately matter relating to the promotion and sale of prescription opioid pain reliever allergan recently agreed to nationwide settlement to resolve such matter which will provide for up to billion to help support state and local effort to address opioid related issue in the united state among other thing however abbvie can not guarantee that the condition to such settlement will be satisfied or that additional suit will not be filed see note legal proceeding and contingency to the consolidated financial statement included under item financial statement and supplementary data abbvie can not predict with certainty the outcome of these proceeding abbvie is subject to governmental regulation and it can be costly to comply with these regulation and to develop compliant product and process abbvie product are subject to rigorous regulation by numerous international supranational federal and state authority described in item business regulation discovery and clinical development business regulation commercialization distribution and manufacturing and business regulation medical device the process of obtaining regulatory approval to market pharmaceutical product can be costly and time consuming and approval may not be granted for future product or additional indication or us of existing product on timely basis if at all delay in the receipt of or failure to obtain approval for future product or new indication and us could result in delayed realization of product revenue reduction in revenue and substantial additional cost the healthcare industry in particular is highly regulated and subject to frequent and substantial regulatory change it is expected that the healthcare industry will continue to be subject to increasing regulation well political and legal action future proposal to reform the healthcare system are considered by the executive branch congress and state legislature abbvie can not predict with certainty when additional change in the healthcare industry in general or the pharmaceutical industry in particular will occur or the impact of such change may be for example the inflation reduction act is to be implemented through forthcoming agency action the outcome of which can not be reasonably determined with certainty in addition abbvie can not guarantee that it will remain compliant with applicable regulatory requirement once approval ha been obtained for product these requirement include among other thing regulation regarding manufacturing practice product labeling and advertising and post marketing reporting including adverse event report and field alert due to manufacturing quality concern abbvie must incur expense and spend time and effort to ensure compliance with these complex regulation form possible regulatory action could result in substantial modification to abbvie business practice and operation refund recall or seizure of abbvie product total or partial shutdown of production in one or more of abbvie or it supplier facility while abbvie or it supplier remedy the alleged violation the inability to obtain future approval and withdrawal or suspension of current product from the market any of these event could disrupt abbvie business and have material adverse effect on it business and result of operation law and regulation affecting government benefit program could impose new obligation on abbvie require it to change it business practice and restrict it operation the health care industry is subject to federal state and international law and regulation pertaining to government benefit program reimbursement rebate price reporting and regulation and health care fraud and abuse in the united state these law include anti kickback and false claim law the medicaid rebate statute the veteran health care act the physician payment sunshine act the tricare program the government pricing rule applicable to the medicaid medicare part drug pricing program and individual state law relating to pricing and sale and marketing practice violation of such law and regulation may be punishable by criminal and or civil sanction including in some instance substantial fine imprisonment and exclusion from participation in federal and state health care program including medicare medicaid and veteran administration health program such violation may also lead to product recall and seizure interruption of production leading to product shortage import ban or denial of import certification delay or denial in the approval of new product or supplemental approval of current product pending resolution of the issue and reputational harm any of which would adversely affect abbvie business these law and regulation are broad in scope and are subject to change and evolving interpretation which could require abbvie to incur substantial cost associated with compliance or to alter one or more of it sale or marketing practice in addition violation of these law and regulation or allegation of such violation could impose new obligation on abbvie require it to change it business practice and restrict it operation public health outbreak epidemic or pandemic such the coronavirus covid have and could in the future have an adverse impact on abbvie operation and financial condition public health outbreak epidemic or pandemic have had and could in the future have an adverse impact on abbvie operation and financial condition the pandemic caused by the novel strain of coronavirus covid caused many country including the united state to declare national emergency and implement preventive measure such travel ban and shelter in place or total lock order the continuation or implementation of these ban and order remains uncertain the covid pandemic caused abbvie to modify certain of it business practice and abbvie may take further action may be required by government authority or abbvie determines are in the best interest of abbvie employee patient customer and business partner while the impact of covid on abbvie operation including among others it manufacturing and supply chain sale and marketing commercial and clinical trial operation to date wa not material abbvie experienced lower new patient start in certain product and market the impact of covid and other public health outbreak on abbvie over the long term is uncertain and can not be predicted with confidence the extent of the adverse impact of covid or any other public health outbreak on abbvie operation will depend on the extent and severity of the continued spread of the disease globally the timing and nature of action taken to respond to it and the resulting economic consequence ultimately effort to mitigate the impact of covid or any other public health outbreak may not completely prevent abbvie business from being adversely affected and future impact remain uncertain the international nature of abbvie business subject it to additional business risk that may cause it revenue and profitability to decline abbvie business is subject to risk associated with business internationally including in emerging market net revenue outside of the united state made up approximately of abbvie total net revenue in the risk associated with abbvie operation outside the united state include fluctuation in currency exchange rate change in medical reimbursement policy and program and pricing restriction multiple legal and regulatory requirement that are subject to change and that could restrict abbvie ability to manufacture market and sell it product differing local product preference and product requirement trade protection measure and import or export licensing requirement form international trade disruption or dispute difficulty in establishing staffing and managing operation differing labor regulation potentially negative consequence from change in or interpretation of tax law political and economic instability including result of the covid pandemic sovereign debt issue price and currency exchange control limitation on participation in local enterprise expropriation nationalization and other governmental action and regulation inflation recession and fluctuation in interest rate restriction on transfer of fund potential deterioration in the economic position and credit quality of certain non country and potential penalty or other adverse consequence for violation of anti corruption anti bribery and other similar law and regulation including the united state foreign corrupt practice act and the united kingdom bribery act in particular in february armed conflict escalated between russia and ukraine in response thereto the united state and other north atlantic treaty organization member state well certain non member state announced targeted economic sanction embargo and export control on russia and belarus although abbvie is continuing to supply essential pharmaceutical product in russia for humanitarian reason while working to maintain compliance with evolving international sanction it ha suspended operation for all aesthetic product in russia abbvie operation in russia belarus and ukraine are not significant however it is not possible to predict with certainty the continued consequence of this conflict which in addition to sanction have included regional instability geopolitical shift and adverse effect on macroeconomic condition currency exchange rate and financial market any such consequence could have an adverse impact on abbvie business and result of operation if abbvie doe not effectively and profitably commercialize it product abbvie revenue and financial condition could be adversely affected abbvie must effectively and profitably commercialize it principal product by creating and meeting continued market demand achieving market acceptance and generating product sale ensuring that the active pharmaceutical ingredient for product and the finished product are manufactured in sufficient quantity and in compliance with requirement of the fda and similar foreign regulatory agency and with acceptable quality and pricing to meet commercial demand and ensuring that the entire supply chain efficiently and consistently delivers abbvie product to it customer the commercialization of abbvie product may not be successful due to among other thing unexpected challenge from competitor new safety issue or concern being reported that may impact or narrow approved indication the relative price of abbvie product compared to alternative treatment option and change to product label that further restrict it marketing if the commercialization of abbvie principal product is unsuccessful abbvie revenue and financial condition could be adversely affected abbvie may acquire other business license right to technology or product form alliance or dispose of asset which could cause it to incur significant expense and could negatively affect profitability abbvie may pursue acquisition technology licensing arrangement joint venture and strategic alliance or dispose of some of it asset part of it business strategy abbvie may not complete these transaction in timely manner on cost effective basis or at all and may not realize the expected benefit if abbvie is successful in making an acquisition the product and technology that are acquired may not be successful or may require significantly greater resource and investment than originally anticipated abbvie may not be able to integrate acquisition successfully into it existing business and could incur or assume significant debt and unknown or contingent liability abbvie could also experience negative effect on it reported result of operation from acquisition or disposition related charge amortization of expense related to intangible and charge for impairment of long term asset these effect could cause deterioration of abbvie credit rating and result in increased borrowing cost and interest expense additionally change in abbvie structure operation revenue cost or efficiency resulting from major transaction such acquisition divestiture merger alliance joint venture restructurings or other strategic initiative may result in form greater than expected cost may take longer than expected to complete or encounter other difficulty including the need for regulatory approval where appropriate abbvie is dependent on wholesale distributor for distribution of it product in the united state and accordingly it business and result of operation could be adversely affected if they encounter financial or other difficulty in three wholesale distributor mckesson corporation cardinal health inc and amerisourcebergen corporation accounted for substantially all of abbvie pharmaceutical product sale in the united state if one of it significant wholesale distributor encounter financial or other difficulty such distributor may decrease the amount of business that it doe with abbvie and abbvie may be unable to collect all the amount that the distributor owes it on timely basis or at all which could adversely affect abbvie business and result of operation abbvie ha debt obligation that could adversely affect it business and it ability to meet it obligation the amount of debt that abbvie ha incurred and intends to incur could have important consequence to abbvie and it investor these consequence include among other thing requiring portion of abbvie cash flow from operation to make interest payment on this debt and reducing the cash flow available to fund capital expenditure and other corporate purpose and to grow abbvie business to the extent abbvie incurs additional indebtedness or interest rate increase these risk could increase further in addition abbvie cash flow from operation may not be sufficient to repay all of the outstanding debt it becomes due and abbvie may not be able to borrow money sell asset or otherwise raise fund on acceptable term or at all to refinance it debt abbvie may need additional financing in the future to meet it capital need or to make opportunistic acquisition and such financing may not be available on favorable term if at all abbvie may need additional financing in the future to meet it capital need or to make opportunistic acquisition for example it may need to increase it investment in research and development activity the capital and credit market may experience extreme volatility and disruption which may lead to uncertainty and liquidity issue for both borrower and investor and abbvie may be unable to obtain any desired additional financing on term favorable to it if at all if abbvie loses it investment grade credit rating or adequate fund are not available on acceptable term abbvie may be unable to fund it expansion successfully develop or enhance product or respond to competitive pressure any of which could negatively affect abbvie business if abbvie raise additional fund by issuing debt or entering into credit facility it may be subject to limitation on it operation due to restrictive covenant failure to comply with these covenant could adversely affect abbvie business abbvie depends on information technology and failure of or significant disruption to those system could have material adverse effect on abbvie business abbvie relies on sophisticated software application and complex information technology system to operate it business which may be vulnerable to malicious intrusion random attack loss of data privacy disruption degradation or breakdown data privacy or security breach by employee or others may in the future result in the failure of critical business operation such breach may cause sensitive data including intellectual property trade secret or personal information belonging to abbvie it patient customer or business partner to be exposed to unauthorized person or to the public to date neither abbvie business operation have been materially impacted by such incident although abbvie ha invested in the protection of it data and information technology and monitor it system on an ongoing basis there can be no assurance that such effort will prevent material breakdown or breach in abbvie information technology system that could have material adverse effect on abbvie business such adverse consequence could include loss of revenue or the loss of critical or sensitive information from abbvie or third party provider database or it system and could also result in legal financial reputational or business harm to abbvie and potentially substantial remediation cost in addition while abbvie maintains cyber insurance it can not guarantee that such insurance will be sufficient to cover the financial legal business or reputational loss that may result from an interruption or breach of abbvie system abbvie balance of intangible asset including developed product right and goodwill acquired are subject to impairment testing and may result in impairment charge which may adversely affect abbvie result of operation and financial condition significant amount of abbvie total asset is related to acquired intangible and goodwill of december the carrying value of abbvie developed product right and other intangible asset wa billion and the carrying value of abbvie goodwill wa billion abbvie developed product right are stated at cost le accumulated amortization abbvie determines original fair value and amortization period for developed product right based on it assessment of various factor impacting estimated form useful life and cash flow of the acquired product significant adverse change to any of these factor require abbvie to perform an impairment test on the affected asset and if evidence of impairment exists require abbvie to take an impairment charge with respect to the asset for asset that are not impaired abbvie may adjust the remaining useful life such charge could adversely affect abbvie result of operation and financial condition abbvie other significant intangible asset include in process research and development ipr intangible project acquired in recent business combination which are indefinite lived intangible asset for ipr asset the risk of failure is significant and there can be no certainty that these asset ultimately will yield successful product abbvie ability to realize value on these significant investment is often contingent upon among other thing regulatory approval and market condition such ipr asset may become impaired and or be written off at some point in the future if the associated research and development effort is abandoned or is curtailed goodwill and abbvie ipr intangible asset are tested for impairment annually or when event occur or circumstance change that could potentially reduce the fair value of the reporting unit or intangible asset impairment testing compare the fair value of the reporting unit or intangible asset to it carrying amount goodwill or ipr impairment if any would be recorded in operating income and could have material adverse effect on abbvie result of operation and financial condition failure to attract develop and retain highly qualified personnel could affect abbvie ability to successfully develop and commercialize product abbvie success is largely dependent on it continued ability to attract develop and retain diverse highly qualified scientific technical and management personnel well personnel with expertise in clinical research and development governmental regulation and commercialization competition for qualified personnel in the biopharmaceutical field is intense and increasing abbvie can not be sure that it will be able to attract and retain quality personnel or that the cost of doing so will not materially increase the illegal distribution and sale by third party of counterfeit or unregistered version of abbvie product could have material adverse impact on it reputation business and result of operation third party may illegally obtain distribute and sell counterfeit or illegally diverted from their intended market version of abbvie product these version of product would not meet abbvie rigorous manufacturing testing distribution and quality standard patient who receives counterfeit stolen or diverted drug may be at risk for number of dangerous health consequence the prevalence of counterfeit diverted medicine is an industry wide issue due to variety of factor including the adoption of commerce which increased during the covid pandemic greatly enhancing consumer ability to obtain prescription and other medical treatment via the internet in lieu of traditional brick and mortar pharmacy this can expose patient to greater risk the internet is preferred vehicle for dangerous counterfeit diverted product offer and scam because of the anonymity it affords abbvie reputation and business could suffer harm result of counterfeit or diverted drug sold under it brand name which may also result in reduced revenue that could negatively affect our result of operation other factor can have material adverse effect on abbvie profitability and financial condition many other factor can affect abbvie result of operation cash flow and financial condition including change in or interpretation of law and regulation including change in accounting standard taxation requirement product marketing application standard data privacy law particularly in the european union and the united state and environmental law difference between the fair value measurement of asset and liability and their actual value particularly for pension and post employment benefit stock based compensation intangible and goodwill and for contingent liability such litigation and contingent consideration the absence of recorded amount or an amount recorded at the minimum compared to the actual amount change in the rate of inflation including the cost of raw material commodity and supply interest rate market value of abbvie equity investment and the performance of investment held by it or it employee benefit trust change in the creditworthiness of counterparties that transact business with or provide service to abbvie or it employee benefit trust environmental liability in connection with abbvie manufacturing process and distribution logistics including the handling of hazardous material form change in the ability of third party that provide information technology accounting human resource payroll and other outsourced service to abbvie to meet their contractual obligation to abbvie the failure or perceived failure of achieving environmental social and governance objective information loss or damage to abbvie reputation brand image or goodwill due to increased use of social medium platform business interruption stemming from natural disaster such climate change earthquake hurricane flooding fire or effort taken by third party to prevent or mitigate such disaster and change in business economic and political condition including war political instability terrorist attack the threat of future terrorist activity and related military action natural disaster the cost and availability of insurance due to any of the foregoing event labor dispute strike slow down or other form of labor or union activity and pressure from third party interest group risk related to abbvie common stockabbvie can not guarantee the timing amount or payment of dividend on it common stock or the repurchase of it common stock although abbvie expects to pay regular cash dividend the timing declaration amount and payment of future dividend to stockholder will fall within the discretion of abbvie board of director the board decision regarding the payment of dividend will depend on many factor such abbvie financial condition earnings capital requirement debt service obligation industry practice legal requirement regulatory constraint and other factor that the board deems relevant for more information see item market for registrant common equity related stockholder matter and issuer purchase of equity security abbvie ability to pay dividend and repurchase share under it share repurchase program will depend on it ongoing ability to generate cash from operation and access capital market abbvie can not guarantee that it will continue to pay dividend in the future an abbvie stockholder percentage of ownership in abbvie may be diluted in the future in the future stockholder percentage ownership in abbvie may be diluted because of equity issuance for capital market transaction equity award that abbvie will be granting to abbvie director officer and employee acquisition or other purpose abbvie employee have option to purchase share of it common stock result of conversion of their abbott stock option in whole or in part to abbvie stock option abbvie anticipates it compensation committee will grant additional stock option or other stock based award to it employee such award will have dilutive effect on abbvie earnings per share which could adversely affect the market price of abbvie common stock from time to time abbvie will issue additional option or other stock based award to it employee under abbvie employee benefit plan in addition abbvie amended and restated certificate of incorporation authorizes abbvie to issue without the approval of abbvie stockholder one or more class or series of preferred stock having such designation power preference and relative participating optional and other special right including preference over abbvie common stock respecting dividend and distribution abbvie board of director generally may determine the term of one or more class or series of preferred stock could dilute the voting power or reduce the value of abbvie common stock for example abbvie could grant the holder of preferred stock the right to elect some number of abbvie director in all event or on the happening of specified event or the right to veto specified transaction similarly the repurchase or redemption right or liquidation preference abbvie could assign to holder of preferred stock could affect the residual value of the common stock certain provision in abbvie amended and restated certificate of incorporation and amended and restated by law and of delaware law may prevent or delay an acquisition of abbvie which could decrease the trading price of abbvie common stock abbvie amended and restated certificate of incorporation and amended and restated by law contain and delaware law contains provision that are intended to deter coercive takeover practice and inadequate takeover bid by encouraging prospective acquirors to negotiate with abbvie board of director rather than to attempt hostile takeover these provision include among others the inability of abbvie stockholder to call special meeting the division of abbvie board of director into three class of director with each class serving staggered three year term form provision that stockholder may only remove director for cause the ability of abbvie director and not stockholder to fill vacancy on abbvie board of director and the requirement that the affirmative vote of stockholder holding at least of abbvie voting stock is required to amend certain provision in abbvie amended and restated certificate of incorporation and abbvie amended and restated by law relating to the number term and election of abbvie director the filling of board vacancy the calling of special meeting of stockholder and director and officer indemnification provision in addition section of the delaware general corporation law provides that subject to limited exception person that acquire or are affiliated with person that acquires more than of the outstanding voting stock of delaware corporation shall not engage in any business combination with that corporation including by merger consolidation or acquisition of additional share for three year period following the date on which that person or it affiliate becomes the holder of more than of the corporation outstanding voting stock abbvie belief these provision protect it stockholder from coercive or otherwise unfair takeover tactic by requiring potential acquirors to negotiate with abbvie board of director and by providing abbvie board of director with more time to ass any acquisition proposal these provision are not intended to make the company immune from takeover however these provision apply even if the offer may be considered beneficial by some stockholder and could delay or prevent an acquisition that abbvie board of director determines is not in the best interest of abbvie and abbvie stockholder these provision may also prevent or discourage attempt to remove and replace incumbent director form cautionary statement regarding forward looking statementsthis annual report on form contains certain forward looking statement regarding business strategy market potential future financial performance and other matter the word believe expect anticipate project and similar expression and us of future or conditional verb generally identify forward looking statement which speak only of the date the statement were made the matter discussed in these forward looking statement are subject to risk uncertainty and other factor that could cause actual result to differ materially from those expressed or implied in the forward looking statement in particular information included under item business item risk factor and item management discussion and analysis of financial condition and result of operation contain forward looking statement where in any forward looking statement an expectation or belief to future result or event is expressed or implied such expectation or belief is based on the current plan and expectation of abbvie management and expressed in good faith and believed to have reasonable basis but there can be no assurance that the expectation or belief will result or be achieved or accomplished factor that could cause actual result or event to differ materially from those anticipated include but are not limited to the matter described under item risk factor and item management discussion and analysis of financial condition and result of operation abbvie doe not undertake and specifically decline any obligation to update the forward looking statement included in this annual report on form to reflect event or circumstance after the date hereof unless abbvie is required by applicable security law to do so item unresolved staff commentsnone item propertiesabbvie corporate office are located at north waukegan road north chicago illinois of december abbvie owns or lease approximately facility worldwide containing an aggregate of approximately million square foot of floor space dedicated to production distribution and administration abbvie significant manufacturing facility are in the following location united state outside the united statesabbott park illinois campoverde di aprilia italybarceloneta puerto rico clonshaugh irelandbranchburg new jersey la aurora costa ricacampbell californialudwigshafen germanycincinnati ohiopringy francedublin california singapore irvine californiasligo irelandnorth chicago illinoiswestport ireland waco texas worcester massachusetts wyandotte michigan _______________________________________________________________________________ leased property abbvie belief it facility are suitable and provide adequate production capacity for it current and projected operation there are no material encumbrance on abbvie owned property in the united state including puerto rico abbvie ha two central distribution center abbvie also ha research and development facility in the united state located at abbott park illinois branchburg new jersey cambridge massachusetts irvine california madison new jersey north chicago illinois pleasanton california santa cruz california south san francisco california and worcester massachusetts outside the united state abbvie principal research and development facility are located in ludwigshafen germany form item legal proceedingsinformation pertaining to legal proceeding is provided in note legal proceeding and contingency to the consolidated financial statement included under item financial statement and supplementary data and is incorporated by reference herein item mine safety disclosuresnot applicable form information about our executive officersthe following table list abbvie executive officer name age positionrichard of the board and chief executive officerrobert chairman and presidentscott vice president chief financial officertimothy vice president chief human resource officerazita saleki gerhardt ph vice president operationsperry vice president general counsel and secretaryjeffrey vice president chief commercial officerthomas hudson vice president research development and chief scientific officerelaine vice president abbvie and president commercial operationscarrie vice president abbvie and president global allergan aestheticsbrian president controller_______________________________________________________________________________mr gonzalez is the chairman and chief executive officer of abbvie served abbott executive vice president of the pharmaceutical product group from july to december and wa responsible for abbott worldwide pharmaceutical business including commercial operation research and development and manufacturing he also served president abbott venture inc abbott medical technology investment arm from to mr gonzalez joined abbott in and held various management position he wa first appointed an abbvie corporate officer in december mr michael is abbvie vice chairman and president mr michael previously served vice chairman finance and commercial operation and chief financial officer from june to june executive vice president chief financial officer from to senior vice president chief financial officer from to and vice president controller from to he served abbvie vice president treasurer from to vice president controller commercial operation from to and vice president financial planning and analysis from to at abbott mr michael served division controller nutrition supply chain from to mr michael joined abbott in and wa first appointed an abbvie corporate officer in march mr reents is abbvie executive vice president chief financial officer he previously served senior vice president chief financial officer from june to november vice president tax and treasury from to june and vice president tax from to mr reents joined abbott in and wa first appointed an abbvie corporate officer in june mr richmond is abbvie executive vice president chief human resource officer he served senior vice president human resource from to mr richmond served abbott divisional vice president of compensation benefit from to group vice president of talent and reward from to and divisional vice president of talent acquisition from to mr richmond joined abbott in and wa first appointed an abbvie corporate officer in december dr saleki gerhardt is abbvie executive vice president operation served senior vice president operation from to dr saleki gerhardt served abbott vice president pharmaceutical manufacturing and supply from to and divisional vice president quality assurance global pharmaceutical operation from to dr saleki gerhardt joined abbott in and wa first appointed an abbvie corporate officer in december she serf on the board of entegris inc mr siatis is abbvie executive vice president general counsel and secretary mr siatis previously served senior vice president deputy general counsel from september until october from until mr siatis also served in various role including senior vice president legal and chief ethic and compliance officer senior vice president of legal transaction and alliance management and chief ethic and compliance officer and vice president biologic strategic development and legal regulatory mr siatis joined abbott in and wa first appointed an abbvie corporate officer in october mr stewart is abbvie executive vice president chief commercial officer he previously served senior vice president commercial operation from to and abbvie president commercial operation from to form prior to abbvie separation from abbott he served vice president abbott proprietary pharmaceutical division united state mr stewart joined abbott in and wa first appointed an abbvie corporate officer in december dr hudson is abbvie senior vice president research development and chief scientific officer he previously served vice president head of oncology discovery and early development from to prior to joining abbvie dr hudson served at the ontario institute for cancer research president and scientific director he also previously served founder and director of the mcgill university and genome quebec innovation centre and assistant director of the whitehead mit center for genome research dr hudson wa first appointed an abbvie corporate officer in july sorg is abbvie senior vice president abbvie and president commercial operation she previously served abbvie president immunology and patient service from to and vice president immunology and oncology from to she served vice president immunology prior to abbvie separation from abbott and until at abbvie sorg joined abbott in and wa first appointed an abbvie corporate officer in november prior to joining abbott sorg served in management role at eli lilly and company for year strom is abbvie senior vice president abbvie and president global allergan aesthetic responsible for the worldwide operation of the aesthetic franchise she wa appointed to the position upon abbvie acquisition of allergan in and wa first appointed an abbvie corporate officer in may at allergan strom previously served senior vice president medical aesthetic from to she joined allergan in mr durkin is abbvie vice president controller mr durkin previously served vice president internal audit from to prior to joining abbvie he served vice president of finance and division controller for abbott vision care business from to and controller pharmaceutical research and development from to mr durkin joined abbott in and wa first appointed an abbvie corporate officer in october the executive officer of abbvie are elected annually by the board of director all other officer are elected by the board or appointed by the chairman of the board all officer are either elected at the first meeting of the board of director held after the annual stockholder meeting or appointed by the chairman of the board after that board meeting each officer hold office until successor ha been duly elected or appointed and qualified or until the officer death resignation or removal there are no family relationship between any of the executive officer listed above form part iiitem market for registrant common equity related stockholder matter and issuer purchase of equity securitiesprincipal marketthe principal market for abbvie common stock is the new york stock exchange symbol abbv abbvie common stock is also listed on the chicago stock exchange and traded on various regional and electronic exchange stockholdersthere were stockholder of record of abbvie common stock of january performance graphthe following graph compare the cumulative total return of abbvie the index and the nyse arca pharmaceutical index for the period from december through december this graph assumes wa invested in abbvie common stock and each index on december and also assumes the reinvestment of dividend the stock price performance on the following graph is not necessarily indicative of future stock price performance this performance graph is furnished and shall not be deemed filed with the sec or subject to section of the security exchange act of nor shall it be deemed incorporated by reference in any of abbvie filing under the security act of amended form dividendson october abbvie board of director declared an increase in the quarterly cash dividend from per share to per share payable on february to stockholder of record of january the timing declaration amount of and payment of any dividend by abbvie in the future is within the discretion of it board of director and will depend upon many factor including abbvie financial condition earnings capital requirement of it operating subsidiary covenant associated with certain of abbvie debt service obligation legal requirement regulatory constraint industry practice ability to access capital market and other factor deemed relevant by it board of director moreover if abbvie determines to pay any dividend in the future there can be no assurance that it will continue to pay such dividend or the amount of such dividend issuer purchase of equity securitiesperiod totalnumberof share or unit purchasedaveragepricepaid per share or unit totalnumber ofshares or unit purchased partof publiclyannouncedplans orprogramsmaximum number orapproximate dollar value ofshares or unit that mayyet be purchased under theplans or programsoctober october november november december december in addition to abbvie share repurchased on the open market under publicly announced program if any these share also included the share purchased on the open market for the benefit of participant in the abbvie employee stock purchase plan in october in november and in december these share do not include the share surrendered to abbvie to satisfy minimum tax withholding obligation in connection with the vesting or exercise of stock based award form item reserved form item management discussion and analysis of financial condition and result of operationsthe following is discussion and analysis of the financial condition of abbvie inc abbvie or the company this commentary should be read in conjunction with the consolidated financial statement and accompanying note appearing in item financial statement and supplementary data this section of form generally discus and item and year to year comparison between and discussion of item and year to year comparison between and that are not included in this form can be found in management discussion and analysis of financial condition and result of operation in part ii item of the company annual report on form for the fiscal year ended december executive overviewcompany overviewabbvie is global diversified research based biopharmaceutical company positioned for success with comprehensive product portfolio that ha leadership position across immunology oncology aesthetic neuroscience and eye care abbvie us it expertise dedicated people and unique approach to innovation to develop and market advanced therapy that address some of the world most complex and serious disease abbvie product are generally sold worldwide directly to wholesaler distributor government agency health care facility specialty pharmacy and independent retailer from abbvie owned distribution center and public warehouse certain product including aesthetic product and device are also sold directly to physician and other licensed healthcare provider in the united state abbvie distributes pharmaceutical product principally through independent wholesale distributor with some sale directly to retailer pharmacy patient or other customer outside the united state abbvie sell product primarily to wholesaler or through distributor and depending on the market work through largely centralized national payer system to agree on reimbursement term certain product are co marketed or co promoted with other company abbvie operates single global business segment and ha approximately employee financial resultsabbvie strategy ha focused on delivering strong financial result maximizing the benefit of the allergan acquisition advancing and investing in it pipeline and returning value to shareholder while ensuring strong sustainable growth business over the long term the company financial performance in included delivering worldwide net revenue of billion operating earnings of billion diluted earnings per share of and cash flow from operation of billion worldwide net revenue increased by on reported basis and on constant currency basis reflecting growth across it immunology neuroscience and aesthetic portfolio diluted earnings per share in wa and included the following after tax cost billion related to the amortization of intangible asset ii billion for the change in fair value of contingent consideration liability iii billion for charge related to litigation matter iv million of acquisition and integration expense and million related to intangible asset impairment these cost were partially offset by an after tax gain of million related to the divestiture of pylera and benefit of million related to certain tax item additionally financial result reflected continued funding to support all stage of abbvie pipeline asset and continued investment in abbvie on market brand following the closing of the allergan acquisition in abbvie implemented an integration plan designed to reduce cost integrate and optimize the combined organization result of the successful execution of the integration plan abbvie realized billion of annual cost synergy in to achieve these integration objective abbvie incurred total cumulative charge of billion through these cost consisted of severance and employee benefit cost cash severance non cash severance including accelerated equity award compensation expense retention and other termination benefit and other integration expense form recent global eventsrussia ukrainein response to the military conflict between russia and ukraine the united state and other north atlantic treaty organization member state well certain non member state announced targeted economic sanction and export control on russia and belarus these include restriction on the export and transfer of product containing certain toxin including botox to russia and belarus however abbvie is not prohibited to continue the sale of essential pharmaceutical product to help ensure patient receive an uninterrupted supply of their medicine in march abbvie announced the suspension of operation for all aesthetic product in russia in april abbvie also announced that all profit from the sale of essential medicine in russia will be donated to support direct humanitarian relief effort in ukraine while the company operation in russia belarus and ukraine are not significant if the conflict escalates and result in broader economic and political concern abbvie business could be adversely impacted impact of the coronavirus disease covid in response to covid abbvie continues to closely manage manufacturing and supply chain resource around the world to help ensure that patient continue to receive an uninterrupted supply of their medicine clinical trial site are being monitored locally to protect the safety of study participant staff and employee while the impact of covid on abbvie operation to date ha not been material abbvie continues to experience lower new patient start in certain product and market abbvie expects this matter could continue to negatively impact it result of operation throughout the duration of the pandemic the extent to which covid may impact abbvie financial condition and result of operation remains uncertain and is dependent on numerous evolving factor including the measure being taken by authority to mitigate against the spread of covid the emergence of new variant and the effectiveness of vaccine and therapeutic strategic objectivesabbvie mission is to discover and develop innovative medicine and product that solve serious health issue today and address the medical challenge of tomorrow while achieving top tier financial performance through outstanding execution abbvie intends to execute it strategy and advance it mission in number of way including maximizing the benefit of diversified revenue base with multiple long term growth driver ii leveraging abbvie commercial strength and international infrastructure across therapeutic area and ensuring strong commercial execution of new product launch iii continuing to invest in and expand it pipeline in support of opportunity in immunology oncology aesthetic neuroscience and eye care well continued investment in key on market product iv generating substantial operating cash flow to support investment in innovative research and development and return cash to shareholder via strong and growing dividend while also reducing debt in addition abbvie anticipates several regulatory submission and data readout from key clinical trial in the next month abbvie expects to achieve it strategic objective through skyrizi and rinvoq revenue growth driven by increasing market share and indication expansion advancing our hematologic oncology portfolio by increasing venclexta market share and new indication strong commercial execution of new product launch and effectively managing market and competitive challenge impacting imbruvica continuing investment in the global expansion of aesthetic and increasing market penetration of botox and juvederm collection neuroscience revenue growth driven by vraylar botox therapeutic ubrelvy and qulipta maximizing abbvie existing eye care portfolio effectively managing the impact of humira biosimilar erosion the favorable impact of pipeline product and indication recently approved or currently under regulatory review where approval is expected in these product are described in greater detail in the section labeled research and development included part of this item form research and developmentresearch and innovation are the cornerstone of abbvie business global biopharmaceutical company abbvie long term success depends to great extent on it ability to continue to discover and develop innovative product and acquire or collaborate on compound currently in development by other biotechnology or pharmaceutical company abbvie pipeline currently includes over compound device or indication in development individually or under collaboration or license agreement and is focused on such important specialty immunology oncology aesthetic neuroscience and eye care of these program approximately are in mid and late stage development the following section summarize transition of significant program from mid stage development to late stage development well development in significant late stage and registration program abbvie expects multiple mid stage program to transition into late stage program in the next month significant program and developmentsimmunologyskyrizi in january abbvie announced that the food and drug administration fda approved skyrizi for the treatment of adult with active psoriatic arthritis in june abbvie announced that the fda approved skyrizi for the treatment of adult with moderately to severely active crohn disease in november abbvie announced that the european commission ec approved skyrizi for the treatment of adult with moderately to severely active crohn disease who have had inadequate response lost response or were intolerant to conventional or biologic therapy rinvoq in january abbvie announced that the fda approved rinvoq for the treatment of moderate to severe atopic dermatitis in adult and child year of age and older whose disease not respond to previous treatment and is not well controlled with other pill or injection including biologic medicine or when use of other pill or injection is not recommended in february abbvie announced top line result from it second phase induction study excel for rinvoq in patient with moderate to severe crohn disease who had an inadequate response or were intolerant to conventional or biologic therapy met the primary and most key secondary endpoint in march abbvie announced that the fda approved rinvoq for the treatment of adult with moderately to severely active ulcerative colitis uc who have had an inadequate response or intolerance to one or more tumor necrosis factor tnf blocker in april abbvie announced that the fda approved rinvoq for the treatment of adult with active ankylosing spondylitis who have had an inadequate response or intolerance to one or more tnf blocker in may abbvie announced positive top line result from endure phase maintenance study for rinvoq in adult patient with moderate to severe crohn disease who had an inadequate response or were intolerant to conventional or biologic therapy the result showed that more patient treated with rinvoq achieved the co primary and secondary endpoint at one year compared to placebo in july abbvie announced that the ec approved rinvoq for the treatment of adult with moderately to severely active uc who have had an inadequate response lost response or were intolerant to either conventional therapy or biologic agent in july abbvie announced it submission of supplemental new drug application snda to the fda and marketing authorization application maa to the ema for rinvoq for the treatment of adult patient with moderately to severely active crohn disease in july abbvie announced that the ec approved rinvoq for the treatment of adult patient with active non radiographic axial spondyloarthritis nr axspa form in october abbvie announced that the fda approved rinvoq for the treatment of adult with active nr axspa with objective sign of inflammation who have had an inadequate response or intolerance to tnf blocker therapy in november abbvie announced that the ema committee for medical product for human use chmp adopted an opinion following review of the benefit risk of medicine within the jak inhibitor class for the treatment of inflammatory disease including rinvoq confirming the recommendation from the pharmacovigilance risk assessment committee prac the chmp did not recommend change to the current rinvoq indication statement and recommended update to dosage and special warning for all jak inhibitor product indicated for the treatment of inflammatory disease these recommendation will be forwarded to the ec which is expected to issue final decision oncologyteliso in january abbvie announced that the fda granted breakthrough therapy designation to investigational telisotuzumab vedotin teliso for the treatment of patient with advanced metastatic epidermal growth factor receptor wild type nonsquamous non small cell lung cancer with high level of met overexpression whose disease ha progressed on or after platinum based therapy in may abbvie initiated phase clinical trial to evaluate teliso versus docetaxel for the treatment of patient with previously treated met overexpressing epidermal growth factor receptor wild type advanced metastatic non squamous non small cell lung cancer epcoritamab in march genmab genmab announced that the fda granted orphan drug designation to the investigational medicine epcoritamab duobody for the treatment of follicular lymphoma genmab and abbvie are co developing epcoritamab and will share commercial responsibility in the and japan with abbvie responsible for further global commercialization in june abbvie and genmab announced primary result from the large cell lymphoma expansion cohort in the epcore nhl phase clinical trial evaluating epcoritamab an investigational subcutaneous bispecific antibody in this study epcoritamab demonstrated efficacy with durable response in patient who had previously received at least two prior line of anti lymphoma therapy including chimeric antigen receptor cell therapy in september abbvie and genmab submitted biological license application bla to the fda for epcoritamab for the treatment of patient with relapsed refractory large cell lymphoma in october abbvie and genmab submitted an maa to the ema for epcoritamab for the treatment of patient with relapsed refractory diffuse large cell lymphoma in october abbvie initiated phase clinical trial to evaluate epcoritamab in combination with rituximab and lenalidomide compared to rituximab and lenalidomide in patient with relapsed or refractory follicular lymphoma in november abbvie announced that the fda ha accepted for priority review the bla for epcoritamab for the treatment of relapsed refractory large cell lymphoma imbruvica in august abbvie announced that the fda approved the use of imbruvica for the treatment of pediatric patient one year and older with chronic graft versus host disease after failure of one or more line of systemic therapy in august the national comprehensive cancer network nccn in the united state issued updated guideline for the management of chronic lymphocytic leukemia cll re categorizing imbruvica from preferred regimen to other recommended regimen form aestheticsjuvederm collection in february abbvie announced that the fda approved juvederm volbella xc for improvement of infraorbital hollow in adult over the age of in august abbvie announced that the fda approved juvederm volux xc for the improvement of jawline definition in adult over the age of with moderate to severe loss of jawline definition bonte in march abbvie initiated three phase clinical trial to evaluate the efficacy and safety of bonte agn for the treatment of glabellar line neurosciencevraylar in december abbvie announced that the fda approved vraylar an adjunctive therapy to antidepressant for the treatment of major depressive disorder in adult qulipta in march abbvie announced result from the phase progress trial for qulipta in the preventive treatment of chronic migraine in adult met the primary endpoint and resulted in significant improvement in all secondary endpoint after adjustment for multiple comparison in june abbvie submitted an snda to the fda for qulipta for the preventative treatment of chronic migraine in adult in july abbvie submitted an maa to the ema for qulipta for the prophylactic treatment of migraine in adult patient who have at least four migraine day per month abbv in may abbvie submitted new drug application to the fda for abbv foscarbidopa foslevodopa for the treatment of motor fluctuation in patient with advanced parkinson disease form result of operationsnet revenuesthe comparison presented at constant currency rate reflect comparative local currency net revenue at the prior year foreign exchange rate this measure provides information on the change in net revenue assuming that foreign currency exchange rate had not changed between the prior and current period abbvie belief that the non gaap measure of change in net revenue at constant currency rate when used in conjunction with the gaap measure of change in net revenue at actual currency rate may provide more complete understanding of the company operation and can facilitate analysis of the company result of operation particularly in evaluating performance from one period to another percent changeat actual currency ratesat constant currency ratesyears ended dollar in million state net revenue form the following table detail abbvie worldwide net revenue percent changeat actual currency ratesat constant currency ratesyears ended december dollar in million state total skyriziunited state total rinvoqunited state total hematologic oncologyimbruvicaunited state collaboration total venclextaunited state total aestheticsbotox cosmetic united state total juvederm collection united state total other aesthetic united state total neurosciencebotox therapeutic united state total vraylar united state mn mn mn mtotal duodopaunited state total ubrelvy united state quliptaunited state mother neuroscience united state total form percent changeat actual currency ratesat constant currency ratesyears ended december dollar in million carelumigan ganfort united state total alphagan combigan united state total restasis united state total other eye care united state total other key productsmavyretunited state total creonunited state linz constella united state total all other total net revenue not meaningful net revenue include allergan product revenue after the acquisition closing date of may the following discussion and analysis of abbvie net revenue by product is presented on constant currency basis global humira sale increased in primarily driven by market growth across therapeutic category partially offset by direct biosimilar competition in international market in the united state humira sale increased in primarily driven by market growth across all indication and favorable pricing this increase wa partially offset by lower market share following the corresponding market share gain of skyrizi and rinvoq internationally humira revenue decreased in primarily driven by direct biosimilar competition on january humira lost exclusivity in the united state following this loss of exclusivity abbvie expects direct biosimilar competition and humira net revenue to decline in the united state abbvie continues to pursue strategy to maintain broad formulary access of humira and manage the impact of biosimilar erosion net revenue for skyrizi increased in primarily driven by continued strong volume and market share uptake since launch treatment for plaque psoriasis well market growth net revenue were also favorably impacted by recent regulatory approval and expansion of skyrizi for the treatment of psoriatic arthritis and crohn disease net revenue for rinvoq increased in primarily driven by continued strong volume and market share uptake since launch for the treatment of moderate to severe rheumatoid arthritis well market growth net revenue were also favorably impacted by recent regulatory approval and expansion of rinvoq for the treatment of psoriatic arthritis atopic dermatitis ankylosing spondylitis ulcerative colitis and non radiographic axial spondyloarthritis net revenue for imbruvica represent product revenue in the united state and collaboration revenue outside of the united state related to abbvie share of imbruvica profit abbvie global imbruvica revenue decreased in result of decreased market demand and lower market share in the united state the decrease in net revenue wa also partially offset by increased collaboration revenue net revenue for venclexta increased in primarily due to continued expansion of venclexta for the treatment of patient with cll and acute myeloid leukemia form net revenue for botox cosmetic increased in due to sustained consumer demand in the united state which wa moderated in the second half of the year by economic pressure impacting consumer discretionary spending and increased investment in key international market net revenue for juvederm collection decreased in due to economic pressure impacting consumer discretionary spending and increased pricing promotion to support the market international net revenue increased by due to increased investment in key market partially offset by the suspension of aesthetic operation in russia and the impact of covid in china net revenue for botox therapeutic increased in due to market growth net revenue for vraylar increased in due to higher market share and market growth net revenue for ubrelvy increased in primarily due to increased market share uptake since launch partially offset by unfavorable pricing net revenue for qulipta increased greater than in due to strong volume and market share uptake since launch for the preventative treatment of episodic migraine in adult net revenue for mavyret decreased in due to the continued disruption of global hepatitis virus market due to the covid pandemic gross marginpercent changeyears ended december dollar in million margin percent of net gross margin percentage of net revenue in increased compared to gross margin percentage for wa favorably impacted by change in product mix partially offset by an intangible asset impairment charge of million selling general and administrativepercent changeyears ended december dollar in million general and administrative percent of net selling general and administrative sg expense percentage of net revenue increased in compared to the prior year primarily due to the unfavorable impact of litigation reserve charge of billion partially offset by leverage from revenue growth and increased synergy realized research and development and acquired ipr and milestonespercent changeyears ended december dollar in million and development percent of net acquired ipr and milestone expense percentage of net revenue decreased in compared to expense percentage for wa favorably impacted by increased scale of the combined company and synergy realized the purchase of priority review voucher from third party in the prior year well lower integration cost related to the acquisition of allergan acquired ipr and milestone expense represents upfront and subsequent development milestone payment incurred prior to regulatory approval to acquire right to in process project through collaboration licensing arrangement or other asset acquisition acquired ipr and milestone expense in included charge of million related to acquiring syndesi therapeutic sa charge related to other upfront payment totaling million and development milestone of million acquired ipr and milestone expense in included charge of million related to exercising the company exclusive right to acquire teneoone charge of million related to collaboration form agreement with regenxbio inc charge related to other upfront payment totaling million and development milestone of million see note to the consolidated financial statement for additional information other operating expense netother operating expense net in included one time charge of million related to an asset divested part of the allergan acquisition partially offset by million of income related to the sale of worldwide commercial right of mature brand pylera other operating expense net in included million charge related to the extension of the calico life science llc collaboration see note to the consolidated financial statement for additional information other non operating expensesyears ended december in million expense interest income interest expense net net foreign exchange loss other expense interest expense in decreased compared to primarily due to lower average debt balance result of deleveraging partially offset by the impact of higher interest rate interest income in increased compared to primarily due to the impact of higher interest rate other expense net included charge related to change in fair value of contingent consideration liability of billion in and billion in the fair value of contingent consideration liability is impacted by the passage of time and multiple other input including the probability of success of achieving regulatory commercial milestone discount rate the estimated amount of future sale of the acquired product and other market based factor in the change in fair value reflected higher estimated skyrizi sale driven by stronger market share uptake and the passage of time partially offset by higher discount rate in the change in fair value reflected higher estimated skyrizi sale driven by stronger market share uptake favorable clinical trial result and the passage of time partially offset by higher discount rate income tax expensethe effective income tax rate wa in in and negative in the effective income tax rate differed from the statutory tax rate of principally due to the impact of foreign operation which reflects the impact of lower income tax rate in location outside the united state tax incentive in puerto rico and other foreign tax jurisdiction business development activity and change in fair value of contingent consideration the effective tax rate for these period also reflected the benefit from tax credit principally related to research and development credit the orphan drug tax credit and puerto rico excise tax credit the puerto rico tax credit relate to excise tax on certain product manufactured in puerto rico the tax is levied on gross inventory purchase from entity in puerto rico and is included in cost of product sold in the consolidated statement of earnings the majority of the tax is creditable for income tax purpose in puerto rico enacted act the puerto rico act allowing for transition from puerto rico excise tax levied on gross inventory purchase to an income based tax beginning in the company completed the transition requirement of the puerto rico act in resulting in the remeasurement of certain deferred tax asset and liability based on income tax rate at which they are expected to reverse in the future the net tax benefit from the remeasurement of deferred tax related to the puerto rico act wa million financial position liquidity and capital resource year ended december in million flow provided by used in operating activity investing activity financing activity operating cash flow in increased from primarily due to improved result of operation resulting from revenue growth and lower income tax payment partially offset by the timing of working capital operating cash flow also reflected abbvie contribution to it defined benefit plan of million in and million in form investing cash flow in included payment made for capital expenditure of million other acquisition and investment of million million cash consideration paid to acquire dj antibody ltd offset by cash acquired and net sale and maturity of investment security totaling million investment cash flow in included million cash consideration paid to acquire soliton inc offset by cash acquired payment made for other acquisition and investment of billion capital expenditure of million and net purchase of investment security totaling million financing cash flow in included repayment of billion aggregate principal amount of the company senior note billion aggregate principal amount of the company senior note billion aggregate principal amount of the company senior note billion aggregate principal amount of the company senior note billion aggregate principal amount of the company senior note and million aggregate principal amount of the company floating rate senior note additionally financing cash flow included repayment of billion floating term loan due may and issuance of new billion floating rate term loan part of the term loan refinancing in february subsequent to december the company repaid billion floating rate three year term loan that wa scheduled to mature in may financing cash flow in included early repayment of billion aggregate principal amount of the company principal note billion aggregate principal amount of the company senior note and million aggregate principal amount of the company senior euro note financing cash flow also included repayment of million aggregate principal amount of floating rate senior note billion aggregate principal amount of senior note billion aggregate principal amount of senior note and million aggregate principal amount of floating rate senior note at maturity additionally financing cash flow included repayment of billion floating rate term loan due may and issuance of new billion floating rate term loan part of the term loan refinancing in september financing cash flow also included cash dividend payment of billion in and billion in the increase in cash dividend payment wa primarily driven by an increase of the dividend rate the company stock repurchase authorization permit purchase of abbvie share from time to time in open market or private transaction at management discretion the program ha no time limit and can be discontinued at any time abbvie repurchased million share for billion in and million share for million in abbvie remaining stock repurchase authorization wa billion of december on february abbvie board of director authorized billion increase to the existing stock repurchase authorization no commercial paper borrowing were issued during or and there were no commercial paper borrowing outstanding of december or december abbvie may issue additional commercial paper or retire commercial paper to meet liquidity requirement needed credit riskabbvie monitor economic condition the creditworthiness of customer and government regulation and funding both domestically and abroad abbvie regularly communicates with it customer regarding the status of receivable balance including their payment plan and obtains positive confirmation of the validity of the receivables abbvie establishes an allowance for credit loss equal to the estimate of future loss over the contractual life of outstanding account receivable abbvie may also utilize factoring arrangement to mitigate credit risk although the receivables included in such arrangement have historically not been significant amount of total outstanding receivables credit facility access to capital and credit ratingscredit facilityabbvie currently ha billion five year revolving credit facility that matures in august this credit facility enables the company to borrow fund on an unsecured basis at variable interest rate and contains various covenant at december the company wa in compliance with all covenant and commitment fee under the credit facility were insignificant no amount were outstanding under the company credit facility of december and december form access to capitalthe company intends to fund short term and long term financial obligation they mature through cash on hand future cash flow from operation or ha the ability to issue additional debt the company ability to generate cash flow from operation issue debt or enter into financing arrangement on acceptable term could be adversely affected if there is material decline in the demand for the company product or in the solvency of it customer or supplier deterioration in the company key financial ratio or credit rating or other material unfavorable change in business condition at the current time the company belief it ha sufficient financial flexibility to issue debt enter into other financing arrangement and attract long term capital on acceptable term to support the company growth objective credit ratingsin moody investor service upgraded abbvie senior unsecured long term credit rating to from affirmed it prime short term credit rating and revised it outlook to positive from stable in addition standard and poor global rating revised it outlook to positive from stable and affirmed it long term issuer credit rating of bbb unfavorable change to the rating may have an adverse impact on future financing arrangement however they would not affect the company ability to draw on it credit facility and would not result in an acceleration of scheduled maturity of any of the company outstanding debt future cash requirementscontractual obligationsthe following table summarizes abbvie estimated material contractual obligation of december in million totalcurrentlong termlong term debt including current portion interest on long term debt contingent consideration liability includes estimated future interest payment on long term debt interest payment on debt are calculated for future period using forecasted interest rate in effect at the end of projected interest payment include the related effect of interest rate swap agreement certain of these projected interest payment may differ in the future based on change in floating interest rate or other factor or event the projected interest payment only pertain to obligation and agreement outstanding at december see note to the consolidated financial statement for additional information regarding the company debt instrument and note for additional information on the interest rate swap agreement outstanding at december includes contingent consideration liability which are recorded at fair value on the consolidated balance sheet potential contingent consideration payment that exceed the fair value recorded on the consolidated balance sheet are not included in the table of contractual obligation see note to the consolidated financial statement for additional information regarding these liability abbvie enters into certain unconditional purchase obligation and other commitment in the normal course of business there have been no change to these commitment that would have material impact on the company ability to meet either short term or long term future cash requirement income taxesfuture income tax cash requirement include one time transition tax liability on mandatory deemed repatriation of previously untaxed earnings of foreign subsidiary resulting from tax reform enacted in the one time transition tax liability wa billion of december and is payable in four future annual installment liability for unrecognized tax benefit totaled billion of december it is not possible to reliably estimate the timing of the future cash outflow related to these liability see note to the consolidated financial statement for additional information on these unrecognized tax benefit quarterly cash dividendon october abbvie announced that it board of director declared an increase in the quarterly cash dividend from per share to per share beginning with the dividend payable on february to stockholder of record of january this reflects an increase of approximately over the previous quarterly rate the timing form declaration amount of and payment of any dividend by abbvie in the future is within the discretion of it board of director and will depend upon many factor including abbvie financial condition earnings capital requirement of it operating subsidiary covenant associated with certain of abbvie debt service obligation legal requirement regulatory constraint industry practice ability to access capital market and other factor deemed relevant by it board of director collaboration licensing and other arrangementsabbvie enters into collaborative licensing and other arrangement with third party that may require future milestone payment to third party contingent upon the achievement of certain development regulatory or commercial milestone individually these arrangement are insignificant in any one annual reporting period however if milestone for multiple product covered by these arrangement happen to be reached in the same reporting period the aggregate charge to expense could be material to the result of operation in that period from business perspective the payment are viewed positive because they signify that the product is successfully moving through development and is now generating or is more likely to generate future cash flow from product sale it is not possible to predict with reasonable certainty whether these milestone will be achieved or the timing for achievement see note to the consolidated financial statement for additional information on these collaboration arrangement critical accounting policy and estimatesthe preparation of financial statement in accordance with generally accepted accounting principle in the united state requires the use of estimate and assumption that affect the reported amount of asset and liability and the reported amount of revenue and expense summary of the company significant accounting policy is included in note to the consolidated financial statement certain of these policy are considered critical these most significantly impact the company financial condition and result of operation and require the most difficult subjective or complex judgment often result of the need to make estimate about the effect of matter that are inherently uncertain actual result may vary from these estimate revenue recognitionabbvie recognizes revenue when control of promised good or service is transferred to the company customer in an amount that reflects the consideration abbvie expects to be entitled to in exchange for those good or service sale value add and other tax collected concurrent with revenue producing activity are excluded from revenue abbvie generates revenue primarily from product sale for the majority of sale the company transfer control invoice the customer and recognizes revenue upon shipment to the customer rebate abbvie provides rebate to pharmacy benefit manager state government medicaid program insurance company that administer medicare drug plan wholesaler group purchasing organization and other government agency and private entity rebate and chargeback accrual are accounted for variable consideration and are recorded reduction to revenue in the period the related product is sold provision for rebate and chargebacks totaled billion in billion in and billion in rebate amount are typically based upon the volume of purchase using contractual or statutory price which may vary by product and by payer for each type of rebate the factor used in the calculation of the accrual for that rebate include the identification of the product subject to the rebate the applicable price term and the estimated lag time between sale and payment of the rebate which can be significant in order to establish it rebate and chargeback accrual the company us both internal and external data to estimate the level of inventory in the distribution channel and the rebate claim processing lag time for each type of rebate to estimate the rebate percentage or net price the company track sale by product and by customer or payer the company evaluates inventory data reported by wholesaler available prescription volume information product pricing historical experience and other factor in order to determine the adequacy of it reserve abbvie regularly monitor it reserve and record adjustment when rebate trend rebate program and contract term legislative change or other significant event indicate that change in the reserve is appropriate historically adjustment to rebate accrual have not been material to net earnings form the following table is an analysis of the three largest accrual for rebate and chargebacks which comprise approximately of the total consolidated rebate and chargebacks recorded reduction to revenue in remaining rebate provision charged against gross revenue are not significant in the determination of operating earnings in million medicaid and medicare rebatesmanaged care rebateswholesalerchargebacksbalance at december addition payment balance at december payment balance at december payment balance at december represents rebate accrual and chargeback allowance assumed in the allergan acquisition other allowancesother allowance include cash discount product return sale incentive and other adjustment which are accounted for variable consideration and are recorded reduction to revenue in the same period the related product is sold reserve for cash discount and sale incentive are readily determinable because the company experience of payment history is fairly consistent product return can be reliably estimated based on the company historical return experience cash discount totaled billion in billion in and billion in allowance other than cash discount are not significant pension and other post employment benefitsabbvie engages outside actuary to assist in the determination of the obligation and cost under the pension and other post employment benefit plan that are direct obligation of abbvie the valuation of the funded status and the net periodic benefit cost for these plan are calculated using actuarial assumption the significant assumption which are reviewed annually include the discount rate the expected long term rate of return on plan asset and the health care cost trend rate and are disclosed in note to the consolidated financial statement the discount rate is selected based on current market rate on high quality fixed income investment at december each year abbvie employ yield curve approach for country where robust bond market exists the yield curve is developed using high quality bond the yield curve approach reflects the plan specific cash flow duration in calculating the benefit obligation by applying the corresponding individual spot rate along the yield curve abbvie reflects the plan specific cash flow and applies them to the corresponding individual spot rate along the yield curve in calculating the service cost and interest cost portion of expense for other country abbvie review various index such corporate bond and government bond benchmark to estimate the discount rate form abbvie assumed discount rate have significant effect on the amount reported for defined benefit pension and other post employment plan of december basis point change in the assumed discount rate would have had the following effect on abbvie calculation of net periodic benefit cost in and projected benefit obligation of december basis point in million bracket denote reduction increasedecreasedefined benefit plansnet periodic benefit cost projected benefit obligation other post employment plansnet periodic benefit cost projected benefit obligation the expected long term rate of return is based on the asset allocation historical performance and the current view of expected future return abbvie considers these input with long term focus to avoid short term market influence the current long term rate of return on plan asset for each plan is supported by the historical performance of the trust actual and target asset allocation abbvie assumed expected long term rate of return ha significant effect on the amount reported for defined benefit pension plan of december and will be used in the calculation of net periodic benefit cost in one percentage point change in assumed expected long term rate of return on plan asset would increase or decrease the net period benefit cost of these plan in by million the health care cost trend rate is selected by reviewing historical trend and current view on projected future health care cost increase the current health care cost trend rate is supported by the historical trend experience of each plan assumed health care cost trend rate have significant effect on the amount reported for health care plan of december and will be used in the calculation of net periodic benefit cost in income taxesabbvie account for income tax under the asset and liability method provision for federal state and foreign income tax are calculated on reported pre tax earnings based on current tax law deferred tax are provided using enacted tax rate on the future tax consequence of temporary difference which are the difference between the financial statement carrying amount of asset and liability and their respective tax base and the tax benefit of carryforwards valuation allowance is established or maintained when based on currently available information it is more likely than not that all or portion of deferred tax asset will not be realized litigationthe company is subject to contingency such various claim legal proceeding and investigation regarding product liability intellectual property commercial security and other matter that arise in the normal course of business see note to the consolidated financial statement for additional information loss contingency provision are recorded for probable loss at management best estimate of loss or when best estimate can not be made minimum loss contingency amount within probable range is recorded accordingly abbvie is often initially unable to develop best estimate of loss and therefore the minimum amount which could be zero is recorded information becomes known either the minimum loss amount is increased resulting in additional loss provision or best estimate can be made also resulting in additional loss provision occasionally best estimate amount is changed to lower amount when event result in an expectation of more favorable outcome than previously expected valuation of goodwill and intangible assetsabbvie ha acquired and may continue to acquire significant intangible asset in connection with business combination that abbvie record at fair value transaction involving the purchase or sale of intangible asset occur between company in the pharmaceutical industry and valuation are usually based on discounted cash flow analysis incorporating the stage of completion the discounted cash flow model requires assumption about the timing and amount of future net cash flow risk cost of capital terminal value and market participant each of these factor can significantly affect the value of the intangible asset in process research and development ipr acquired in business combination is capitalized an indefinite lived intangible asset until regulatory approval is obtained at which time it is accounted for definite lived asset and amortized over it estimated useful life or discontinuation at which point the intangible asset will be written off ipr acquired in transaction that are not business combination is expensed immediately unless deemed to have an alternative form future use payment made to third party subsequent to regulatory approval are capitalized and amortized over the remaining useful life abbvie review the recoverability of definite lived intangible asset whenever event or change in circumstance indicate the carrying value of an asset may not be recoverable goodwill and indefinite lived intangible asset are reviewed for impairment annually or when an event occurs that could result in an impairment see note to the consolidated financial statement for additional information annually the company test it goodwill for impairment by first assessing qualitative factor to determine whether it is more likely than not that the fair value is le than it carrying amount some of the factor considered in the assessment include general macro economic condition condition specific to the industry and market cost factor the overall financial performance and whether there have been sustained decline in the company share price if the company concludes it is more likely than not that the fair value of the reporting unit is le than it carrying amount quantitative impairment test is performed abbvie test indefinite lived intangible asset for impairment by first assessing qualitative factor to determine whether it is more likely than not that the fair value is le than it carrying amount if the company concludes it is more likely than not that the fair value is le than it carrying amount quantitative impairment test is performed for it quantitative impairment test the company us an estimated future cash flow approach that requires significant judgment with respect to future volume revenue and expense growth rate change in working capital use the selection of an appropriate discount rate asset grouping and other assumption and estimate the estimate and assumption used are consistent with the company business plan and market participant view the use of alternative estimate and assumption could increase or decrease projected cash flow and the estimated fair value of the related intangible asset future change to these estimate and assumption could have material impact on the company result of operation actual result may differ from the company estimate contingent considerationthe fair value measurement of contingent consideration liability are determined of the acquisition date based on significant unobservable input including the discount rate estimated probability and timing of achieving specified development regulatory and commercial milestone and the estimated amount of future sale of the acquired product contingent consideration liability are revalued to fair value at each subsequent reporting date until the related contingency is resolved the potential contingent consideration payment are estimated by applying probability weighted expected payment model for contingent milestone payment and monte carlo simulation model for contingent royalty payment which are then discounted to present value change to the fair value of the contingent consideration liability can result from change to one or number of input including discount rate the probability of achieving the milestone the time required to achieve the milestone and estimated future sale significant judgment is employed in determining the appropriateness of certain of these input which are disclosed in note to the consolidated financial statement change to the input described above could have material impact on the company financial position and result of operation in any given period form item quantitative and qualitative disclosure about market riskthe company is exposed to risk that it earnings cash flow and equity could be adversely impacted by change in foreign exchange rate and interest rate certain derivative instrument are used when available on cost effective basis to hedge the company underlying economic exposure see note to the consolidated financial statement for additional information regarding the company financial instrument and hedging strategy foreign currency riskabbvie primary net foreign currency exposure are the euro japanese yen canadian dollar chinese yuan and british pound the following table reflects the total foreign currency forward exchange contract outstanding at december and of december in million contract amountweighted average exchange ratefair and carrying value receivable payable contract amountweighted average exchange ratefair and carrying value receivable payable receive primarily dollar in exchange for the following currency euro canadian british chinese japanese all other total the company estimate that appreciation in the underlying currency being hedged from their level against the dollar with all other variable held constant would decrease the fair value of foreign exchange forward contract by billion at december if realized this appreciation would negatively affect earnings over the remaining life of the contract however gain and loss on the hedging instrument offset loss and gain on the hedged transaction and reduce the earnings and stockholder equity volatility relating to foreign exchange appreciation is believed to be reasonably possible near term change in foreign currency of december the company ha billion aggregate principal amount of unsecured senior euro note outstanding which are exposed to foreign currency risk the company designated these foreign currency denominated note hedge of it net investment in certain foreign subsidiary and affiliate result any foreign currency translation gain or loss related to the euro note will be included in accumulated other comprehensive loss see note to the consolidated financial statement for additional information regarding the senior euro note and note to the consolidated financial statement for additional information regarding the net investment hedging program interest rate riskthe company estimate that an increase in interest rate of basis point would adversely impact the fair value of abbvie interest rate swap contract by approximately million at december if realized the fair value reduction would affect earnings over the remaining life of the contract the company estimate that an increase of basis point in long term interest rate would decrease the fair value of long term debt by billion at december basis point change is believed to be reasonably possible near term change in interest rate form item financial statement and supplementary data pageconsolidated financial statement consolidated statement of statement of comprehensive balance statement of statement of cash to consolidated financial statementsnote of significant accounting financial per acquisition and other and intangible and restructuring credit facility and commitment and instrument and fair value employment proceeding and and geographic area quarter financial result unaudited of independent registered public accounting firm pcaob id form abbvie inc and subsidiariesconsolidated statement of earningsyears ended december in million except per share data revenue cost of product selling general and research and acquired ipr and other operating expense total operating cost and operating interest expense net foreign exchange other expense earnings before income tax income tax expense benefit net net earnings attributable to noncontrolling net earnings attributable to abbvie inc per share databasic earnings per share attributable to abbvie inc diluted earnings per share attributable to abbvie inc weighted average basic share weighted average diluted share the accompanying note are an integral part of these consolidated financial statement form abbvie inc and subsidiariesconsolidated statement of comprehensive incomeyears ended december in million earnings foreign currency translation adjustment net of tax expense benefit of in in and in net investment hedging activity net of tax expense benefit of in in and in pension and post employment benefit net of tax expense benefit of in in and in cash flow hedging activity net of tax expense benefit of in in and in other comprehensive income comprehensive comprehensive income attributable to noncontrolling comprehensive income attributable to abbvie inc the accompanying note are an integral part of these consolidated financial statement form abbvie inc and subsidiariesconsolidated balance sheet of december in million except share data assetscash and equivalent short term account receivable prepaid expense and total current property and equipment intangible asset other total asset liability and equitycurrent liabilitiesshort term borrowing current portion of long term debt and finance lease account payable and accrued total current long term debt and finance lease deferred income other long term commitment and contingenciesstockholders equity common stock par value share authorized share issued of december and of december common stock held in treasury at cost share of december and of december additional paid in retained accumulated other comprehensive loss total stockholder noncontrolling total total liability and equity the accompanying note are an integral part of these consolidated financial statement form abbvie inc and subsidiariesconsolidated statement of equityyears ended december in million common share outstandingcommon stocktreasury stockadditional paid in capitalretained earningsaccumulated other comprehensive lossnoncontrolling interesttotalbalance at december net earnings attributable to abbvie inc other comprehensive income net of tax dividend declared common share and equity award issued for acquisition of allergan purchase of treasury stock stock based compensation plan and change in noncontrolling interest balance at december net earnings attributable to abbvie inc other comprehensive income net of tax dividend declared purchase of treasury stock stock based compensation plan and change in noncontrolling interest balance at december net earnings attributable to abbvie inc other comprehensive income net of tax dividend declared purchase of treasury stock stock based compensation plan and change in noncontrolling interest balance at december the accompanying note are an integral part of these consolidated financial statement form abbvie inc and subsidiariesconsolidated statement of cash flow year ended december in million bracket denote cash outflow flow from operating activitiesnet earnings adjustment to reconcile net earnings to net cash from operating activity amortization of intangible deferred income tax change in fair value of contingent consideration stock based acquired ipr and other charge related to collaboration gain on divestiture non cash litigation reserve adjustment net of cash impairment of intangible other net change in operating asset and liability net of acquisition account receivable inventory prepaid expense and other asset account payable and other income tax asset and liability cash flow from operating cash flow from investing activitiesacquisition of business net of cash acquired other acquisition and investment acquisition of property and equipment purchase of investment security sale and maturity of investment other cash flow from investing activity cash flow from financing activitiesproceeds from issuance of long term repayment of long term debt and finance lease obligation debt issuance cost dividend paid purchase of treasury stock proceeds from the exercise of stock payment of contingent consideration liability other cash flow from financing activity effect of exchange rate change on cash and equivalent net change in cash and equivalent cash and equivalent beginning of cash and equivalent end of year other supplemental informationinterest paid net of portion capitalized income tax supplemental schedule of non cash investing and financing activitiesissuance of common share associated with acquisition of business the accompanying note are an integral part of these consolidated financial statement form abbvie inc and subsidiariesnotes to consolidated financial statementsnote background backgroundthe principal business of abbvie inc abbvie or the company is the discovery development manufacturing and sale of broad line of therapy that address some of the world most complex and serious disease abbvie product are generally sold worldwide directly to wholesaler distributor government agency health care facility specialty pharmacy and independent retailer from abbvie owned distribution center and public warehouse certain product including aesthetic product and device are also sold directly to physician and other licensed healthcare provider in the united state abbvie distributes pharmaceutical product principally through independent wholesale distributor with some sale directly to retailer pharmacy patient or other customer outside the united state abbvie sell product primarily to wholesaler or through distributor and depending on the market work through largely centralized national payer system to agree on reimbursement term abbvie wa incorporated in delaware on april on january abbvie became an independent publicly traded company result of the distribution by abbott laboratory abbott of of the outstanding common stock of abbvie to abbott shareholder on may abbvie completed it acquisition of allergan plc allergan refer to note for additional information regarding this acquisition note summary of significant accounting policy use of estimatesthe consolidated financial statement have been prepared in accordance with generally accepted accounting principle gaap and necessarily include amount based on estimate and assumption by management actual result could differ from those amount significant estimate include amount for rebate pension and other post employment benefit income tax litigation valuation of goodwill and intangible asset contingent consideration liability financial instrument and inventory and account receivable exposure basis of consolidationthe consolidated financial statement include the account of abbvie and all of it subsidiary in which controlling interest is maintained controlling interest is determined by majority ownership interest and the absence of substantive third party participating right or in the case of variable interest entity where abbvie is determined to be the primary beneficiary investment in company over which abbvie ha significant influence but not controlling interest are accounted for using the equity method with abbvie share of earnings or loss reported in other expense net in the consolidated statement of earnings intercompany balance and transaction are eliminated during abbvie revised it classification of development milestone expense associated with licensing and collaboration arrangement in the consolidated statement of earnings milestone payment incurred prior to regulatory approval which were previously included in research and development expense are now presented acquired ipr and milestone expense in the consolidated statement of earnings the reclassification decreased expense and increased acquired ipr and milestone expense by million in and million in the company belief this presentation assist user of the financial statement to better understand the total upfront and subsequent development milestone payment incurred to acquire in process research and development project prior period have been reclassified to conform to the current period presentation certain other reclassification have been made to conform the prior period consolidated financial statement to the current period presentation revenue recognitionabbvie recognizes revenue when control of promised good or service is transferred to the company customer in an amount that reflects the consideration abbvie expects to be entitled to in exchange for those good or service sale value add and other tax collected concurrent with revenue producing activity are excluded from revenue abbvie generates revenue primarily from product sale for the majority of sale the company transfer control invoice the customer and recognizes revenue upon shipment to the customer the company recognizes shipping and handling cost an form expense in cost of product sold when the company transfer control to the customer payment term vary depending on the type and location of the customer are based on customary commercial term and are generally le than one year abbvie doe not adjust revenue for the effect of significant financing component for contract where abbvie expects the period between the transfer of the good or service and collection to be one year or le cash discount rebate and chargebacks sale incentive product return and certain other adjustment are accounted for variable consideration provision for variable consideration are based on current pricing executed contract government pricing legislation and historical data and are provided for in the period the related revenue are recorded rebate amount are typically based upon the volume of purchase using contractual or statutory price which may vary by product and by payer for each type of rebate factor used in the calculation of the accrual include the identification of the product subject to the rebate the applicable price term and the estimated lag time between sale and payment of the rebate which can be significant in addition to revenue from contract with customer the company also recognizes certain collaboration revenue see note for additional information related to the collaboration with janssen biotech inc and genentech inc additionally see note for disaggregation of revenue by product and geography research and development expensesinternal cost are expensed incurred clinical trial cost incurred by third party are expensed the contracted work is performed acquired ipr and milestone expense in an asset acquisition payment incurred prior to regulatory approval to acquire right to in process project are expensed acquired ipr and milestone expense in the consolidated statement of earnings unless the project ha an alternative future use these cost include upfront and development milestone payment related to collaboration licensing arrangement or other asset acquisition that provide right to develop manufacture and or sell pharmaceutical product where contingent development milestone payment are due to third party prior to regulatory approval the payment obligation are expensed when the milestone result are achieved regulatory and commercial milestone payment made to third party subsequent to regulatory approval are capitalized intangible asset and amortized to cost of product sold over the remaining useful life of the related product business combinationsabbvie utilizes the acquisition method of accounting for business combination this method requires among other thing that result of operation of acquired company are included in abbvie result of operation beginning on the acquisition date and that asset acquired and liability assumed are recognized at fair value of the acquisition date any excess of the fair value of consideration transferred over the fair value of the net asset acquired is recognized goodwill contingent consideration liability are recognized at the estimated fair value on the acquisition date subsequent change to the fair value of contingent consideration liability are recognized in other expense net in the consolidated statement of earnings the fair value of asset acquired and liability assumed in certain case may be subject to revision based on the final determination of fair value during period of time not to exceed month from the acquisition date legal cost due diligence cost business valuation cost and all other business acquisition cost are expensed when incurred in business combination the fair value of ipr project acquired is capitalized and accounted for indefinite lived intangible asset until the underlying project receives regulatory approval at which point the intangible asset will be accounted for definite lived intangible asset or discontinuation at which point the intangible asset will be written off cost incurred by the company after the acquisition are expensed to incurred collaboration and other arrangementsthe company enters into collaborative agreement with third party to develop and commercialize drug candidate collaborative activity may include joint research and development and commercialization of new product abbvie generally receives certain licensing right under these arrangement these collaboration often require upfront payment and may include additional milestone research and development cost sharing royalty or profit share payment contingent upon the occurrence of certain future event linked to the success of the asset in development and commercialization upfront payment associated with collaborative arrangement and subsequent payment made to the partner for the achievement of development milestone prior to regulatory approval are expensed to acquired ipr and milestone expense in the consolidated statement of earnings regulatory and commercial milestone payment made to the partner subsequent to regulatory approval are capitalized intangible asset and amortized to cost of product sold over the estimated useful life of the related asset royalty are expensed to cost of product sold in the consolidated statement of earnings when incurred form advertisingcosts associated with advertising are expensed incurred and are included in selling general and administrative sg expense in the consolidated statement of earnings advertising expense were billion in billion in and billion in pension and other post employment benefitsabbvie record annual expense relating to it defined benefit pension and other post employment benefit plan based on calculation which utilize various actuarial assumption including discount rate rate of return on asset compensation increase turnover rate and health care cost trend rate abbvie review it actuarial assumption on an annual basis and make modification to the assumption based on current rate and trend actuarial gain and loss are deferred in accumulated other comprehensive income loss aoci net of tax and are amortized over the remaining service attribution period of the employee under the corridor method difference between the expected long term return on plan asset and the actual annual return are generally amortized to net periodic benefit cost over five year period income taxesincome tax are accounted for under the asset and liability method provision for federal state and foreign income tax are calculated on reported pre tax earnings based on current tax law deferred tax are provided using enacted tax rate on the future tax consequence of temporary difference which are the difference between the financial statement carrying amount of asset and liability and their respective tax base and the tax benefit of carryforwards valuation allowance is established or maintained when based on currently available information it is more likely than not that all or portion of deferred tax asset will not be realized cash and equivalentscash and equivalent include money market fund and time deposit with original maturity of three month or le investmentsinvestments consist primarily of equity security held to maturity debt security marketable debt security and time deposit investment in equity security that have readily determinable fair value are recorded at fair value investment in equity security that do not have readily determinable fair value are recorded at cost and are remeasured to fair value based on certain observable price change or impairment event they occur held to maturity debt security are recorded at cost gain or loss on investment are included in other expense net in the consolidated statement of earnings investment in marketable debt security are classified available for sale and are recorded at fair value with any unrealized holding gain or loss net of tax included in aoci on the consolidated balance sheet until realized at which time the gain or loss are recognized in earnings abbvie periodically ass it marketable debt security for impairment and credit loss when decline in fair value of marketable debt security is due to credit related factor an allowance for credit loss is recorded with corresponding charge to other expense net in the consolidated statement of earnings when abbvie determines that non credit related impairment ha occurred the amortized cost basis of the investment net of allowance for credit loss is written down with charge to other expense net in the consolidated statement of earnings and an available for sale investment unrealized loss is reclassified from aoci to other expense net in the consolidated statement of earnings realized gain and loss on sale of investment are computed using the first in first out method adjusted for any impairment and credit loss that were recorded in net earnings account receivableaccounts receivable are stated at amortized cost le allowance for credit loss the allowance for credit loss reflects the best estimate of future loss over the contractual life of outstanding account receivable and is determined on the basis of historical experience specific allowance for known troubled account other currently available information including customer financial condition and both current and forecasted economic condition form inventoriesinventories are valued at the lower of cost first in first out basis or market cost includes material and conversion cost inventory consisted of the following of december in million good work in raw inventory property and equipmentas of december in million construction in property and equipment le accumulated depreciation property and equipment net depreciation for property and equipment is recorded on straight line basis over the estimated useful life of the asset the estimated useful life for building range from to year building include leasehold improvement which are amortized over the lesser of the remainder of the lease term or the useful life of the leasehold improvement the estimated useful life for equipment range from to year equipment includes certain computer software and software development cost incurred in connection with developing or obtaining software for internal use and is amortized over to year depreciation expense wa million in million in and million in leasesshort term lease with term of month or le are not recorded on the balance sheet for lease commencing or modified in or later abbvie doe not separate lease component from non lease component the company record lease liability based on the present value of lease payment over the lease term abbvie generally us an incremental borrowing rate to discount it lease liability the rate implicit in the lease is typically not readily determinable certain lease agreement include renewal option that are under the company control abbvie includes optional renewal period in the lease term only when it is reasonably certain that abbvie will exercise it option variable lease payment include payment to lessor for tax maintenance insurance and other operating cost well payment that are adjusted based on an index or rate the company lease agreement do not contain any significant residual value guarantee or restrictive covenant litigation and contingenciesloss contingency provision are recorded when it is probable that liability ha been incurred and the amount of the liability can be reasonably estimated based on existing information when best estimate can not be made the minimum loss contingency amount in probable range is recorded legal fee are expensed incurred abbvie accrues for product liability claim on an undiscounted basis the liability are evaluated quarterly and adjusted if necessary additional information becomes available receivables for insurance recovery for product liability claim if any are recorded asset on an undiscounted basis when it is probable that recovery will be realized goodwill and intangible assetsintangible asset acquired in business combination are recorded at fair value using discounted cash flow model the discounted cash flow model requires assumption about the timing and amount of future net cash flow risk the cost of capital and terminal value of market participant definite lived intangible are amortized over their estimated useful life using the estimated pattern of economic benefit abbvie review the recoverability of definite lived intangible asset whenever event or change in circumstance indicate the carrying value of an asset may not be recoverable abbvie first compare the projected undiscounted cash flow to be generated by the asset to it carrying value if the undiscounted cash form flow of an intangible asset are le than the carrying value the intangible asset is written down to it fair value where cash flow can not be identified for an individual asset the review is applied at the lowest level for which cash flow are largely independent of the cash flow of other asset and liability goodwill and indefinite lived asset are not amortized but are subject to an impairment review annually and more frequently when indicator of impairment exist an impairment of goodwill could occur if the carrying amount of reporting unit exceeded the fair value of that reporting unit an impairment of indefinite lived intangible asset would occur if the fair value of the intangible asset is le than the carrying value the company test it goodwill for impairment by first assessing qualitative factor to determine whether it is more likely than not that the fair value is le than it carrying amount if the company concludes it is more likely than not that the fair value of the reporting unit is le than it carrying amount quantitative impairment test is performed abbvie test indefinite lived intangible asset for impairment by first assessing qualitative factor to determine whether it is more likely than not that the fair value is le than it carrying amount if the company concludes it is more likely than not that the fair value is le than it carrying amount quantitative impairment test is performed for it quantitative impairment test the company us an estimated future cash flow approach that requires significant judgment with respect to future volume revenue and expense growth rate change in working capital use the selection of an appropriate discount rate asset grouping and other assumption and estimate the estimate and assumption used are consistent with the company business plan and market participant view the use of alternative estimate and assumption could increase or decrease projected cash flow and the estimated fair value of the related intangible asset future change to these estimate and assumption could have material impact on the company result of operation actual result may differ from the company estimate foreign currency translationforeign subsidiary earnings are translated into dollar using average exchange rate the net asset of foreign subsidiary are translated into dollar using period end exchange rate the dollar affect that arise from translating the net asset of these subsidiary at changing rate are recognized in other comprehensive income loss in the consolidated statement of comprehensive income the net asset of subsidiary in highly inflationary economy are remeasured if the functional currency were the reporting currency the remeasurement is recognized in net foreign exchange loss in the consolidated statement of earnings derivativesall derivative instrument are recognized either asset or liability at fair value on the consolidated balance sheet and are classified current or long term based on the scheduled maturity of the instrument for derivative formally designated hedge the company ass at inception and quarterly thereafter whether the hedging derivative are highly effective in offsetting change in the fair value or cash flow of the hedged item the change in fair value of derivative designated fair value hedge and of the hedged item attributable to the hedged risk are recognized in earnings immediately the effective portion of change in the fair value of derivative designated cash flow hedge are reported in aoci and are subsequently recognized in earnings consistent with the underlying hedged item if it is determined that derivative is no longer highly effective hedge the company discontinues hedge accounting prospectively if hedged forecasted transaction becomes probable of not occurring any gain or loss are reclassified from aoci to earnings derivative that are not designated hedge are adjusted to fair value through current earnings the company also us derivative instrument or foreign currency denominated debt to hedge it net investment in certain foreign subsidiary and affiliate realized and unrealized gain and loss from these hedge are included in aoci derivative cash flow with the exception of net investment hedge are principally classified in the operating section of the consolidated statement of cash flow consistent with the underlying hedged item cash flow related to net investment hedge are classified in the investing section of the consolidated statement of cash flow form note supplemental financial information interest expense netyears ended december in million expense interest income interest expense net account payable and accrued liabilitiesas of december in million rebate dividend account current portion of contingent consideration salary wage and royalty and license account payable and accrued liability other long term liabilitiesas of december in million consideration liability liability for unrecognized tax income tax pension and other post employment other long term liability form note earnings per shareabbvie grant certain restricted stock unit rsus that are considered to be participating security due to the presence of participating security abbvie calculates earnings per share eps using the more dilutive of the treasury stock or the two class method for all period presented the two class method wa more dilutive the following table summarizes the impact of the two class method year ended december in million except per share data epsnet earnings attributable to abbvie inc earnings allocated to participating earnings available to common shareholder weighted average basic share of common stock basic earnings per share attributable to abbvie inc diluted epsnet earnings attributable to abbvie inc earnings allocated to participating earnings available to common shareholder weighted average share of common stock effect of dilutive weighted average diluted share of common stock diluted earnings per share attributable to abbvie inc certain share issuable under stock based compensation plan were excluded from the computation of eps because the effect would have been antidilutive the number of common share excluded wa insignificant for all period presented form note licensing acquisition and other arrangementsacquisition of dj antibody ltdin october abbvie entered into an agreement to acquire dj antibody ltd dj including it lead program dj and proprietary heptad platform dj is an antagonist antibody currently in preclinical study for the treatment of idiopathic pulmonary fibrosis and other fibrotic disease heptad platform is potential novel approach to antibody discovery with specific capability targeting transmembrane protein target the aggregate purchase price of million wa comprised of million upfront cash payment and million for the acquisition date fair value of contingent consideration liability for which abbvie may owe up to million in future payment upon achievement of certain development milestone the transaction wa accounted for business combination using the acquisition method of accounting of the acquisition date abbvie acquired million of intangible asset for in process research and development million of intangible asset for developed product right and million of deferred tax liability other asset and liability assumed were insignificant the acquisition resulted in the recognition of million of goodwill which is not deductible for tax purpose acquisition of soliton inc in december abbvie completed it previously announced acquisition of soliton inc soliton soliton resonic rapid acoustic pulse device ha food and drug administration fda clearance for the long term improvement in the appearance of cellulite up to one year the transaction wa accounted for business combination using the acquisition method of accounting total consideration transferred allocated to the purchase price consisted of cash consideration of million paid to holder of soliton common stock equity based award and warrant of the transaction date abbvie acquired million of intangible asset for developed product right and assumed deferred tax liability totaling million other asset and liability were insignificant the acquisition resulted in the recognition of million of goodwill which is not deductible for tax purpose acquisition of luminerain october abbvie entered into an agreement with luminera privately held aesthetic company based in israel to acquire luminera full dermal filler portfolio and pipeline including harmonyca dermal filler intended for facial soft tissue augmentation the aggregate accounting purchase price of million wa comprised of million upfront cash payment and million for the acquisition date fair value of contingent consideration liability for which abbvie may owe up to million in future payment upon achievement of certain commercial milestone the agreement wa accounted for business combination using the acquisition method of accounting of the acquisition date abbvie acquired million of intangible asset for in process research and development and million of intangible asset for developed product right other asset and liability assumed were insignificant the acquisition resulted in the recognition of million of goodwill which is not deductible for tax purpose acquisition of allerganon may abbvie completed it acquisition of all outstanding equity interest in allergan in cash and stock transaction allergan is global pharmaceutical leader focused on developing manufacturing and commercializing branded pharmaceutical device biologic surgical and regenerative medicine product for patient around the world the combination created diverse entity with leadership position across immunology hematologic oncology aesthetic neuroscience and eye care abbvie existing product portfolio and pipeline is enhanced with numerous allergan asset and allergan product portfolio benefit from abbvie commercial strength expertise and international infrastructure under the term of the acquisition each ordinary share of allergan common stock wa converted into the right to receive in cash and ii of share of abbvie common stock total consideration for the acquisition of allergan is summarized follows in million cash consideration paid to allergan shareholder fair value of abbvie common stock issued to allergan shareholder fair value of abbvie equity award issued to allergan equity award holder total consideration represents cash consideration transferred of per outstanding allergan ordinary share based on million allergan ordinary share outstanding at closing form represents the acquisition date fair value of million share of abbvie common stock issued to allergan shareholder based on the exchange ratio of abbvie share for each outstanding allergan ordinary share at the may closing price of per share represents the pre acquisition service portion of the fair value of million abbvie stock option and million rsus issued to allergan equity award holder the acquisition of allergan ha been accounted for business combination using the acquisition method of accounting the acquisition method requires among other thing that asset acquired and liability assumed in business combination be recognized at their fair value of the acquisition date the valuation of asset acquired and liability assumed wa finalized during the second quarter of measurement period adjustment to the preliminary purchase price allocation during included an increase to intangible asset of million ii an increase to deferred income tax liability of million iii other individually insignificant adjustment for net increase to identifiable net asset of million and iv corresponding decrease to goodwill of million the measurement period adjustment primarily resulted from the completion of the valuation of certain license agreement intangible asset based on fact and circumstance that existed of the acquisition date and did not result from intervening event subsequent to such date these adjustment did not have significant impact on abbvie result of operation in and would not have had significant impact on prior period result if these adjustment had been made of the acquisition date the following table summarizes the final fair value of asset acquired and liability assumed of the acquisition date in million asset acquired and liability assumedcash and equivalent short term account prepaid expense and other current property and intangible assetsdefinite lived intangible in process research and other noncurrent short term borrowing current portion of long term debt and finance lease obligation account payable and accrued liability long term debt and finance lease obligation deferred income tax other long term liability total identifiable net total asset acquired and liability assumed the fair value step up adjustment to inventory of billion wa amortized to cost of product sold when the inventory wa sold to customer and wa fully amortized of december intangible asset relate to billion of definite lived intangible asset and billion of ipr the acquired definite lived intangible asset consist of developed product right and license agreement and are being amortized over weighted average estimated useful life of approximately twelve year using the estimated pattern of economic benefit the estimated fair value of identifiable intangible asset were determined using the income approach which is valuation technique that provides an estimate of the fair value of an asset based on market participant expectation of the cash flow an asset would generate over it remaining useful life some of the more significant assumption inherent in the development of these asset valuation include the estimated net cash flow for each year for each asset or product the appropriate discount rate necessary to measure the risk inherent in each future cash flow stream the life cycle of each asset the potential regulatory and commercial success risk competitive trend impacting the asset and each cash flow stream well other factor form the fair value of long term debt wa determined by quoted market price of the acquisition date and the total purchase price adjustment of billion is being amortized reduction to interest expense net over the life of the related debt goodwill wa calculated the excess of the consideration transferred over the net asset recognized and represents the future economic benefit arising from the other asset acquired that could not be individually identified and separately recognized specifically the goodwill recognized from the acquisition of allergan represents the value of additional growth platform and an expanded revenue base well anticipated operational synergy and cost saving from the creation of single combined global organization the goodwill is not deductible for tax purpose following the acquisition date the operating result of allergan have been included in the consolidated financial statement for the period from the acquisition date through december net revenue attributable to allergan were billion and operating loss attributable to allergan were billion inclusive of billion of intangible asset amortization and billion of inventory fair value step up amortization acquisition related expense which were comprised primarily of regulatory financial advisory and legal fee totaled million for the year ended december which were included in sg expense in the consolidated statement of earnings in the fourth quarter of abbvie recovered certain acquisition related regulatory fee totaling million which wa recorded reduction to sg expense in the consolidated statement of earnings for the year ended december pro forma financial informationthe following table present the unaudited pro forma combined result of abbvie and allergan for if the acquisition of allergan had occurred on january year ended december in million revenue net the unaudited pro forma combined financial information wa prepared using the acquisition method of accounting and wa based on the historical financial information of abbvie and allergan in order to reflect the occurrence of the acquisition on january required the unaudited pro forma financial information includes adjustment to reflect incremental amortization expense to be incurred based on the final fair value of the identifiable intangible asset acquired the incremental cost of product sold related to the fair value adjustment associated with acquisition date inventory the additional interest expense associated with the issuance of debt to finance the acquisition and the reclassification of acquisition related cost incurred during the year ended december to the year ended december the unaudited pro forma financial information is not necessarily indicative of what the consolidated result of operation would have been had the acquisition been completed on january in addition the unaudited pro forma financial information is not projection of future result of operation of the combined company nor doe it reflect the expected realization of any synergy or cost saving associated with the acquisition other licensing acquisition activity cash outflow related to other acquisition and investment totaled million in billion in and billion in abbvie recorded acquired ipr and milestone expense of million in billion in and billion in significant arrangement impacting and some of which require contingent milestone payment are summarized below syndesi therapeutic sain february abbvie acquired syndesi therapeutic sa and it portfolio of novel modulators of the synaptic vesicle protein including it lead molecule sdi and accounted for the transaction an asset acquisition sdi is small molecule currently in phase study which is being evaluated to target nerve terminal to enhance synaptic efficiency under the term of the agreement abbvie made an upfront payment of million which wa recorded to acquired ipr and milestone expense in the consolidated statement of earnings in the first quarter of the agreement also includes form additional future payment of up to million upon the achievement of certain development regulatory and commercial milestone juvise pharmaceuticalsin june abbvie and laboratory juvise pharmaceutical juvise entered into an asset purchase agreement where juvise acquired worldwide commercial right of mature brand pylera which is used for the treatment of peptic ulcer with an infection by the bacterium helicobacter pylorus the transaction wa accounted for the sale of an asset upon completion of the transaction abbvie received net cash proceeds of million and recognized pre tax gain of million which wa recorded in other operating income in the consolidated statement of earnings in the second quarter of calico life science llcin july abbvie and calico life science llc calico entered into an extension of their collaboration to discover develop and bring to market new therapy for patient with age related disease including neurodegeneration and cancer this is the second collaboration extension and build on the partnership established in and extended in under the term of the agreement abbvie and calico will each contribute an additional million and the term is extended for an additional three year abbvie contribution is payable in two equal installment beginning in calico will be responsible for research and early development until and will advance collaboration project into phase through following completion of the phase study abbvie will have the option to exclusively license the collaboration compound upon exercise abbvie would be responsible for late stage development and commercial activity collaboration cost and profit will be shared equally by both party post option exercise during the third quarter of abbvie recorded million other operating expense in the consolidated statement of earnings related to it commitment under the agreement teneoone and tnb september abbvie acquired teneoone an affiliate of teneobio inc and tnb bcma targeting immunotherapeutic for the potential treatment of relapsed or refractory multiple myeloma mm in february abbvie and teneoone entered strategic transaction to develop and commercialize tnb bispecific antibody that simultaneously target bcma and and is designed to direct the body own immune system to target and kill bcma expressing tumor cell abbvie exercised it exclusive right to acquire teneoone and tnb based on an interim analysis of an ongoing phase study and accounted for the transaction an asset acquisition under the term of the agreement abbvie made an exercise payment of million which wa recorded to acquired ipr and milestone expense in the consolidated statement of earnings in the third quarter of the agreement also included additional payment of up to million upon the achievement of certain development regulatory and commercial milestone regenxbio inc in september abbvie and regenxbio inc regenxbio entered into collaboration to develop and commercialize rgx an investigational gene therapy for wet age related macular degeneration diabetic retinopathy and other chronic retinal disease the collaboration provides abbvie with an exclusive global license to develop and commercialize rgx regenxbio will be responsible for completion of ongoing trial abbvie and regenxbio will collaborate and share cost of additional trial and abbvie will lead the clinical development and commercialization of rgx globally regenxbio and abbvie will share equally in pre tax profit from net revenue of rgx in the and abbvie will pay regenxbio tiered royalty on net revenue outside the upon closing in the fourth quarter of abbvie made an upfront payment of million to exclusively license rgx which wa recorded to acquired ipr and milestone expense in the consolidated statement of earnings for the year ended december the agreement also included additional payment of up to billion upon the achievement of certain development regulatory and commercial milestone mab biopharmain september abbvie and mab biopharma mab entered into collaboration agreement for the development and commercialization of lemzoparlimab an anti monoclonal antibody internally discovered and developed by mab for the treatment of multiple cancer both company will collaborate to design and conduct further global clinical trial to evaluate lemzoparlimab the collaboration provides abbvie an exclusive global license excluding greater china to develop and commercialize lemzoparlimab the company will share manufacturing responsibility with abbvie being the primary manufacturer for global supply the agreement also allows for potential collaboration on future related therapeutic agent subject to further license to explore each other related program in their respective territory the term of the arrangement include an initial upfront payment of million to exclusively license lemzoparlimab along with milestone payment of million based on the phase result for total of million which wa recorded to acquired ipr and milestone expense in the consolidated statement of earnings in the fourth quarter of after regulatory approval of the form transaction in addition mab will be eligible to receive up to billion upon the achievement of certain clinical development regulatory and commercial milestone and abbvie will pay tiered royalty from low to mid teen percentage on global net revenue outside of greater china genmab sin june abbvie and genmab genmab entered into collaboration agreement to jointly develop and commercialize three of genmab early stage investigational bispecific antibody therapeutic and entered into discovery research collaboration for future differentiated antibody therapeutic for the treatment of cancer under the term of the agreement genmab granted abbvie an exclusive license to it epcoritamab duobody duohexabody and duobody program for epcoritamab the company will share commercial responsibility in the and japan with abbvie responsible for further global commercialization genmab will record net revenue in the and japan and the party will share equally in pre tax profit from these sale genmab will receive tiered royalty on remaining global sale for the discovery research partnership genmab will conduct phase study for these program and abbvie retains the right to opt in to program development during abbvie made an upfront payment of million which wa recorded to acquired ipr and milestone expense in the consolidated statement of earnings abbvie could make additional payment of up to billion upon the achievement of certain development regulatory and commercial milestone for all program other arrangementsin addition to the significant arrangement described above abbvie entered into several other arrangement resulting in charge related to upfront payment of million in million in and million in in connection with the other individually insignificant early stage arrangement entered into in abbvie could make additional payment of up to billion upon the achievement of certain development regulatory and commercial milestone acquired ipr and milestone expense also included development milestone of million in million in and million in note collaboration the company ha ongoing transaction with other entity through collaboration agreement the following represent the significant collaboration agreement impacting and collaboration with janssen biotech inc in december pharmacyclics wholly owned subsidiary of abbvie entered into worldwide collaboration and license agreement with janssen biotech inc and it affiliate janssen one of the janssen pharmaceutical company of johnson johnson for the joint development and commercialization of imbruvica novel orally active selective covalent inhibitor of bruton tyrosine kinase and certain compound structurally related to imbruvica for oncology and other indication excluding all immune and inflammatory mediated disease or condition and all psychiatric or psychological disease or condition in the united state and outside the united state the collaboration provides janssen with an exclusive license to commercialize imbruvica outside of the united state and co exclusively with abbvie in the united state both party are responsible for the development manufacturing and marketing of any product generated result of the collaboration the collaboration ha no set duration or specific expiration date and provides for potential future development regulatory and approval milestone payment of up to million to abbvie the collaboration also includes cost sharing arrangement for associated collaboration activity except in certain case janssen is responsible for approximately of collaboration development cost and abbvie is responsible for the remaining of collaboration development cost form in the united state both party have co exclusive right to commercialize the product however abbvie is the principal in the end customer product sale abbvie and janssen share pre tax profit and loss equally from the commercialization of product sale of imbruvica are included in abbvie net revenue janssen share of profit is included in abbvie cost of product sold other cost incurred under the collaboration are reported in their respective expense line item net of janssen share outside the united state janssen is responsible for and ha exclusive right to commercialize imbruvica abbvie and janssen share pre tax profit and loss equally from the commercialization of product abbvie share of profit is included in abbvie net revenue other cost incurred under the collaboration are reported in their respective expense line item net of janssen share the following table show the profit and cost sharing relationship between janssen and abbvie year ended december in million state janssen share of profit included in cost of product sold international abbvie share of profit included in net revenue global abbvie share of other cost included in respective line item abbvie receivable from janssen included in account receivable net wa million at december and million at december abbvie payable to janssen included in account payable and accrued liability wa million at december and million at december collaboration with genentech inc abbvie and genentech inc genentech member of the roche group are party to collaboration and license agreement executed in to jointly research develop and commercialize human therapeutic product containing bcl inhibitor and certain other compound inhibitor which includes venclexta bcl inhibitor used to treat certain hematological malignancy abbvie share equally with genentech all pre tax profit and loss from the development and commercialization of venclexta in the united state abbvie pay royalty on venclexta net revenue outside the united state abbvie manufacture and distributes venclexta globally and is the principal in the end customer product sale sale of venclexta are included in abbvie net revenue genentech share of united state profit is included in abbvie cost of product sold abbvie record sale and marketing cost associated with the united state collaboration part of sg expense and global development cost part of expense net of genentech share royalty paid for venclexta revenue outside the united state are also included in abbvie cost of product sold the following table show the profit and cost sharing relationship between genentech and abbvie year ended december in million share of profit including royalty included in cost of product sold abbvie share of sale and marketing cost from collaboration included in sg abbvie share of development cost included in form note goodwill and intangible asset goodwillthe following table summarizes the change in the carrying amount of goodwill in million balance of december addition measurement period adjustment foreign currency translation adjustment and other balance of december addition foreign currency translation adjustment and other balance of december goodwill addition related to the acquisition of soliton in the fourth quarter of see note measurement period adjustment recorded in related to the acquisition of allergan see note goodwill addition related to the acquisition of dj in the fourth quarter of see note the company performs it annual goodwill impairment assessment in the third quarter or earlier if impairment indicator exist of december and there were no accumulated goodwill impairment loss intangible asset netthe following table summarizes intangible asset of december in million gross carrying amountaccumulated amortizationnet carrying amountgross carrying amountaccumulated amortizationnet carrying amountdefinite lived intangible assetsdeveloped product right license total definite lived intangible indefinite lived intangible total intangible asset net definite lived intangible assetsin september the company made strategic decision to reduce ongoing sale and marketing investment related to vuity an on market product to treat presbyopia this strategic decision contributed to significant decrease in the estimated future cash flow for the product and represented triggering event which required the company to evaluate the underlying definite lived intangible asset for impairment the company utilized discounted cash flow analysis to estimate the fair value of the intangible asset resulting in full impairment of both the gross and net carrying amount based on the revised cash flow the company recorded pre tax impairment charge of million to cost of product sold in the consolidated statement of earnings for the third quarter of definite lived intangible asset are amortized over their estimated useful life which range between to year with an average of year for developed product right and year for license agreement amortization expense wa billion in billion in and billion in and wa included in cost of product sold in the consolidated statement of earnings the anticipated annual amortization expense for definite lived intangible asset recorded of december is follows in billion annual amortization expense form indefinite lived intangible assetsindefinite lived intangible asset represent acquired ipr associated with product that have not yet received regulatory approval indefinite lived intangible asset of december primarily relate to the acquisition of allergan and dj the company performs it annual impairment assessment of indefinite lived intangible asset in the third quarter or earlier if impairment indicator exist note integration and restructuring plan allergan integration planfollowing the closing of the allergan acquisition abbvie implemented an integration plan designed to reduce cost integrate and optimize the combined organization and incurred total cumulative charge of billion through these cost consisted of severance and employee benefit cost cash severance non cash severance including accelerated equity award compensation expense retention and other termination benefit and other integration expense the following table summarizes the charge benefit associated with the allergan acquisition integration plan severance and employee benefitsother integrationyear ended december in million of product sold research and development selling general and administrative total charge benefit the following table summarizes the cash activity in the recorded liability associated with the integration plan year ended december in million severance and employee benefitsother integrationcharges payment and other adjustment accrued balance of december payment and other adjustment accrued balance of december charge benefit payment and other adjustment accrued balance of december other restructuringabbvie continuously evaluates it operation to identify opportunity to optimize it manufacturing and operation commercial infrastructure and administrative cost and to respond to change in it business environment result abbvie management periodically approves individual restructuring plan to achieve these objective in and no such plan were individually significant restructuring charge recorded were million in million in and million in and were primarily related to employee severance and contractual obligation these charge were recorded in cost of product sold expense and sg expense in the consolidated statement of earnings based on the classification of the affected employee or operation form the following table summarizes the cash activity in the restructuring reserve for and in million accrued balance of december restructuring payment and other adjustment accrued balance of december restructuring payment and other adjustment accrued balance of december restructuring payment and other adjustment accrued balance of december note lease abbvie lease portfolio primarily consists of real estate property vehicle and equipment the following table summarizes the amount and location of operating and finance lease on the consolidated balance sheet of december in million balance sheet asset financeproperty and equipment total lease asset liabilitiesoperatingcurrentaccounts payable and accrued liability noncurrentother long term financecurrentcurrent portion of long term debt and finance lease noncurrentlong term debt and finance lease total lease liability the following table summarizes the lease cost recognized in the consolidated statement of earnings year ended december in million lease cost short term lease variable lease total lease cost in december the company entered into an agreement to sublease portion of it madison new jersey office space through the end of the original lease maturity in result of this agreement the company recognized an impairment loss on it right of use asset of million and wrote off the related leasehold improvement of million these loss were recorded to sg expense in the consolidated statement of earnings for the year ended december the company used discounted cash flow method to value the right of use asset to determine the impairment amount sublease income and finance lease cost were insignificant in and form the following table present the weighted average remaining lease term and weighted average discount rate for operating and finance lease year ended december average remaining lease term year average discount the following table present supplementary cash flow information regarding the company lease year ended december in million paid for amount included in the measurement of lease liabilitiesoperating cash flow from operating lease right of use asset obtained in exchange for new operating lease finance lease cash flow were insignificant in and right of use asset obtained in exchange for new operating lease liability of december included million of right of use asset acquired in the allergan acquisition the following table summarizes the future maturity of abbvie operating and finance lease liability of december in million operatingleasesfinanceleasestotal total lease le present value of lease liability lease payment recognized part of lease liability for optional renewal period are insignificant form note debt credit facility and commitment and contingency the following table summarizes long term debt of december dollar in million effective interest rate effective interest rate aggregate note due senior note due senior note due floating rate term loan due senior euro note due principal senior note due senior note due senior euro note due principal senior note due senior euro note due principal senior note due senior note due floating rate term loan due floating rate term loan due senior note due senior note due senior euro note due principal senior note due senior euro note due principal senior euro note due principal senior note due senior euro note due principal senior euro note due principal senior note due senior note due senior note due senior note due senior note due senior note due senior note due senior note due senior note due senior note due senior note due senior note due fair value hedge unamortized bond discount unamortized deferred financing cost unamortized bond premium total long term debt and finance lease current noncurrent portion excludes the effect of any related interest rate swap represents unamortized purchase price adjustment of allergan debt form senior note and floating rate term loan are redeemable prior to maturity at redemption price equal to the principal amount plus make whole premium and abbvie may redeem these debt security at par generally between one and six month prior to maturity at december the company wa in compliance with it senior note covenant and term loan covenant maturity of long term debtas of and for the year ending december in million total obligation and fair value hedge unamortized bond premium discount deferred financing cost and finance lease total long term debt and finance lease obligation repayment and issuance of long term debt in the company repaid billion aggregate principal amount of senior note billion aggregate principal amount of senior note billion aggregate principal amount of senior note these repayment were made by exercising under the term of the note ranging between and day early redemption at of the principal amount during the quarter ended december the company also paid billion aggregate principal amount of senior note billion aggregate principal amount of senior note and million aggregate principal amount of floating rate senior note at maturity additionally in the company refinanced it billion floating rate five year term loan part of the refinancing the company repaid the existing billion term loan due may and borrowed billion under new term loan at lower floating rate all other significant term of the loan including the maturity date remained unchanged after the refinancing subsequent to december the company repaid billion floating rate three year term loan that wa scheduled to mature in may in the company repaid billion aggregate principal amount of senior note million aggregate principal amount of senior euro note and billion aggregate principal amount of senior note these repayment were made by exercising under the term of the note ranging between and day early redemption at of the principal amount the company also repaid billion aggregate principal amount of senior note billion aggregate principal amount of senior note and billion aggregate principal amount of floating rate senior note at maturity additionally in the company refinanced it billion floating rate three year term loan part of the refinancing the company repaid the existing billion term loan due may and borrowed billion under new term loan at lower floating rate all other significant term of the loan including the maturity date remained unchanged after the refinancing short term borrowingsthere were no commercial paper borrowing outstanding of december and december no commercial paper borrowing were issued during or there were commercial paper borrowing issued during and the weighted average interest rate wa abbvie currently ha billion five year revolving credit facility that matures in august this credit facility enables the company to borrow fund on an unsecured basis at variable interest rate and contains various covenant all of which the company wa in compliance with of december commitment fee under abbvie revolving credit facility were insignificant in and no amount were outstanding under the company credit facility of december and december contingency and guaranteesin connection with the separation abbvie ha indemnified abbott for all liability resulting from the operation of abbvie business other than income tax liability with respect to period prior to the distribution date and other liability agreed to by abbvie and abbott abbvie ha no material exposure to off balance sheet arrangement and no special purpose entity in the ordinary course of business abbvie ha periodically entered into third party agreement such the assignment of product right which have resulted in abbvie becoming secondarily liable for obligation for which abbvie had previously been primarily liable based upon past experience the likelihood of payment under these agreement is remote form note financial instrument and fair value measuresrisk management policythe company is exposed to foreign currency exchange rate and interest rate risk related to it business operation abbvie hedging policy attempt to manage these risk to an acceptable level based on the company judgment of the appropriate trade off between risk opportunity and cost the company us derivative and nonderivative instrument to reduce it exposure to foreign currency exchange rate abbvie also periodically enters into interest rate swap in which the company agrees to exchange at specified interval the difference between fixed and floating interest amount calculated by reference to an agreed upon notional amount derivative instrument are not used for trading purpose or to manage exposure to change in interest rate for investment security and none of the company outstanding derivative instrument contain credit risk related contingent feature collateral is generally not required financial instrumentsvarious abbvie foreign subsidiary enter into foreign currency forward exchange contract to manage exposure to change in foreign exchange rate for anticipated intercompany transaction denominated in currency other than the functional currency of the local entity these contract with notional amount totaling billion at december and billion at december are designated cash flow hedge and are recorded at fair value the duration of these forward exchange contract were generally le than month accumulated gain and loss of december will be reclassified from aoci and included in cost of product sold at the time the product are sold generally not exceeding six month from the date of settlement in the company entered into treasury rate lock agreement with notional amount totaling billion to hedge exposure to variability in future cash flow resulting from change in interest rate related to the issuance of long term debt in connection with the acquisition of allergan the treasury rate lock agreement were designated cash flow hedge and recorded at fair value the agreement were net settled upon issuance of the senior note in and the resulting net gain wa recognized in other comprehensive income this gain is reclassified to interest expense net over the term of the related debt the company wa party to interest rate swap contract designated cash flow hedge that matured in november for which the notional amount wa million at december the effect of the hedge contract wa to change floating rate interest obligation to fixed rate for that portion of the floating rate debt realized and unrealized gain or loss were included in aoci and were reclassified to interest expense net over the life of the floating rate debt the company also enters into foreign currency forward exchange contract to manage it exposure to foreign currency denominated trade payable and receivables and intercompany loan these contract are not designated hedge and are recorded at fair value resulting gain or loss are reflected in net foreign exchange loss in the consolidated statement of earnings and are generally offset by loss or gain on the foreign currency exposure being managed these contract had notional amount totaling billion at december and billion at december the company also us foreign currency forward exchange contract or foreign currency denominated debt to hedge it net investment in certain foreign subsidiary and affiliate the company had an aggregate principal amount of senior euro note designated net investment hedge of billion at december and december in addition the company had foreign currency forward exchange contract designated net investment hedge with notional amount totaling billion billion million and million at december and billion at december the company us the spot method of assessing hedge effectiveness for derivative instrument designated net investment hedge realized and unrealized gain and loss from these hedge are included in aoci and the initial fair value of hedge component excluded from the assessment of effectiveness is recognized in interest expense net over the life of the hedging instrument the company is party to interest rate swap contract designated fair value hedge with notional amount totaling billion at december and december the effect of the hedge contract is to change fixed rate interest obligation to floating rate for that portion of the debt abbvie record the contract at fair value and adjusts the carrying amount of the fixed rate debt by an offsetting amount no amount are excluded from the assessment of effectiveness for cash flow hedge or fair value hedge form the following table summarizes the amount and location of abbvie derivative instrument on the consolidated balance sheet fair value derivative in asset positionfair value derivative in liability positionas of december in million balance sheet sheet currency forward exchange contractsdesignated cash flow hedgesprepaid expense and other account payable and accrued liability designated cash flow hedgesother other long term liability designated net investment hedgesprepaid expense and account payable and accrued designated net investment hedgesother other long term not designated hedgesprepaid expense and account payable and accrued interest rate swap contractsdesignated cash flow hedgesprepaid expense and other account payable and accrued liability designated fair value hedgesprepaid expense and other account payable and accrued designated fair value hedgesother asset other long term total derivative while certain derivative are subject to netting arrangement with the company counterparties the company doe not offset derivative asset and liability within the consolidated balance sheet the following table present the pre tax amount of gain loss from derivative instrument recognized in other comprehensive income year ended in december in million currency forward exchange contractsdesignated cash flow hedge designated net investment interest rate swap contract designated cash flow assuming market rate remain constant through contract maturity the company expects to reclassify pre tax gain of million into cost of product sold for foreign currency cash flow hedge and pre tax gain of million into interest expense net for treasury rate lock agreement cash flow hedge during the next month related to abbvie non derivative foreign currency denominated debt designated net investment hedge the company recognized in other comprehensive income pre tax gain of million in pre tax gain of million in and pre tax loss of million in form the following table summarizes the pre tax amount and location of derivative instrument net gain loss recognized in the consolidated statement of earnings including the net gain loss reclassified out of aoci into net earnings see note for the amount of net gain loss reclassified out of aoci year ended december in million statement of earnings currency forward exchange contractsdesignated cash flow hedgescost of product sold designated net investment hedgesinterest expense not designated hedgesnet foreign exchange loss treasury rate lock agreement designated cash flow hedgesinterest expense interest rate swap contractsdesignated cash flow hedgesinterest expense net designated fair value hedgesinterest expense net debt designated hedged item in fair value hedgesinterest expense fair value measuresthe fair value hierarchy consists of the following three level level valuation based on unadjusted quoted price in active market for identical asset that the company ha the ability to access level valuation based on quoted price for similar instrument in active market quoted price for identical or similar instrument in market that are not active and model based valuation in which all significant input are observable in the market and level valuation using significant input that are unobservable in the market and include the use of judgment by the company management about the assumption market participant would use in pricing the asset or liability form the following table summarizes the base used to measure certain asset and liability carried at fair value on recurring basis on the consolidated balance sheet of december basis of fair value measurement in million totalquoted price in active market for identical asset level significant other observable input level significant unobservable input level assetscash and equivalent money market fund and time debt equity foreign currency total asset liabilitiesinterest rate swap contract foreign currency contingent total liability the following table summarizes the base used to measure certain asset and liability carried at fair value on recurring basis on the consolidated balance sheet of december basis of fair value measurement in million totalquoted price in active market for identical asset level significant other observable input level significant unobservable input level assetscash and equivalent money market fund and time debt equity interest rate swap foreign currency total asset liabilitiesinterest rate swap contract foreign currency contingent total liability money market fund and time deposit are valued using relevant observable market input including quoted price for similar asset and interest rate curve equity security primarily consist of investment for which the fair value were determined by using the published market price per unit multiplied by the number of unit held without consideration of transaction cost the derivative entered into by the company were valued using observable market input including published interest rate curve and both forward and spot price for foreign currency the fair value measurement of the contingent consideration liability were determined based on significant unobservable input including the discount rate estimated probability and timing of achieving specified development regulatory and commercial milestone and the estimated amount of future sale of the acquired product the potential contingent consideration payment are estimated by applying probability weighted expected payment model for contingent milestone payment and monte carlo simulation model for contingent royalty payment which are then discounted to present value change to the fair value of the contingent consideration liability can result from change to one or number of input including discount rate the probability of achieving the milestone the time required to achieve the milestone form and estimated future sale significant judgment is employed in determining the appropriateness of certain of these input change to the input described above could have material impact on the company financial position and result of operation in any given period the fair value of the company contingent consideration liability wa calculated using the following significant unobservable input ended december in million rangeweighted average rangeweighted average discount probability of payment for unachieved probability of payment for royalty by indication projected year of unobservable input were weighted by the relative fair value of the contingent consideration liability excluding approved indication the estimated probability of payment wa at december and ranged from to at december there have been no transfer of asset or liability into or out of level of the fair value hierarchy the following table present the change in fair value of contingent consideration liability which are measured using level input year ended december in million balance addition change in fair value recognized in net payment ending balance addition during the year ended december represent contingent consideration liability assumed in the dj acquisition addition during the year ended december represent contingent consideration liability assumed in the allergan and luminera acquisition see note the change in fair value recognized in net earnings is recorded in other expense net in the consolidated statement of earnings and included charge of billion in billion in and billion in in the change in fair value reflected higher estimated skyrizi sale driven by stronger market share uptake and the passage of time partially offset by higher discount rate in the change in fair value reflected higher estimated skyrizi sale driven by stronger market share uptake favorable clinical trial result and the passage of time partially offset by higher discount rate in the change in fair value reflected higher estimated skyrizi sale driven by stronger market share uptake lower discount rate the passage of time and favorable clinical trial result form certain financial instrument are carried at historical cost or some basis other than fair value the book value approximate fair value and base used to measure the approximate fair value of certain financial instrument of december are shown in the table below basis of fair value measurement in million book value approximate fair valuesquoted price in active market for identical asset level significant other observable input level significant unobservable input level liabilitiesshort term borrowing current portion of long term debt and finance lease obligation excluding fair value long term debt and finance lease obligation excluding fair value total liability the book value approximate fair value and base used to measure the approximate fair value of certain financial instrument of december are shown in the table below basis of fair value measurement in million book value approximate fair valuesquoted price in active market for identical asset level significant other observable input level significant unobservable input level liabilitiesshort term borrowing current portion of long term debt and finance lease obligation excluding fair value hedge long term debt and finance lease obligation excluding fair value total liability abbvie also hold investment in equity security that do not have readily determinable fair value the company record these investment at cost and remeasures them to fair value based on certain observable price change or impairment event they occur the carrying amount of these investment wa million of december and million of december no significant cumulative upward or downward adjustment have been recorded for these investment of december concentration of riskof total net account receivable three wholesaler accounted for of december and of december and substantially all of abbvie pharmaceutical product net revenue in the united state were to these three wholesaler humira adalimumab is abbvie single largest product and accounted for approximately of abbvie total net revenue in in and in form note post employment benefit abbvie sponsor various pension and other post employment benefit plan including defined benefit defined contribution and termination indemnity plan which cover most employee worldwide in addition abbvie provides medical benefit primarily to eligible retiree in the united state and puerto rico through other post retirement benefit plan net obligation for these plan have been reflected on the consolidated balance sheet of december and the following table summarizes benefit plan information for the global abbvie sponsored defined benefit and other post employment plan defined benefit plansother post employment plansas of and for the year ended december in million benefit obligationsbeginning of period service interest employee amendment actuarial gain loss benefit paid other primarily foreign currency translation adjustment end of fair value of plan assetsbeginning of actual return on plan asset company employee benefit paid other primarily foreign currency translation adjustment end of funded status end of period amount recognized on the consolidated balance sheetsother asset account payable and accrued liability other long term liability net obligation actuarial loss net prior service cost credit accumulated other comprehensive loss related to international defined benefit plan the projected benefit obligation in the table above included billion at december and billion at december for plan reflected in the table above the accumulated benefit obligation were billion at december and billion at december the actuarial gain of billion for qualified pension plan and actuarial gain of million for other post employment plan were primarily driven by an increase in the discount rate the actuarial gain of million for qualified pension plan and actuarial loss of million for other post employment plan were primarily driven by an increase in the assumed discount rate offset by change in demographic assumption from form information for pension plan with an accumulated benefit obligation in excess of plan assetsas of december in million benefit obligation fair value of plan information for pension plan with projected benefit obligation in excess of plan assetsas of december in million benefit obligation fair value of plan abbvie pension plan wa modified to close the plan to new entrant effective january in addition change to abbvie retiree health benefit plan wa approved in and communicated to employee and retiree in october beginning in medicare eligible retiree and medicare eligible dependent choose health care coverage from insurance provider through private medicare exchange abbvie will continue to provide financial support to medicare eligible retiree this change to the retiree health benefit plan decreased abbvie post employment benefit obligation and increased abbvie unrecognized prior service credit of december by million form amount recognized in other comprehensive incomethe following table summarizes the pre tax loss gain included in other comprehensive income year ended december in million benefit plansactuarial loss gain amortization of prior service cost amortization of actuarial loss foreign exchange loss gain and total loss gain other post employment plansactuarial loss gain prior service credit amortization of prior service amortization of actuarial loss total loss gain net periodic benefit costyears ended december in million benefit plansservice cost interest expected return on plan asset amortization of prior service amortization of actuarial net periodic benefit cost other post employment plansservice cost interest amortization of prior service credit amortization of actuarial net periodic benefit cost the component of net periodic benefit cost other than service cost are included in other expense net in the consolidated statement of earnings weighted average assumption used in determining benefit obligation at the measurement dateas of december benefit plansdiscount rate of compensation cash balance interest crediting other post employment plansdiscount the assumption used in calculating the december measurement date benefit obligation will be used in the calculation of net periodic benefit cost in form weighted average assumption used in determining net periodic benefit costyears ended december benefit plansdiscount rate for determining service discount rate for determining interest expected long term rate of return on plan expected rate of change in cash balance interest crediting other post employment plansdiscount rate for determining service discount rate for determining interest for the december post retirement health care obligation remeasurement the company assumed pre post annual rate of increase in the per caput cost of covered health care benefit the pre rate wa assumed to decrease gradually to post in and remain at that level thereafter for purpose of measuring the post retirement health care cost the company assumed pre post annual rate of increase in the per caput cost of covered health care benefit the pre rate wa assumed to decrease gradually to post for and remain at that level thereafter form defined benefit pension plan assetsbasis of fair value measurementas of december in million price in active market for identical asset level significant other observable input level significant unobservable input level equitiesu large cap mid cap international fixed income securitiesu government security corporate debt instrument non government security other absolute return fund real other total total asset measured at fair value of plan asset basis of fair value measurementas of december in million price in active market for identical asset level significant other observable input level significant unobservable input level equitiesu large cap mid cap international fixed income securitiesu government security corporate debt instrument non government security other absolute return fund real other total total asset measured at fair value of plan asset mix of index fund and actively managed equity account that are benchmarked to various large cap index mix of index fund and actively managed equity account that are benchmarked to various mid cap index mix of index fund and actively managed equity account that are benchmarked to various non equity index in both developed and emerging market security held by actively managed account index fund and mutual fund form primarily fund having global mandate with the flexibility to allocate capital broadly across wide range of asset class and strategy including but not limited to equity fixed income commodity financial future currency and other security with objective to outperform agreed upon benchmark of specific return and volatility target investment in cash and cash equivalent equity and registered investment company having quoted price are valued at the published market price fixed income security that are valued using significant other observable input are quoted at price obtained from independent financial service industry recognized vendor investment held in pooled investment fund common collective trust or limited partnership are valued at the net asset value nav practical expedient to estimate fair value the nav is provided by the fund administrator and is based on the value of the underlying asset owned by the fund minus it liability the investment mix of equity security fixed income and other asset allocation strategy is based upon achieving desired return balancing higher return more volatile equity security and lower return le volatile fixed income security investment allocation are established for each plan and are generally made across range of market industry sector capitalization size and in the case of fixed income security maturity and credit quality the target investment allocation for the abbvie pension plan wa in equity security in fixed income security and in asset allocation strategy and other holding there are no known significant concentration of risk in the plan asset of the abbvie pension plan or of any other plan the expected return on plan asset assumption for each plan is based on management expectation of long term average rate of return to be achieved by the underlying investment portfolio in establishing this assumption management considers historical and expected return for the asset class in which the plan are invested well current economic and capital market condition expected benefit paymentsthe following table summarizes total benefit payment expected to be paid to plan participant including payment funded from both plan and company asset year ending december in million defined benefit plansother post employment to defined contribution planabbvie maintains defined contribution saving plan for the benefit of it eligible employee the expense recognized for these plan wa million in million in and million in abbvie provides certain other post employment benefit primarily salary continuation arrangement to qualifying employee and accrues for the related cost over the service life of the employee note equity stock based compensationin may stockholder of the company approved the abbvie amended and restated incentive stock program the amended plan which amends and restates the abbvie incentive stock program isp abbvie grant stock based award to eligible employee pursuant to the amended plan which provides for several different form of benefit including non qualified stock option rsus and various performance based award under the amended plan total of million share of abbvie common stock have been reserved for issuance award to abbvie employee form abbvie measure compensation expense for stock based award based on the grant date fair value of the award and the estimated number of award that are expected to vest forfeiture are estimated based on historical experience at the time of grant and are revised in subsequent period if actual forfeiture differ from those estimate compensation cost for stock based award is amortized over the service period which could be shorter than the vesting period if an employee is retirement eligible retirement eligible employee generally are those who are age or older and have at least year of service stock based compensation expense is principally related to award issued pursuant to the isp and the amended plan and is summarized follows year ended december in million of product sold research and selling general and pre tax compensation tax after tax compensation expense realized excess tax benefit associated with stock based compensation totaled million in million in and million in stock optionsstock option awarded to employee typically have contractual term of year and generally vest in one third increment over three year period the exercise price is equal to at least of the market value on the date of grant the fair value is determined using the black scholes model the weighted average grant date fair value of stock option granted were in in and in in connection with the allergan acquisition during the second quarter of abbvie issued million stock option to holder of allergan option result of the conversion of such option these option were fair valued using lattice valuation model refer to note for additional information regarding the allergan acquisition the following table summarizes abbvie stock option activity in option in thousand aggregate intrinsic value in million optionsweighted average exercise priceweighted average remaining life in year aggregate intrinsic valueoutstanding at december exercised lapsed and forfeited outstanding at december exercisable at december the total intrinsic value of option exercised wa million in million in and million in the total fair value of option vested during wa million of december million of unrecognized compensation cost related to stock option is expected to be recognized expense over approximately the next two year rsus and performance sharesrsus awarded to employee other than senior executive and other key employee generally vest in ratable increment over three or four year period recipient of these rsus are entitled to receive dividend equivalent dividend are declared and paid during the rsu vesting period the majority of the equity award abbvie grant to it senior executive and other key employee are performance based equity award granted to senior executive and other key employee consist of combination of performance vested rsus and performance share well non qualified stock option described above the performance vested rsus have the potential to vest in one third increment during three year performance period and may be earned based on abbvie return on invested capital roic performance relative to defined peer group of pharmaceutical biotech and life science company the recipient may receive one share of abbvie common stock for each vested award the performance share form have the potential to vest over three year performance period and may be earned based on abbvie eps achievement and abbvie total stockholder return tsr market condition relative to defined peer group of pharmaceutical biotech and life science company dividend equivalent on performance vested rsus and performance share accrue during the performance period and are payable at vesting only to the extent that share are earned the weighted average grant date fair value of rsus and performance share generally is determined based on the number of share unit granted and the quoted price of abbvie common stock on the date of grant the weighted average grant date fair value of performance share with tsr market condition are determined using the monte carlo simulation model the following table summarizes abbvie rsu and performance share activity for share unit in thousand share unitsweighted average grant date fair valueoutstanding at december vested forfeited outstanding at december the fair market value of rsus and performance share applicable vested wa billion in million in and million in in connection with the allergan acquisition during the second quarter of abbvie issued million rsus to holder of allergan equity award based on conversion factor described in the transaction agreement refer to note for additional information regarding the allergan acquisition of december million of unrecognized compensation cost related to rsus and performance share is expected to be recognized expense over approximately the next two year cash dividendscash dividend declared per common share totaled in in and in the following table summarizes quarterly cash dividend declared during and declaredpayment datedividend per sharedate declaredpayment datedividend per sharedate declaredpayment datedividend per repurchase programthe company stock repurchase authorization permit purchase of abbvie share from time to time in open market or private transaction at management discretion the program ha no time limit and can be discontinued at any time share repurchased under these program are recorded at acquisition cost including related expense and are available for general corporate purpose abbvie repurchased million share for billion in million share for million in and million share for million in abbvie remaining stock repurchase authorization wa billion of december on february abbvie board of director authorized billion increase to the existing stock repurchase authorization form accumulated other comprehensive lossthe following table summarizes the change in each component of accumulated other comprehensive loss net of tax for and in million bracket denote loss foreign currency translation adjustmentsnet investment hedging activitiespension and post employment benefitscash flow hedging activitiestotalbalance of december other comprehensive income loss before net loss gain reclassified from accumulated other comprehensive loss net current period other comprehensive income loss balance of december other comprehensive income loss before reclassification net loss gain reclassified from accumulated other comprehensive loss net current period other comprehensive income loss balance of december other comprehensive income loss before reclassification net loss gain reclassified from accumulated other comprehensive loss net current period other comprehensive income loss balance of december other comprehensive income for included pension and post employment benefit plan gain of billion primarily due actuarial gain driven by higher discount rate partially offset by loss on plan asset other comprehensive income for also included foreign currency translation adjustment totaling loss of million principally due to the impact of the weakening of the euro on the translation of the company euro denominated asset and the offsetting impact of net investment hedging activity totaling gain of million other comprehensive income for included foreign currency translation adjustment totaling loss of billion principally due to the impact of the weakening of the euro on the translation of the company euro denominated asset and the offsetting impact of net investment hedging activity totaling gain of million other comprehensive income for included foreign currency translation adjustment totaling gain of billion principally due to the impact of the strengthening of the euro on the translation of the company euro denominated asset and the offsetting impact of net investment hedging activity totaling loss of million form the table below present the impact on abbvie consolidated statement of earnings for significant amount reclassified out of each component of accumulated other comprehensive loss year ended december in million bracket denote gain investment hedging activitiesgains on derivative amount excluded from effectiveness testing tax total reclassification net of tax pension and post employment benefitsamortization of actuarial loss and other tax benefit total reclassification net of tax cash flow hedging activitieslosses gain on foreign currency forward exchange contract gain on treasury rate lock agreement loss on interest rate swap contract tax expense benefit total reclassification net of tax amount are included in interest expense net see note amount are included in the computation of net periodic benefit cost see note amount are included in cost of product sold see note otherin addition to common stock abbvie authorized capital includes million share of preferred stock par value of december no share of preferred stock were issued or outstanding form note income tax earnings before income tax expenseyears ended december in million total earnings before income tax expense income tax expenseyears ended december in million total current tax deferreddomestic foreign total deferred tax total income tax expense benefit effective tax rate reconciliationyears ended december tax effect of foreign operation tax credit impact related to tax reform non deductible tax law change and related restructuring tax audit and all other net effective tax the effective income tax rate fluctuates year to year due to the allocation of the company taxable earnings among jurisdiction well certain discrete factor and event in each year including change in tax law acquisition and collaboration the effective income tax rate in and differed from the statutory tax rate principally due to the impact of foreign operation which reflects the impact of lower income tax rate in location outside the united state tax incentive in puerto rico and other foreign tax jurisdiction business development activity change in enacted tax rate and law and related restructuring tax audit and settlement and change in fair value of contingent consideration the effective tax rate for these period also reflected the benefit from tax credit principally related to research and development credit the orphan drug tax credit and puerto rico excise tax credit the puerto rico tax credit relate to excise tax on certain product manufactured in puerto rico the tax is levied on gross inventory purchase from entity in puerto rico and is included in cost of product sold in the consolidated statement of earnings the majority of the tax is creditable for income tax purpose in puerto rico enacted act the puerto rico act allowing for transition from puerto rico excise tax levied on gross inventory purchase to an income based tax beginning in the company completed the transition requirement of the puerto rico act in resulting in the remeasurement of certain deferred tax asset and liability based on income tax rate at which they are expected to reverse in the future the net tax benefit from the remeasurement of deferred tax related to the puerto rico act wa million the effective income tax rate included the recognition of net tax benefit of billion related to change in tax law and related restructuring including certain intra group transfer of intellectual property and deferred tax remeasurement form the tax cut and job act the act wa signed into law in december resulting in significant change to the corporate tax system including one time transition tax on mandatory deemed repatriation of earnings of certain foreign subsidiary that were previously untaxed the act also created minimum tax on certain foreign sourced earnings the company accounting policy for the minimum tax on foreign sourced earnings is to report the tax effect on the basis that the minimum tax will be recognized in tax expense in the year it is incurred period expense deferred tax asset and liabilitiesas of december in million tax assetscompensation and employee benefit accrual and chargebacks and advance net operating loss and other total deferred tax valuation allowance total net deferred tax deferred tax liabilitiesexcess of book basis over tax basis of intangible asset excess of book basis over tax basis in investment other total deferred tax liability net deferred tax asset liability the increase in net deferred tax asset is primarily related to capitalization of expense and increase in accrual and reserve offset by decrease in advance payment the decrease in deferred tax liability is primarily related to amortization of intangible asset in connection with the allergan acquisition the company recorded adjustment within the measurement period in related to foreign net operating loss and other credit carryforwards that are not expected to be realized the adjustment reflected an increase of billion to deferred tax asset and an offsetting increase to valuation allowance resulting in no net impact to deferred tax asset the company had valuation allowance of billion of december and billion of december these were principally related to foreign and state net operating loss and other credit carryforwards that are not expected to be realized of december the company had federal state and foreign credit carryforwards of million well federal state and foreign net operating loss carryforwards of billion which will expire at various time through the remaining federal and foreign loss carryforwards of billion have no expiration the act significantly changed the timing and manner in which earnings of foreign subsidiary are subject to tax therefore unremitted foreign earnings subject to the act transition tax are not considered indefinitely reinvested post earnings subject to the minimum tax on foreign sourced earnings or eligible for the percent foreign dividend received deduction are also not considered indefinitely reinvested earnings however the company generally considers instance of outside basis difference in foreign subsidiary that would incur additional tax upon reversal capital gain distribution to be permanent in duration the unrecognized tax liability is not practicable to determine form unrecognized tax benefitsyears ended december in million balance increase due to acquisition increase due to current year tax increase due to prior year tax decrease due to prior year tax position settlement lapse of statute of limitation ending balance if recognized the net amount of potential tax benefit that would impact the company effective tax rate is billion in and billion in the increase due to current year tax position and increase due to prior year tax position in the table above include amount related to federal state and international tax item increase due to acquisition in the table above includes amount related to federal state and international tax item recorded in acquisition accounting related to the allergan acquisition abbvie recognizes interest and penalty related to income tax matter in income tax expense in the consolidated statement of earnings abbvie recognized gross income tax expense of million in million in and million in for interest and penalty related to income tax matter abbvie had an accrual for the payment of gross interest and penalty of billion at december million at december and million at december the company is routinely audited by the tax authority in significant jurisdiction and number of audit are currently underway it is reasonably possible during the next month that uncertain tax position may be settled which could result in decrease in the gross amount of unrecognized tax benefit due to the potential for resolution of federal state and foreign examination and the expiration of various statute of limitation the company gross unrecognized tax benefit balance may change within the next month up to million all significant federal state local and international matter have been concluded for year through the company belief adequate provision ha been made for all income tax uncertainty note legal proceeding and contingency abbvie is subject to contingency such various claim legal proceeding and investigation regarding product liability intellectual property commercial security and other matter that arise in the normal course of business the most significant matter are described below loss contingency provision are recorded for probable loss at management best estimate of loss or when best estimate can not be made minimum loss contingency amount within probable range is recorded for litigation matter discussed below for which loss is probable or reasonably possible the company is unable to estimate the possible loss or range of loss if any beyond the amount accrued initiation of new legal proceeding or change in the status of existing proceeding may result in change in the estimated loss accrued by abbvie while it is not feasible to predict the outcome of all proceeding and exposure with certainty management belief that their ultimate disposition should not have material adverse effect on abbvie consolidated financial position result of operation or cash flow subject to certain exception specified in the separation agreement by and between abbott laboratory abbott and abbvie abbvie assumed the liability for and control of all pending and threatened legal matter related to it business including liability for any claim or legal proceeding related to product that had been part of it business but were discontinued prior to the distribution well assumed or retained liability and will indemnify abbott for any liability arising out of or resulting from such assumed legal matter antitrust litigationlawsuits are pending against abbvie and others generally alleging that the patent litigation settlement involving niaspan entered into between ko pharmaceutical inc company acquired by abbott in and presently subsidiary of abbvie and generic company violates federal and state antitrust law and state unfair and deceptive trade practice and unjust enrichment law plaintiff generally seek monetary damage and or injunctive relief and attorney fee the lawsuit pending in federal court consist of four individual plaintiff lawsuit and two consolidated purported class action one brought form by niaspan direct purchaser and one brought by niaspan end payors the case are pending in the united state district court for the eastern district of pennsylvania for coordinated or consolidated pre trial proceeding under the mdl rule in re niaspan antitrust litigation mdl no in august the court certified class of direct purchaser of niaspan in june and august the court denied the end payors motion to certify class in october the orange county california district attorney office filed lawsuit on behalf of the state of california regarding the niaspan patent litigation settlement in orange county superior court asserting claim under the unfair competition provision of the california business and profession code seeking injunctive relief restitution civil penalty and attorney fee in august direct purchaser of androgel filed lawsuit king drug co of florence inc et al abbvie inc et al against abbvie and others in the united state district court for the eastern district of pennsylvania alleging that patent litigation settlement and related agreement by solvay pharmaceutical inc company abbott acquired in february and now known abbvie product llc with three generic company violated federal antitrust law and also alleging that patent litigation by abbott with two generic company regarding androgel wa sham litigation and the settlement of those litigation violated federal antitrust law plaintiff generally seek monetary damage and or injunctive relief and attorney fee in november the state of oregon filed lawsuit in the multnomah county oregon circuit court making similar allegation regarding the patent litigation with one of the generic company lawsuit are pending against forest laboratory llc an abbvie subsidiary and others generally alleging that and patent litigation settlement involving namenda entered into between forest and generic company and other conduct by forest involving namenda violated state antitrust unfair and deceptive trade practice and unjust enrichment law plaintiff generally seek monetary damage and or injunctive relief and attorney fee the lawsuit purported class action filed by indirect purchaser of namenda are consolidated in re namenda indirect purchaser antitrust litigation in the united state district court for the southern district of new york in november the party reached an agreement to settle this matter that ha received preliminary court approval lawsuit are pending against forest laboratory llc and others generally alleging that and patent litigation settlement involving bystolic with six generic manufacturer violated federal and state antitrust law and state unfair and deceptive trade practice and unjust enrichment law plaintiff generally seek monetary damage and or injunctive relief and attorney fee the lawsuit purported class action filed on behalf of direct and indirect purchaser of bystolic are consolidated in re bystolic antitrust litigation in the united state district court for the southern district of new york government proceedingslawsuits are pending against allergan and several other manufacturer generally alleging that they improperly promoted and sold prescription opioid product approximately matter are pending against allergan most of the federal court case are consolidated for pre trial purpose in the united state district court for the northern district of ohio under the mdl rule in re national prescription opiate litigation mdl no approximately matter are pending in various state court the plaintiff in these case which include state county city other municipal entity native american tribe union trust fund and other third party payors private hospital and personal injury claimant generally seek compensatory and punitive damage in november allergan finalized the term of settlement with state and local government entity and native american tribe that settlement is subject to certain condition including allergan determination that sufficient number of government entity elect to participate in the settlement abbvie recorded charge of billion to selling general and administrative expense in the consolidated statement of earnings in the second quarter of related to this potential settlement shareholder and security litigationin june lawsuit elliott associate et al abbvie inc wa filed by five investment fund against abbvie in the cook county illinois circuit court alleging that abbvie made misrepresentation and omission in connection with it proposed transaction with shire similar lawsuit were filed between july and october against abbvie and in some instance it chief executive officer in the same court by additional investment fund in september the illinois court granted abbvie motion for summary judgment on all pending claim in all pending case dismissing them with prejudice in november the illinois appellate court affirmed summary judgment in abbvie favor and in december that court denied plaintiff petition for rehearing in october federal security lawsuit holwill abbvie inc et al wa filed in the united state district court for the northern district of illinois against abbvie it chief executive officer and former chief financial officer alleging that reason stated for humira sale growth in financial filing between and were misleading because they omitted alleged misconduct in connection with humira patient and reimbursement support service and other service and item of value that allegedly induced humira prescription in september the court granted plaintiff motion to certify class in may shareholder derivative lawsuit ranney gonzalez et al wa filed in delaware chancery court alleging that form certain abbvie director and officer breached their fiduciary duty based on related allegation in december after abbvie and the director officer defendant filed motion to dismiss the plaintiff voluntarily dismissed the lawsuit with prejudice lawsuit are pending against allergan and certain of it current and former officer alleging they made misrepresentation and omission regarding allergan textured breast implant the lawsuit which were filed by allergan shareholder have been consolidated in the united state district court for the southern district of new york in re allergan plc security litigation the plaintiff generally seek compensatory damage and attorney fee in september the court partially granted allergan motion to dismiss in september the court granted plaintiff motion to certify class in december the court granted allergan motion for summary judgment on the remaining claim dismissing them with prejudice plaintiff are appealing the court motion to dismiss and summary judgment ruling in april federal security lawsuit nakata abbvie inc wa filed in the united state district court for the northern district of illinois against abbvie and certain officer alleging misstatement regarding the potential effect that safety information about another company product would have on the food and drug administration approval and labeling for abbvie rinvoq in may and july two shareholder derivative lawsuit treppel family trust gonzalez et al and katcher gonzalez et al were filed in the same court alleging that certain abbvie director and officer breached fiduciary and other legal duty based on related allegation product liability and general litigationin qui tam lawsuit ex rel silbersher allergan inc et al wa filed in the united state district court for the northern district of california against several allergan entity and others alleging that their conduct before the patent office resulted in false claim for payment being made to federal and state healthcare payors for namenda xr and namzaric the plaintiff relator seek damage and attorney fee under the federal false claim act and state law analogue the federal government and state government declined to intervene in the lawsuit in august the united state court of appeal reversed the district court denial of allergan motion to dismiss the case ha been remanded to the district court for further proceeding consistent with that ruling intellectual property litigationpharmacyclics llc wholly owned subsidiary of abbvie is seeking to enforce it patent right relating to ibrutinib tablet drug pharmacyclics sell under the trademark imbruvica case were filed in the united state district court for the district of delaware in march against alvogen pine brook llc and natco pharma ltd in august the court issued decision holding all asserted patent infringed and valid the judgment precludes defendant from obtaining regulatory approval and launching until the last patent expires in on august defendant appealed on november the court of appeal for the federal circuit affirmed the judgment janssen biotech inc which is in global collaboration with pharmacyclics concerning the development and marketing of imbruvica is the co plaintiff in these suit abbvie inc is seeking to enforce patent right relating to venetoclax drug sold under the trademark venclexta litigation wa filed in the united state district court for the district of delaware in july against dr reddy laboratory ltd and dr reddy laboratory inc and alembic pharmaceutical ltd alembic pharmaceutical inc and alembic global holding sa abbvie alleges defendant proposed generic venetoclax product infringe certain patent and seek declaratory and injunctive relief genentech inc which is in global collaboration with abbvie concerning the development and marketing of venclexta is the co plaintiff in this suit note segment and geographic area informationabbvie operates single global business segment dedicated to the research and development manufacturing commercialization and sale of innovative medicine and therapy this operating structure enables the chief executive officer chief operating decision maker codm to allocate resource and ass business performance on global basis in order to achieve established long term strategic goal consistent with this structure global research and development and supply chain organization is responsible for the discovery manufacturing and supply of product commercial effort that coordinate the marketing sale and distribution of these product are organized by geographic region or therapeutic area all of these activity are supported by global corporate administrative staff the determination of single business segment is consistent with the consolidated financial information regularly reviewed by the codm for purpose of assessing performance allocating resource and planning and forecasting future period form substantially all of abbvie net revenue in the united state are to three wholesaler outside the united state product are sold primarily to health care provider or through distributor depending on the market served the following table detail abbvie worldwide net revenue year ended december in million state total skyriziunited state total rinvoqunited state total hematologic oncologyimbruvicaunited state collaboration total venclextaunited state total aestheticsbotox cosmetic united state total juvederm collection united state total other aesthetic united state total neurosciencebotox therapeutic united state total vraylar united state total duodopaunited state total ubrelvy united state quliptaunited state other neuroscience united state total form year ended december in million carelumigan ganfort united state total alphagan combigan united state total restasis united state total other eye care united state total other key productsmavyretunited state total creonunited state linz constella united state total all other total net revenue net revenue include allergan product revenue after the acquisition closing date of may net revenue to external customer by geographic area based on product shipment destination were follows year ended december in million state united all other total net revenue long lived asset primarily net property and equipment by geographic area were follows of december in million state and puerto rico all total long lived asset form note fourth quarter financial result unaudited quarter ended december in million except per share data revenue gross net earnings attributable to abbvie inc basic earnings per share attributable to abbvie inc diluted earnings per share attributable to abbvie inc cash dividend declared per common share form report of independent registered public accounting firmto the stockholder and the board of director of abbvie inc opinion on the financial statement we have audited the accompanying consolidated balance sheet of abbvie inc and subsidiary the company of december and the related consolidated statement of earnings comprehensive income equity and cash flow for each of the three year in the period ended december and the related note collectively referred to the financial statement in our opinion the financial statement present fairly in all material respect the financial position of the company at december and and the result of it operation and it cash flow for each of the three year in the period ended december in conformity with generally accepted accounting principle we also have audited in accordance with the standard of the public company accounting oversight board united state pcaob the company internal control over financial reporting of december based on criterion established in internal control integrated framework issued by the committee of sponsoring organization of the treadway commission framework and our report dated february expressed an unqualified opinion thereon basis for opinionthese financial statement are the responsibility of the company management our responsibility is to express an opinion on the company financial statement based on our audit we are public accounting firm registered with the pcaob and are required to be independent with respect to the company in accordance with the federal security law and the applicable rule and regulation of the security and exchange commission and the pcaob we conducted our audit in accordance with the standard of the pcaob those standard require that we plan and perform the audit to obtain reasonable assurance about whether the financial statement are free of material misstatement whether due to error or fraud our audit included performing procedure to ass the risk of material misstatement of the financial statement whether due to error or fraud and performing procedure that respond to those risk such procedure included examining on test basis evidence regarding the amount and disclosure in the financial statement our audit also included evaluating the accounting principle used and significant estimate made by management well evaluating the overall presentation of the financial statement we believe that our audit provide reasonable basis for our opinion critical audit mattersthe critical audit matter communicated below are matter arising from the current period audit of the financial statement that were communicated or required to be communicated to the audit committee and that relate to account or disclosure that are material to the financial statement and involved our especially challenging subjective or complex judgment the communication of critical audit matter doe not alter in any way our opinion on the financial statement taken whole and we are not by communicating the critical audit matter below providing separate opinion on the critical audit matter or on the account or disclosure to which they relate form sale rebate accrual for medicaid medicare and managed care programsdescription of the matteras discussed in note to the consolidated financial statement under the caption revenue recognition the company established provision for sale rebate in the same period the related product is sold at december the company had million in sale rebate accrual large portion of which were for rebate provided to pharmacy benefit manager state government medicaid program insurance company that administer medicare drug plan and private entity for medicaid medicare and managed care program in order to establish these sale rebate accrual the company estimated it rebate based upon the identification of the product subject to rebate the applicable price and rebate term and the estimated lag time between the sale and payment of the rebate auditing the medicaid medicare and managed care sale rebate accrual wa complex and required significant auditor judgment because the accrual consider multiple subjective and complex estimate and assumption these estimate and assumption included the estimated inventory in the distribution channel which impact the lag time between the sale to the customer and payment of the rebate and the final payer related to product sale which impact the applicable price and rebate term in deriving these estimate and assumption the company used both internal and external source of information to estimate product in the distribution channel payer mix prescription volume and historical experience management supplemented it historical data analysis with qualitative adjustment based upon change in rebate trend rebate program and contract term legislative change or other significant event which indicate change in the reserve is appropriate how we addressed the matter in our auditwe obtained an understanding evaluated the design and tested the operating effectiveness of control over the company sale rebate accrual for medicaid medicare and managed care program this included testing control over management review of the significant assumption and other input used in the estimation of medicaid medicare and managed care rebate among others including the significant assumption discussed above the testing wa inclusive of management control to evaluate the accuracy of it reserve judgment to actual rebate paid rebate validation and processing and control to ensure that the data used to evaluate and support the significant assumption wa complete accurate and where applicable verified to external data source to test the sale rebate accrual for medicaid medicare and managed care program our audit procedure included among others understanding and evaluating the significant assumption and underlying data used in management calculation our testing of significant assumption included corroboration to external data source we evaluated the reasonableness of assumption considering industry and economic trend product profile and other regulatory factor we assessed the historical accuracy of management estimate by comparing actual activity to previous estimate and performed analytical procedure based on internal and external data source to evaluate the completeness of the reserve for medicaid we involved specialist with an understanding of statutory reimbursement requirement to ass the consistency of the company calculation methodology with applicable government regulation and policy form valuation of contingent considerationdescription of the matteras discussed in note to the consolidated financial statement under the caption business combination and in note under the caption fair value measure the company recognized contingent consideration liability at the estimated fair value on the acquisition date in connection with applying the acquisition method of accounting for business combination subsequent change to the fair value of the contingent consideration liability were recorded within the consolidated statement of earnings in the period of change at december the company had million in contingent consideration liability which represented level fair value measurement in the fair value hierarchy due to the significant unobservable input used in determining the fair value and the use of management judgment about the assumption market participant would use in pricing the liability auditing the valuation of contingent consideration liability wa complex and required significant auditor judgment due to the use of monte carlo simulation model and the high degree of subjectivity in evaluating certain assumption required to estimate the fair value of contingent royalty payment in particular the fair value measurement wa sensitive to the significant assumption underlying the estimated amount of future sale of the acquired product management utilized it expertise within the industry including commercial dynamic trend and utilization well knowledge of clinical development and regulatory approval process to determine certain of these assumption how we addressed the matter in our auditwe obtained an understanding evaluated the design and tested the operating effectiveness of control over the company contingent consideration liability process including among others management process to establish the significant assumption and measure the liability this included testing control over management review of the significant assumption and other input used in the determination of fair value the testing wa inclusive of key management review control to monitor and evaluate clinical development of the acquired product and estimated future sale and control to ensure that the data used to evaluate and support the significant assumption wa complete accurate and where applicable verified to external data source to test the estimated fair value of contingent consideration liability our audit procedure included among others inspecting the term of the executed agreement assessing the monte carlo simulation model used and testing the key contractual input and significant assumption discussed above we evaluated the assumption and judgment considering observable industry and economic trend and standard external data source and regulatory factor estimated amount of future sale were evaluated for reasonableness in relation to internal and external analysis clinical development progress and timeline probability of success benchmark and regulatory notice our procedure included evaluating the data source used by management in determining it assumption and where necessary included an evaluation of available information that either corroborated or contradicted management conclusion we involved valuation specialist to ass the company monte carlo simulation model and to perform corroborative fair value calculation ernst young llpwe have served the company auditor since chicago illinoisfebruary form item change in and disagreement with accountant on accounting and financial disclosurenone item control and proceduresdisclosure control and procedure internal control over financial reporting evaluation of disclosure control and procedure the chief executive officer richard gonzalez and the chief financial officer scott reents evaluated the effectiveness of abbvie disclosure control and procedure of the end of the period covered by this report and concluded that abbvie disclosure control and procedure were effective to ensure that information abbvie is required to disclose in the report that it file or submits with the security and exchange commission under the security exchange act of is recorded processed summarized and reported within the time period specified in the commission rule and form and to ensure that information required to be disclosed by abbvie in the report that it file or submits under the security exchange act of is accumulated and communicated to abbvie management including it principal executive officer and principal financial officer appropriate to allow timely decision regarding required disclosure change in internal control over financial reporting there were no change in abbvie internal control over financial reporting defined in rule under the security exchange act of that have materially affected or are reasonably likely to materially affect abbvie internal control over financial reporting during the quarter ended december inherent limitation on effectiveness of control abbvie management including it chief executive officer and it chief financial officer do not expect that abbvie disclosure control or internal control over financial reporting will prevent or detect all error and all fraud control system no matter how well designed and operated can provide only reasonable not absolute assurance that the control system objective will be met the design of control system must reflect the fact that there are resource constraint and the benefit of control must be considered relative to their cost further because of the inherent limitation in all control system no evaluation of control can provide absolute assurance that misstatement due to error or fraud will not occur or that all control issue and instance of fraud if any have been detected these inherent limitation include the reality that judgment in decision making can be faulty and that breakdown can occur because of simple error or mistake control can also be circumvented by the individual act of some person by collusion of two or more people or by management override of the control the design of any system of control is based in part on certain assumption about the likelihood of future event and there can be no assurance that any design will succeed in achieving it stated goal under all potential future condition projection of any evaluation of control effectiveness to future period are subject to risk over time control may become inadequate because of change in condition or deterioration in the degree of compliance with policy or procedure management annual report on internal control over financial reporting management of abbvie is responsible for establishing and maintaining adequate internal control over financial reporting such term is defined in rule under the security exchange act of abbvie internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statement for external purpose in accordance with generally accepted accounting principle in the united state however all internal control system no matter how well designed have inherent limitation therefore even those system determined to be effective can provide only reasonable assurance with respect to financial statement preparation and reporting management assessed the effectiveness of abbvie internal control over financial reporting of december in making this assessment management used the criterion set forth by the committee of sponsoring organization of the treadway commission coso in internal control integrated framework framework based on that assessment management concluded that abbvie maintained effective internal control over financial reporting of december based on the coso criterion the effectiveness of abbvie internal control over financial reporting of december ha been audited by ernst young llp an independent registered public accounting firm stated in their attestation report below which express an unqualified opinion on the effectiveness of abbvie internal control over financial reporting of december report of independent registered public accounting firm the report of abbvie independent registered public accounting firm related to it assessment of the effectiveness of internal control over financial reporting is included below form report of independent registered public accounting firmto the stockholder and the board of director of abbvie inc opinion on internal control over financial reportingwe have audited abbvie inc and subsidiary internal control over financial reporting of december based on criterion established in internal control integrated framework issued by the committee of sponsoring organization of the treadway commission framework the coso criterion in our opinion abbvie inc and subsidiary the company maintained in all material respect effective internal control over financial reporting of december based on the coso criterion we also have audited in accordance with the standard of the public company accounting oversight board united state pcaob the consolidated balance sheet of abbvie inc and subsidiary of december and the related consolidated statement of earnings comprehensive income equity and cash flow for each of the three year in the period ended december and the related note and our report dated february expressed an unqualified opinion thereon basis for opinionthe company management is responsible for maintaining effective internal control over financial reporting and for it assessment of the effectiveness of internal control over financial reporting included in the accompanying management annual report on internal control over financial reporting our responsibility is to express an opinion on the company internal control over financial reporting based on our audit we are public accounting firm registered with the pcaob and are required to be independent with respect to the company in accordance with the federal security law and the applicable rule and regulation of the security and exchange commission and the pcaob we conducted our audit in accordance with the standard of the pcaob those standard require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting wa maintained in all material respect our audit included obtaining an understanding of internal control over financial reporting assessing the risk that material weakness exists testing and evaluating the design and operating effectiveness of internal control based on the assessed risk and performing such other procedure we considered necessary in the circumstance we believe that our audit provides reasonable basis for our opinion definition and limitation on internal control over financial reportinga company internal control over financial reporting is process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statement for external purpose in accordance with generally accepted accounting principle company internal control over financial reporting includes those policy and procedure that pertain to the maintenance of record that in reasonable detail accurately and fairly reflect the transaction and disposition of the asset of the company provide reasonable assurance that transaction are recorded necessary to permit preparation of financial statement in accordance with generally accepted accounting principle and that receipt and expenditure of the company are being made only in accordance with authorization of management and director of the company and provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition use or disposition of the company asset that could have material effect on the financial statement because of it inherent limitation internal control over financial reporting may not prevent or detect misstatement also projection of any evaluation of effectiveness to future period are subject to the risk that control may become inadequate because of change in condition or that the degree of compliance with the policy or procedure may deteriorate ernst young llpchicago illinoisfebruary form item other informationnone item disclosure regarding foreign jurisdiction that prevent inspectionsnot applicable form part iiiitem director executive officer and corporate governanceincorporated herein by reference are information concerning director nominee the board of director and it committee committee of the board of director communicating with the board of director and deadline for notice of stockholder action to be considered at the annual meeting of stockholder to be included in the abbvie inc proxy statement the definitive proxy statement will be filed on or about march also incorporated herein by reference is the text found in this form under the caption information about our executive officer abbvie code of business conduct requires all it business activity to be conducted in compliance with all applicable law regulation and ethical principle and value all director officer and employee of abbvie are required to read understand and abide by the requirement of the code of business conduct applicable to them abbvie code of business conduct is available in the corporate governance section of abbvie investor relation website at www abbvieinvestor com any waiver of the code of business conduct for director or executive officer may be made only by abbvie audit committee abbvie will disclose any amendment to or waiver from provision of the code of conduct for the principal executive officer principal financial officer principal accounting officer or controller or person performing similar function on it website within four business day following the date of the amendment or waiver in addition abbvie will disclose any waiver from the code of business conduct for the other executive officer and for director on the website abbvie ha chief ethic and compliance officer who report to the executive vice president general counsel and secretary and to the public policy committee the chief ethic and compliance officer is responsible for overseeing administering and monitoring abbvie compliance program item executive compensationthe material to be included in the abbvie inc proxy statement under the heading director compensation executive compensation and compensation committee report is incorporated herein by reference the definitive proxy statement will be filed on or about march form item security ownership of certain beneficial owner and management and related stockholder matter equity compensation plan information the following table present information of december about abbvie equity compensation plan under which abbvie common stock ha been authorized for issuance plan category number of security to be issued upon exercise of outstanding option warrant and right weighted average exercise price of outstanding option warrant and right number of security remaining available for future issuance under equity compensation plan excluding security reflected in column equity compensation plan approved by security equity compensation plan not approved by security holder includes share issuable under abbvie incentive stock program pursuant to award granted by abbott and adjusted into abbvie award in connection with abbvie separation from abbott the weighted average exercise price doe not include outstanding restricted stock unit restricted stock award and performance share that have no exercise price excludes share issuable upon the exercise of stock option and pursuant to other right granted under the stemcentrx equity incentive plan which wa assumed by abbvie upon the consummation of it acquisition of stemcentrx inc of december option remained outstanding under this plan the option have weighted average exercise price of no further award will be granted under this plan information concerning security ownership incorporated herein by reference is the material under the heading security ownership security ownership of executive officer and director in the abbvie inc proxy statement the definitive proxy statement will be filed on or about march item certain relationship and related transaction and director independencethe material to be included in the abbvie inc proxy statement under the heading the board of director and it committee corporate governance material and procedure for approval of related person transaction is incorporated herein by reference the definitive proxy statement will be filed on or about march item principal accounting fee and servicesthe material to be included in the abbvie inc proxy statement under the heading audit fee and non audit fee and policy on audit committee pre approval of audit and permissible non audit service of the independent registered public accounting firm is incorporated herein by reference the definitive proxy statement will be filed on or about march form part ivitem exhibit financial statement schedule document filed part of this form financial statement see item financial statement and supplementary data for list of financial statement financial statement schedule all schedule omitted are inapplicable or the information required is shown in the consolidated financial statement or note thereto exhibit required by item of regulation the information called for by this paragraph is set forth in item below exhibit exhibitnumberexhibit transaction agreement dated of june between abbvie inc allergan plc and venice subsidiary llc incorporated by reference to exhibit of the company current report on form filed on june appendix iii to the rule announcement dated of june condition appendix incorporated by reference to exhibit of the company current report on form filed on june expense reimbursement agreement dated of june between abbvie inc and allergan plc incorporated by reference to exhibit of the company current report on form filed on june amendment to the transaction agreement dated of may between abbvie inc allergan plc and venice subsidiary llc incorporated by reference to exhibit of the company quarterly report on form for the quarterly period ended march amended and restated certificate of incorporation of abbvie inc incorporated by reference to exhibit of the company current report on form filed on january second amended and restated by law of abbvie inc incorporated by reference to exhibit of the company current report on form filed on october of the company security registered pursuant to section of the security exchange act of indenture dated of november between abbvie inc and bank national association incorporated by reference to exhibit of amendment no to the company registration statement on form filed on november supplemental indenture no dated of november among abbvie inc and bank national association including form of note incorporated by reference to exhibit of amendment no to the company registration statement on form filed on november supplemental indenture no dated may between abbvie inc and bank national association trustee including form of note incorporated by reference to exhibit of the company current report on form filed on may supplemental indenture no dated may between abbvie inc and bank national association trustee including form of note incorporated by reference to exhibit of the company current report on form filed on may supplemental indenture no dated of november among abbvie inc bank national association trustee elavon financial service dac branch paying agent and elavon financial service dac transfer agent and registrar including form of note incorporated by reference to exhibit of the company current report on form filed on november supplemental indenture no dated september between abbvie inc and bank national association trustee including form of note incorporated by reference to exhibit of the company current report on form filed on september form exhibitnumberexhibit supplemental indenture no dated september among abbvie inc bank national association trustee transfer agent and registrar and elavon financial service dac uk branch paying agent including form of note incorporated by reference to exhibit of the company current report on form filed on september supplemental indenture no dated november by and between abbvie inc and bank national association trustee including form of note incorporated by reference to exhibit of the company current report on form filed on november supplemental indenture no dated may by and between abbvie inc and bank national association trustee incorporated by reference to exhibit of the company current report on form filed on may supplemental indenture no dated may among abbvie inc bank and national association trustee transfer agent and registrar and elavon financial service dac branch paying agent incorporated by reference to exhibit of the company current report on form filed on may agency agreement dated of november among abbvie inc bank national association trustee elavon financial service dac branch paying agent and elavon financial service dac transfer agent and registrar incorporated by reference to exhibit of the company current report on form filed on november agency agreement dated september among abbvie inc bank national association trustee transfer agent and registrar and elavon financial service dac branch paying agent incorporated by reference to exhibit of the company current report on form filed on september registration right agreement dated november among abbvie inc and morgan stanley co llc bofa security inc and barclays capital inc acting for themselves and representative of the several initial purchaser incorporated by reference to exhibit of the company current report on form filed on november agency agreement dated may among abbvie inc bank national association trustee transfer agent and registrar and elavon financial service dac branch paying agent and calculation agent incorporated by reference to exhibit of the company current report on form filed on may registration right agreement dated may among abbvie inc and morgan stanley co llc bofa security inc citigroup global market inc bnp paribas security corp hsbc security usa inc mizuho security usa llc and well fargo security llc incorporated by reference to exhibit of the company current report on form filed on may form of agreement regarding change in control by and between abbvie inc and it named executive officer incorporated by reference to exhibit of amendment no to the company registration statement on form filed on november abbvie amended and restated incentive stock program incorporated by reference to appendix to the abbvie inc definitive proxy statement on schedule dated march abbvie deferred compensation plan amended and restated incorporated by reference to exhibit of the company annual report on form for the fiscal year ended december abbvie deferred compensation plan plus incorporated by reference to exhibit of the company quarterly report on form for the quarterly period ended september form of abbvie inc non qualified stock option agreement incorporated by reference to exhibit of the company quarterly report on form for the quarterly period ended march form of abbvie inc non employee director restricted stock unit agreement incorporated by reference to exhibit of the company quarterly report on form for the quarterly period ended march form of abbvie inc non qualified stock option agreement incorporated by reference to exhibit of the company quarterly report on form for the quarterly period ended march form of abbvie inc non employee director restricted stock unit agreement incorporated by reference to exhibit of the company quarterly report on form for the quarterly period ended march form of abbvie inc non qualified stock option agreement incorporated by reference to exhibit of the company quarterly report on form for the quarterly period ended march form of abbvie inc non employee director rsu agreement incorporated by reference to exhibit of the company quarterly report on form for the quarterly period ended march form exhibitnumberexhibit form of abbvie inc non qualified stock option agreement incorporated by reference to exhibit of the company quarterly report on form for the quarterly period ended march form of abbvie inc non employee director rsu agreement incorporated by reference to exhibit of the company quarterly report on form for the quarterly period ended march form of abbvie inc non qualified stock option agreement incorporated by reference to exhibit of the company quarterly report on form for the quarterly period ended march form of abbvie inc performance share award agreement incorporated by reference to exhibit of the company quarterly report on form for the quarterly period ended march form of abbvie inc performance vested restricted stock unit agreement incorporated by reference to exhibit of the company quarterly report on form for the quarterly period ended march form of abbvie inc non employee director rsu agreement incorporated by reference to exhibit of the company quarterly report on form for the quarterly period ended march form of abbvie inc non qualified stock option agreement incorporated by reference to exhibit of the company quarterly report on form for the quarterly period ended march amended and restated revolving credit agreement dated of august among abbvie inc the lender and other party party thereto and jpmorgan chase bank administrative agent incorporated by reference to exhibit of the company current report on form filed on august day bridge credit agreement dated of june among abbvie inc morgan stanley senior funding inc and the lender party thereto incorporated by reference to exhibit of the company current report on form filed on june underwriting agreement dated september among abbvie inc and morgan stanley co international plc hsbc bank plc and merrill lynch international acting for themselves and representative of the several underwriter named therein incorporated by reference to exhibit of the company current report on form filed on september purchase agreement dated november among abbvie inc and morgan stanley co llc bofa security inc and barclays capital inc acting for themselves and representative of the several initial purchaser named therein incorporated by reference to exhibit of the company current report on form filed on november form of abbvie inc performance vested restricted stock unit agreement incorporated by reference to exhibit of the company quarterly report on form for the quarterly period ended march form of abbvie inc performance share award agreement incorporated by reference to exhibit of the company quarterly report on form for the quarterly period ended march form of abbvie inc non employee director rsu agreement incorporated by reference to exhibit of the company quarterly report on form for the quarterly period ended march form of abbvie inc non qualified stock option agreement incorporated by reference to exhibit of the company quarterly report on form for the quarterly period ended march form of abbvie inc retention rsu agreement ratable vesting incorporated by reference to exhibit of the company quarterly report on form for the quarterly period ended march abbvie performance incentive plan amended and restated incorporated by reference to exhibit of the company annual report on form for the fiscal year ended december abbvie supplemental pension plan amended and restated incorporated by reference to exhibit of the company annual report on form for the fiscal year ended december abbvie supplemental saving plan amended and restated incorporated by reference to exhibit of the company annual report on form for the fiscal year ended december form of abbvie inc performance vested restricted stock unit agreement incorporated by reference to exhibit of the company quarterly report on form for the quarterly period ended march form of abbvie inc performance share award agreement incorporated by reference to exhibit of the company quarterly report on form for the quarterly period ended march form of abbvie inc non employee director rsu agreement incorporated by reference to exhibit of the company quarterly report on form for the quarterly period ended march form exhibitnumberexhibit form of abbvie inc non qualified stock option agreement incorporated by reference to exhibit of the company quarterly report on form for the quarterly period ended march form of abbvie inc retention rsu agreement ratable vesting incorporated by reference to exhibit of the company quarterly report on form for the quarterly period ended march form of abbvie inc retention rsu agreement cliff vesting with dividend equivalent accrual incorporated by reference to exhibit of the company quarterly report on form for the quarterly period ended march form of abbvie non employee director fee plan amended and restated incorporated by reference to exhibit of the company quarterly report on form for the quarterly period ended june abbvie deferred compensation plan plus incorporated by reference to exhibit to the company quarterly report on form for the quarterly period ended september form of agreement regarding change in control by and between abbvie inc and it named executive officer incorporated by reference to exhibit to the company current report on form filed on october of abbvie inc of independent registered public accounting firm of chief executive officer required by rule cfr of chief financial officer required by rule cfr of chief executive officer pursuant to section adopted pursuant to section of the sarbanes oxley act of of chief financial officer pursuant to section adopted pursuant to section of the sarbanes oxley act of following financial statement and note from the abbvie inc annual report on form for the year ended december filed on february formatted in inline xbrl extensible business reporting language consolidated statement of earnings ii consolidated statement of comprehensive income iii consolidated balance sheet iv consolidated statement of equity consolidated statement of cash flow and vi the note to consolidated financial statement page interactive data file the cover page from the abbvie inc annual report on form formatted inline xbrl and contained in exhibit the abbvie inc definitive proxy statement will be filed with the security and exchange commission under separate cover on or about march _______________________________________________________________________________ incorporated herein by reference commission file number denotes management contract or compensatory plan or arrangement required to be filed an exhibit hereto exhibit and above are furnished herewith and should not be deemed to be filed under the security exchange act of abbvie will furnish copy of any of the above exhibit to stockholder upon written request to the secretary abbvie inc north waukegan road north chicago illinois form item form summarynone form signaturespursuant to the requirement of section or of the security exchange act of abbvie inc ha duly caused this report to be signed on it behalf by the undersigned thereunto duly authorized abbvie inc by richard gonzalez name richard gonzalez title chairman of the board andchief executive officerdate february to the requirement of the security exchange act of this report ha been signed below by the following person on behalf of abbvie inc on february in the capacity indicated below richard gonzalez scott reentsrichard gonzalezchairman of the board andchief executive officer principal executive officer scott reentsexecutive vice president chief financial officer principal financial officer brian durkinbrian durkinvice president controller principal accounting officer robert alpern roxanne austinrobert alpern director of abbvie inc roxanne austindirector of abbvie inc william burnside thomas freymanwilliam burnsidedirector of abbvie inc thomas freymandirector of abbvie inc brett hartbrett hartdirector of abbvie inc melody meyer edward rappmelody meyerdirector of abbvie inc edward rappdirector of abbvie inc rebecca robert glenn tiltonrebecca robertsdirector of abbvie inc glenn tiltondirector of abbvie inc frederick waddellfrederick waddelldirector of abbvie inc form copy and paste below content previous next setting hover over fact for quick information on off auto scrolling position top center selecting fact from the section menu or the fact menu will automatically scroll that element to the top or middle of the viewer window this setting will have no use on ie or safari tagged data savereset search result savereset selected fact savereset tag shading hover savereset copy and paste below content previous next nested fact previous next copy and paste below content previous next